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“Yet what is any ocean, but a multitude of drops?” 
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The comprehensive transcriptional and epigenetic characterization of human hepatocyte subpopulations is 
necessary to achieve a better understanding of regulatory processes in health and complex metabolic 
diseases as well as during in vitro differentiation. Based on integrative analysis of genome-wide sequencing 
data, this thesis aims to unravel hepatocyte heterogeneity in different biological contexts. 
A deeper understanding of spatial organization of cells in human tissues is an important challenge. Using 
a unique experimental set-up based on laser capture microdissection coupled to next generation 
sequencing, which preserves spatial orientation and still provides genome-wide data of well defined 
subpopulations, the first combined spatial analysis of transcriptomes and methylomes across three micro-
dissected zones of human liver provides a wealth of new positional insights, both in health and in context 
of fatty liver disease. In addition, these spatial maps serve as reference for projection of single cell data into 
hepatic pseudospace, which is still a major challenge. Hence, a novel pseudospace inference approach, 
which considerably improves spatial reconstruction of single cells into tissue context, is demonstrated for 
human liver. Finally, the identification of underlying regulatory networks by integrative epigenomic analysis 
of in vitro differentiated hepatocyte-like cells contributes to the development of reasonable cell culture 























Die umfassende transkriptionelle und epigenetische Charakterisierung humaner Leberzellsubpopulationen 
ist notwendig für die Aufklärung regulatorischer Prozesse in gesundem Gewebe, sowie im Zusammenhang 
mit komplexen metabolischen Erkrankungen und während der in vitro Differenzierung. Ziel dieser Arbeit ist 
es, basierend auf der integrativen Analyse genomweiter Sequenzierungsdaten, die Heterogenität von 
Leberzellen besser zu verstehen. 
Die räumliche Organisation von Zellen in humanem Gewebe stellt eine große Herausforderung dar. Mit 
Hilfe von Lasermikrodissektion gekoppelt an Hochdurchsatzsequenzierung ist es möglich definierte 
Subpopulationen hinsichtlich ihres Gewebekontextes zu analysieren. Somit konnte die erste räumliche 
Analyse von Transkriptom und Methylom dreier Zonen der humanen Leber erstellt werden, die eine Vielzahl 
neuer Erkenntnisse sowohl in gesundem Lebergewebe als auch in Zusammenhang mit 
Fettlebererkrankungen liefert. Außerdem wurde auf Grundlage dieser räumlichen Karten ein neuer Ansatz 
zur Projektion von Einzelzelldaten in den räumlichen Gewebekontext etabliert. Schließlich konnte durch die 
integrative Analyse der ausschlaggebenden regulatorischen Netzwerke während der in vitro 
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Epigenetics is the study of changes in genomic regulation that can be mitotically and or meiotically heritable, 
but do not comprise alterations in the underlying nucleotide sequence (Feil and Fraga, 2012). Already in 
1942, its eponym Conrad H. Waddington described this new field of research as ‘‘the branch of biology 
which studies the causal interactions between genes and their products, which bring the phenotype into 
being’’ (Waddington, 1968, 2012).  
In mammals, key epigenetic mechanisms are DNA methylation and a set of posttranscriptional histone 
modifications, which, together with non-coding RNAs and regulatory proteins, shape the epigenetic 
landscape of each cell (Figure 1). The fact that multicellular organisms develop from a single omnipotent 
zygote is a striking example of the importance of epigenetic regulation. The zygote’s progeny, which all 
share the same DNA sequence, have the potential to differentiate into a multitude of cell-types with defined 
gene expression profiles, resulting in highly specialized functions. The establishment of those specific 
programs, which is based on epigenetic memory, but also fast transcriptional changes as reaction to external 
stimuli, is only possible due to the intricate interplay of several layers of epigenetic regulation. 
 
Figure 1:  Epigenetic mechanisms and chromatin condensation (Lee et al., 2014, modified). In mammals, DNA 
methylation at CpG positions, histone modifications and non-coding RNAs are the major players of epigenetic regulation. 
For instance, they are involved in the intricate regulation of dynamic chromatin condensation, which is determined by 





1.1.1 Chromatin structure and histone modifications 
The DNA of a single diploid human cell consists of approximately 6 billion base pairs. In total, this would 
sum up to a length of 2 m, while the nucleus – the cellular compartment containing the DNA – is only 6 µm 
in diameter. Thus, in eukaryotic cells, the DNA forms a complex nucleoprotein structure called chromatin, 
which enables a strictly regulated dynamic DNA condensation.  
The basic repeating unit of chromatin is the nucleosome, typically consisting out of 147 bp of DNA wrapped 
around a histone protein octamer (Kornberg and Thomas, 1974). There are five major histone families, which 
are highly conserved across species. The canonical core histones H2A, H2B, H3 and H4 form the 
nucleosome particles (Figure 2 A, Luger et al., 1997), while the linker histone H1 stabilizes naked DNA 
(Thoma and Koller, 1977) linking neighboring nucleosomes like beads on a string.  
Histones serve not only as coils for DNA packaging, but – together with further epigenetic mechanisms – 
certain histone variants and histone modifications also exhibit regulatory potential by influencing the dynamic 
state of chromatin condensation (Henikoff et al., 2004; Jenuwein and Allis, 2001). The two major states of 
chromatin condensation are open euchromatin and closed heterochromatin. Euchromatic nucleosomes are 
loosely packaged, making the DNA accessible for regulatory proteins such as transcription factors or the 
transcriptional machinery. In contrast, in heterochromatin nucleosomes are tightly condensed, forming an 
inaccessible structure that for example impedes transcriptional activity or contributes to genomic stability by 
silencing of repetitive elements (Strålfors and Ekwall, 2011). 
Canonical histone proteins are generally expressed during S-phase to complex newly synthesized DNA 
during replication (Marzluff et al., 2002). In contrast, the replacement of canonical histones by histone 
variants is a targeted process, supported by ATP-depending histone chaperones, which is replication 
independent (Talbert and Henikoff, 2017). Histone variants play a role in active transcription, 
heterochromatin formation as well as DNA repair. For example, H2A.Z in promoter regions is involved in 
transcriptional initiation (Fan et al., 2002; Guillemette et al., 2005; Hardy et al., 2009), while H2A.W promotes 
heterochromatin condensation (Yelagandula et al., 2014). Phosphorylated Ὑ-H2A.X accumulates around 
DNA double strand breaks (Rogakou et al., 1998) and recruits members of the DNA repair machinery such 
as MDC1 (Stucki et al., 2005), a mediator of the DNA repair initiating MRN complex (Lamarche et al., 2010). 
Moreover, histone variants interact with posttranslational histone modifications (Li and Fang, 2015). 
Presumably, the best described reversible histone modifications are lysine acetylation and successive 
mono-, di- or tri-methylation of lysines (K) and arginines (R) at distinct positions of the positively charged 
histone tails protruding the nucleosome complex (Figure 2 B). However, there are also histone core 
modifications such as H3K122ac that have regulatory potential (Pradeepa et al., 2016). Besides acetylation 
and methylation, further posttranslational histone modifications include ubiquitination of lysines, 
phosphorylation of serine, threonine and tyrosine (Jenuwein and Allis, 2001), and also more recently 
described serotonylation of glutamines (Farrelly et al., 2019). The regulatory potential of histone 
modifications is largely attributed to changing interaction affinities with chromatin associated regulatory 
proteins (Jenuwein and Allis, 2001). However, lysine acetylation may also be directly involved in the 
stabilization of euchromatin (Sterner and Berger, 2000), as acetyl groups contribute to the partial 




between neighboring nucleosomes could contribute to the formation and maintenance of a more accessible 
chromatin structure (Fletcher and Hansen, 1996).  
The so called histone code can be used to segment the genome into regions by their potential function 
(Biesinger et al., 2013), as certain histone modification patterns correlate with genomic states. For example, 
H3K4me3, accompanied by several further active histone modifications such as H3K4me1 and H3K27ac, 
is a strong indicator for promoter regions (Koch et al., 2007; Santos-Rosa et al., 2002) . In absence of 
H3K4me3, enrichment of H3K27ac (Creyghton et al., 2010) and or H3K122ac indicates enhancer activity 
(Pradeepa et al., 2016). H3K36me3 covers the bodies of transcribed genes and is therefore closely linked 
to active transcription (Kolasinska-Zwierz et al., 2009). H3K27me3 is a repressive mark that can either be 
involved in local polycomb repressed gene silencing or span large heterochromatic domains together with 
H3K9me3 (Pauler et al., 2009).  
Interestingly, there are genomic regions enriched for both activating H3K4me3 and repressive H3K27me3. 
These regions, which are referred to as bivalent domains (Bernstein et al., 2006; Kinkley et al., 2016; Young 
et al., 2011), are probably involved in the silencing of strictly regulated genes such as developmental genes 
that need to be transcriptionally activated at precise time-points. Thus, the bivalent character probably 




Figure 2: Histone modifications. A – Nucleosomes consist out of approximately 146 bp DNA wrapped around 4 histone 
protein dimers (Kato et al., 2015, modified). B – The most common modifications of histones H2A, H2B, H3 and H4 with 
regulatory implications are acetylation, methylation, phosphorylation and ubiquitination at specific amino acids of the 
nucleosome core protruding histone tails (Bhaumik et al., 2007). 
Beside the nucleosome-based level of condensation, chromatin also forms three dimensional (3D) higher-
order structures, with metaphasis chromosomes representing the highest degree of compaction. Although, 
to date, the organization of those structures is still not well characterized, it is evident that chromosomes do 
not fold randomly into the nucleus. During recent years it was shown that the overall nuclear organization, 
including long range interactions across and between chromosomes or the association of chromatin with 
the nuclear lamina, are of regulatory importance. For instance, long-range interactions between distant 
regulatory elements suggest an essential impact of spatial genome compartmentalization on the regulation 
of transcription and replication (Pombo and Dillon, 2015) . Moreover, lamina associated domains (LADs), 




nuclear lamina and correlate with low transcriptional activity and late replication timing (Guelen et al., 2008; 
Pope et al., 2014). More recently, the development of chromosome conformation capture techniques such 
as Hi-C (Lieberman-Aiden et al., 2009) entailed the detection of topologically associated domains (TADs, 
Dixon et al., 2012; Sexton et al., 2012). These are large genomic regions that exhibit preferential long range 
interactions within themselves. The disruption or formation of additional TAD boundaries can result in 
changes of gene expression patterns and the development of diseases such as cancer (Lupiáñez et al., 
2016; Taberlay et al., 2016). Thus, TADs are considered as fundamental structural units, which, for example, 
regulate distant promoter enhancer interactions and represent stable replication domains (Pope et al., 2014). 
However, precise mechanisms are still under investigation. 
 
1.1.2 DNA methylation 
DNA methylation was first discovered in 1948 by Rollin Hotchkiss. Since then, it has become the most 
studied epigenetic modification in mammalian cells and many fundamental functions, such as in regulation 
of gene silencing (Holliday and Pugh, 1975), genomic imprinting (Li et al., 1993), X chromosome inactivation 
(Heard et al., 1997; Riggs, 1975) and genome stability (Yoder et al., 1997), have been described. 
Furthermore, DNA methylation, representing a kind of epigenetic memory, plays a crucial role during early 
embryogenesis and cellular differentiation, but is also implicated in the development and progression of 
many diseases including cancer (Portela and Esteller, 2010). 
In mammals, DNA methylation occurs almost exclusively at the C5 position of cytosines (Hotchkiss, 1948), 
although more recently N6-methyladenine was detected in mouse embryonic stem cells (Wu et al., 2016). 
Cytosine methylation is catalyzed by different classes of DNA methyltransferases (DNMTs) that transfer a 
methyl-group from their cofactor S-adenyl methionine (SAM), resulting in covalently linked 5-methyl-cytosine 
(5mC, Figure 3 A). Maintenance methyltransferase DNMT1, which preferentially methylates hemi-
methylated DNA, is responsible for re-establishment of DNA methylation patterns on the newly synthesized 
DNA strand after replication (Hermann et al., 2004). In contrast, the de novo methyltransferases DNTM3A 
and DNTM3B can methylate unmethylated as well as hemi-methylated DNA, allowing the introduction of 
newly methylated CpG sites (Jurkowska et al., 2011; Okano et al., 1999). 
Regarding DNA demethylation two different mechanisms have been described. Passive loss of methylation 
takes place when DNA methylation patterns are not maintained by DNMT1 after replication, thus it requires 
cell divisions (Howlett and Reik, 1991). Active DNA demethylation, which can also occur in non-dividing cells 
(Mayer et al., 2000; Oswald et al., 2000), is a more complex process. Mediated by ten-eleven translocation 
family (TET) enzymes, 5mC can be oxidized to 5-hydroxy-cytosine (5hmC), 5-formyl-cytosine (5fC) and 5-
carboxy-cytosine (5cC) in a iterative manner (Ito, 2011; Tahiliani et al., 2009). These modifications might 
themselves have regulatory functions (Bachman et al., 2015), but are also essential for active DNA 
demethylation (Figure 3 A). For instance, both 5fC and 5cC can be recognized and removed by the thymine 
DNA glycoxylase (TDG), which mediates base excision repair (BER), entailing the incorporation of 
unmodified cytosine (Dalton and Bellacosa, 2012). 
In the genome cytosine methylation is primarily found in a CpG dinucleotide context (Doskočil and Šorm, 
1962). The palindromic sequence facilitates the maintenance of symmetric DNA methylation patterns over 




pluripotent stem cells and neurons (Laurent et al., 2010; Lister et al., 2013). While CpG dinucleotides are 
underrepresented throughout the genome, they are enriched in so called CpG islands, mostly at highly 
regulatory promoter regions (Ioshikhes and Zhang, 2000). CpG islands upstream of transcriptionally active 
genes are generally unmethylated (Figure 3, A), as high DNA methylation in those regions results in gene 
silencing of the corresponding gene (Lister et al., 2009). Outside of CpG islands, most CpGs across the 
genome are methylated (Ehrlich et al., 1982), thereby contributing to genome stability (Meng et al., 2015), 
for instance by silencing of transposable and repetitive elements (Figure 3, A).  
 
Figure 3: DNA methylation. A – Methylation of Cytosines at the 5’ carbon is catalyzed by DNMTs. 5mC can be further 
oxidized to hydroxy-, formyl- or carboxy-Cytosine by TET enzymes. Active Demethylation can occur by TDG followed 
by base excision repair (Raiber et al., 2017)  B – CpGs are underrepresented in the mammalian genome, but cluster at 
certain regulatory regions (grey). While most CpGs are methylated to retain genomic stability, promoter CpG islands are 
mostly unmethylated, and further regions with regulatory potential such as enhancers can have variable CpG 
methylation patterns (red) depending on their current regulatory state (Baubec and Schübeler, 2014). 
For a long time DNA methylation and gene expression were considered as purely anti-correlated (Razin and 
Cedar, 1991), with hypomethylation promoting active transcription. Regarding promoter regions and in 
particular CpG islands, this dogma certainly holds true, but in other regulatory elements such as enhancers, 
insulators or along the gene body, the situation appears to be much more complex. For example, DNA 




splicing (Shayevitch et al., 2018) or inhibits unwanted spurious initiation of transcription (Neri et al., 2017). 
DNA methylation in interaction with histone modifications influences chromatin condensation and can recruit 
regulatory proteins as further described in chapter 1.1.4. 
 
1.1.3 Non-coding RNAs 
The full transcriptome of a cell does not only contain protein coding messenger-RNA (mRNA), but also 
different classes of non-coding RNAs with diverse functions. The total amount of non-coding RNAs in the 
genome is still unknown and many newly described classes have still to be assessed regarding their 
functions. The most abundant RNAs are ribosomal RNA (rRNA) and transfer RNAs (tRNA), which are crucial 
factors for mRNA translation into proteins (Blanco and Blanco, 2017). Moreover, small non-coding RNAs of 
20 to 30 nucleotides are involved in multiple regulatory pathways. In particular, micro-RNAs (miRNA), short 
interfering RNAs (siRNA) and PIWI interacting RNAs (piRNA) play a fundamental role in transcriptional and 
posttranscriptional RNA silencing, which basically relies on complementary binding to the targeted mRNA 
(O’Brien et al., 2018; Siomi et al., 2011; Tijsterman et al., 2002). There are further small non-coding RNAs 
such as small nucleolar RNAs (snoRNA) that guide modifying enzymes to other RNA classes (Dupuis-
Sandoval et al., 2015) or small nuclear RNAs (snRNAs) involved in pre-processing of nuclear pre-mRNA 
(Guiro and Murphy, 2017). In most cases the functionality of long non-coding RNAs (lncRNA), which are 
typically longer than 200 nucleotides and frequently show features of processed mRNA like 5’ cap or 
polyadenylation, is still not well understood (Uszczynska-Ratajczak et al., 2018). Functional studies imply a 
diverse set of regulatory processes including transcriptional and post-transcriptional regulation as well as 
chromatin remodeling. For example, the lncRNA Xist induces extensive changes of the chromatin structure 
in mammalian female cells, ultimately leading to X chromosome inactivation (Morey et al., 2004). However, 
the full regulatory potential of lncRNAs is to date only starting to become apparent. 
 
1.1.4 Regulatory interplay of epigenetic modifications  
Cellular mechanisms, such as active transcription, are orchestrated by a complex interplay of multiple layers 
of regulation including DNA methylation, histone modifications and non-coding RNAs, together with 
regulatory proteins such as chromatin remodeling factors, transcription factors and structural proteins. The 
patterns of different epigenetic marks, especially at certain putative regulatory elements, already suggest a 
crosstalk between the different layers of epigenetic control (Figure 4). Frequently, CpG island harbouring 
promoter regions of active genes are unmethylated and nucleosome-depleted (Figure 5), while flanking 
nucleosomes are marked by H3K4me3, H3K27ac and a more wide-spread H3K4me1 (Figure 4, green). 
This pattern typically corresponds to an accessible chromatin structure, which allows the binding of 
transcription factors as well as of the transcriptional machinery (Fuda et al., 2009). Gene bodies of actively 
transcribed genes are marked by H3K36me3 and CpG methylation, preventing aberrant transcription and 
apparently influencing alternative splicing (Jones, 2012; Teissandier and Bourc’his, 2017). Furthermore, 
potentially active enhancer regions (Figure 4, blue) are characterized by a strong enrichment of H3K27ac, 




display diverse DNA methylation patterns (Figure 5, Stadler et al., 2011), which might be due to high DNA 
methylation dynamics mediated by TET enzymes (Wang et al., 2018). 
 
Figure 4: Multiple layers of NGS based epigenomic and transcriptional data in the hepatocyte-like cell line HepG2. 
Exemplary genome browser view of data generated within the DEEP project (Behjati Ardakani et al., 2018; Kattler, 2015; 
Kattler, 2013; Salhab et al., 2018). The first track displays whole genome bisulfite sequencing derives DNA methylation 
with unmethylated CpG positions in green and methylated CpGs in red. Accessible chromatin assessed by ATAC-seq 
is shown in purple. A set of 7 histone modifications (H3K4me1 in red, H3K4me3 in green, H3K27ac in light blue, 
H3K122ac in dark green, H3K36me3 in orange, H3K27me3 in grey and H3K9me3 in black) was analyzed by ChIP-seq. 
Bulk mRNA transcription data as well as single cell expression data of 64 HepG2 cells generated by SmartSeq2 are 
displayed in blue. The 1,598 kb window covers a large heterochromatic region (black), an active bidirectional promoter 
(green), silenced genes (grey) and a potential enhancer (blue). 
In contrast, promoters of silenced genes are highly methylated or accumulate nucleosomes with repressive 
histone modifications, in particular H3K27me3, resulting in a facultative heterochromatin structure (Figure 
4, grey). Interestingly, it was reported for several cell-types that CpG methylation and H3K27me3 deposition 
appear to be mutually exclusive, as high DNA methylation levels seem to prevent the binding of polycomb 
repressive complex 2, which is associated with histone methyltransferases like EzH that mediates H3K27 
trimethylation (Reddington et al., 2013). Gene-poor constitutive heterochromatin is generally characterized 
by high CpG methylation, enrichment of H3K9me3 and absence of any activating histone marks. Figure 4 
displays genome-wide data generated from the liver cancer derived cell line HepG2. Here, hypomethylation 
of large heterochromatic regions can be observed (Figure 4, black). This immortalization-related loss of DNA 
methylation is presumably compensated by enrichment of H3K9me3, together with polycomb-mediated 




such as the perturbation of the original epigenetic mechanism (Saksouk et al., 2015), and nicely illustrates 
the interoperability between epigenetic layers. 
 
Figure 5: Transcription is regulated by a complex interplay of epigenetic mechanisms (Jones, 2012). Promoters of active 
genes are generally accessible nucleosome-depleted regions (NDR) with unmethylated CpG sites. Flanking 
nucleosomes are frequently marked by the activating histone modifications H3K4me1 (yellow) and H3K4me3 (orange), 
together with the histone variant H2A.Z (green), which is antagonistic to DNA methylation and DNMT binding. DNA 
methylation patterns of gene bodies can influence alternative splicing events. Enhancers, which can loop back to the 
promoter region over short or long distances, often show variable DNA methylation patterns. DNA methylation at 
insulators can prevent CTCF binding which may also impact gene expression. The figure provides a simplified overview 
of transcriptional control, as it does not include further factors such as non-coding RNAs, transcription factor binding 
and further regulatory proteins. 
The establishment of these epigenetic patterns is a highly complex process. The binding of many regulatory 
proteins, including DNA sequence motive-specific transcription factors, frequently relies on the state of 
chromatin condensation. Thus, most transcription factors bind only in accessible chromatin regions 
(Grossman et al., 2018). However, epigenetic modifications can also themselves recruit regulatory proteins. 
For instance, there are transcription factors, such as homeodomain proteins, that selectively bind to 
methylated CpGs (Yin et al., 2017). Moreover, CpG methylation can recruit DNA methylation binding 
proteins such as MBD1, which is again associated with chromatin modifying complexes like Suv39H1, 
responsible for the deposition of H3K9me3 (Fujita et al., 2003; Ng et al., 2000). In turn, H3K9me3 binds 
URHF1, which is involved in the regulation of DNMT1 (Liu et al., 2013) and also interacts with H3K9 specific 
histone methyltransferase G9a (Kim et al., 2009) as well as with several histone deacetylases (Ghoshal et 
al., 2002), thereby constituting a kind of self-enhancing feedback loop, resulting in spreading of 




G9a (Ruan et al., 2012), binds to H3K9me2 and H3K9me3, further stabilizing heterochromatic structures 
(Eissenberg and Elgin, 2014).  
On the other hand, bromo-domain containing trithorax group complexes are associated with histone 
acetyltransferases (HATs) and H3K4 specific histone methyltransferases (Tie et al., 2014), thus promoting 
accessible chromatin (Schuettengruber et al., 2007). HATs are also often associated with transcription 
activator complexes (Ogryzko et al., 1996). In this context, nucleosome depletion, H3K4me3 and histone 
variant H2A.Z are reported to prevent de novo methylation at active regulatory elements (Jones, 2012). 
The state of chromatin condensation can also be directly altered by chromatin remodeling complexes, which 
are recruited to specific sites by small regulatory RNAs (Holoch and Moazed, 2015). For example, SWI/SNF 
family complexes can disrupt DNA-histone contacts, leading to nucleosome shifting (Bouazoune et al., 
2009). Nucleosomes can also be exchanged directly by histone chaperones, for example to allow the 
replication-independent incorporation of histone variants (Venkatesh and Workman, 2015).  
The spatial organization within the nucleus represents an additional layer of regulation. Higher order 
chromatin structures promote a nuclear compartmentalization. For instance, association of chromatin to the 
nuclear lamina results in heterochromatin formation (Finlan et al., 2008). TADs are suggested to contribute 
to the regulation of gene expression by guiding enhancers to their target genes (Andrey and Mundlos, 2017). 
The looping between enhancers and promoters, which can be disrupted by insulators, is a crucial element 
of transcriptional regulation (Figure 5). In turn, methylation of CpG sites in insulators prevents the binding of 
CTCF (Figure 5), which itself exhibits multiple functions including insulator activity and transcriptional control, 
but presumably also the regulation of long range chromatin interactions, as it is enriched at TAD and LAD 
boundaries (Phillips and Corces, 2009; Wutz et al., 2017).  
Together, the mechanisms described above form an intricately balanced network, which is in its extent not 
yet fully understood. The examples outlined in this chapter, however, illustrate the vast complexity of 
epigenetic regulation and transcriptional control.  
 
1.2 Methods for genome-wide transcriptional and epigenetic profiling 
Recently, enormous progress has been made in the mapping of epigenomes, especially by large sequencing 
consortia such as the international human epigenome consortium (IHEC) including the German contribution 
DEEP. This was only feasible by the advent of next generation sequencing (NGS) and the plethora of NGS 
based methods for genome-wide transcriptional and epigenetic profiling that have been published since. 
Although long read sequencing techniques are advancing (Pollard et al., 2018), the currently most popular 
sequencing approach is still sequencing by synthesis of short sequences (Ambardar et al., 2016). It allows 
high-throughput sequencing of 50 to 200 bp reads with very high accuracy. Thus, it is possible to assess 
transcriptomes and several layers of epigenetic modifications for whole tissues or isolated cell populations, 
and some methods can even be scaled to single cell level. Several genome-wide methods relevant for this 





1.2.1 Transcriptome analysis 
Genome-wide transcriptome analysis relies on the reverse transcription of RNA and sequencing of the 
resulting cDNA, as direct sequencing of RNA remains technically challenging (Marinov, 2017). For many 
studies the main interest lies in differential expression analysis of protein coding genes. Thus, the most 
common approach is based on capturing polyadenylated RNA fragments prior to cDNA preparation. If 
sequencing of total RNA is desired, the high level of ribosomal RNA should be taken into account. To this 
end, so called ribo-depletion protocols can be employed which exclude non-informative ribosomal RNA from 
sequencing library preparation (Sooknanan et al., 2010; Zhulidov, 2004).  
 
Figure 6: Smartseq2 workflow for RNA-seq of isolated RNA or single cells (modified after Picelli et al., 2013). After 
single cell isolation respective total RNA isolation, polyadenylated RNA is reverse transcribed using a reverse 
transcriptase which adds a CCC overhang to the first strand 3’ end. This overhang allows the binding of a template 
switch oligonucleotide (TSO), ensuring full-length coverage during second strand synthesis. cDNA is preamplified by 
PCR, purified and controlled for degradation. A typical mammalian cDNA yields mainly fragments around 2 kb. Finally, 
sequencing libraries can be prepared from cDNA using Nextera kits (Illumina). 
To date, many different RNA-seq protocols have been developed. One of the most cited protocols is the 
Smartseq2 protocol (Picelli et al., 2013), which was originally published for single cell mRNA-seq. As it yields 
high quality full length transcriptomes and library preparation is affordable and straightforward, it became 




isolated single cells in a triton based lysis buffer or with purified total RNA. Polyadenylated RNA is reverse 
transcribed using poly-dT primers and a reverse transcriptase that produces a CCC overhang at the 3’ end 
of the first strand. This allows a template switch, ensuring full length transcript coverage in the second strand 
synthesis. cDNA is preamplified, purified, and can be quantified and controlled for degradation on an Agilent 
Bioanalyzer. A typical high quality mammalian cDNA fragment size distribution (Figure 6) shows mainly 
fragments around 2 kb. Tagmentation based library preparation can then be easily achieved by commercially 
available kits such as Illumina’s Nextera kits. After sequencing, reads are aligned to a gene annotated 
reference and transformed to count-based estimations of gene-wise transcription levels. 
 
1.2.2 DNA methylation analysis 
Whole genome bisulfite sequencing (WGBS) is currently considered as the gold standard for genome-wide 
DNA methylation analysis. Bisulfite treatment of DNA results in conversion of unmethylated cytosines into 
uracil, due to sulfonation, followed by hydrolytic deamination and final desulfonation (Frommer et al., 1992). 
In subsequent PCR, uracil is paired with adenine, ultimately leading to an exchange of unmethylated 
cytosine by thymine in the analyzed sequences. In contrast, methylated cytosines are protected from 
conversion because of their methyl-group. Thus, sequencing of bisulfite treated DNA and comparing the 
obtained sequence with the genomic reference sequence allow the efficient detection of methylated CpGs 
at base resolution. 
However, covering the whole genome with sufficient sequencing depth requires high amounts of reads per 
sample, which is immensely increasing costs and limits the number of affordable replicates. Moreover, for 
many projects DNA methylation analysis focuses mainly on potential regulatory regions, representing only 
a small proportion of the genome. Thus, reduced representation bisulfite sequencing (RRBS) can be a 
reasonable alternative. For RRBS genomic DNA is digested using CpG methylation insensitive restriction 
enzymes such as MspI, HaeIII or AluI, that cut at distinct sequence motives accumulated in CpG-rich 
regions. In the subsequent adapter ligation based library preparation (Figure 7) those regions are enriched. 
Consequently, the number of necessary reads per sample is significantly decreased, allowing higher CpG 
coverage and more samples, respective replicates, for a given project.  
The choice of the restriction enzyme decides about the predominantly covered regions. In the human 
genome the classical MspI restriction yields about 1 million CpGs, mostly located in CpG islands (Gu et al., 
2011). If interested in further regulatory regions, HaeIII is also a valid choice. HaeIII RRBS yields roughly 4 
to 5 million CpGs, covering promoter regions but also gene bodies. For even broader coverage a mixture of 
different restriction enzymes is advisable. For example, the combination of HaeIII and AluI yields around 10 
million CpGs covering about 35 % of all CpGs in the human genome. Those CpGs are enriched in regions 
of interest such as promoters, gene bodies and distal regulatory elements. Moreover, the rather broad CpG 
coverage of HaeIII or HaeIII/AluI RRBS allows also more complex analysis such as the assessment of 
partially methylated domains (Salhab et al., 2018). 
Initial RRBS protocols required up to 300 ng of genomic DNA for library preparation (Gu et al., 2011). More 
recent developments allow the downscaling to low amounts of DNA (Schillebeeckx et al., 2013) and even 
to single cell level (Guo et al., 2013). However, single cell RRBS provides rather sparse data, covering 




meaningful biological conclusions. Thus, RRBS of specific, carefully isolated cell populations, for example 
by fluorescence-activated cell sorting or laser capture microdissection, is to date a more reasonable way to 
answer many biological questions. In summary, RRBS represents a versatile method for the comprehensive 
study of genome-wide DNA methylation in many samples. 
 
Figure 7: Reduced Representation Bisulfite Sequencing workflow. Genomic DNA is digested by a CpG methylation 
insensitive restriction enzyme such as HaeIII. After A-tailing, ligation of methylated TruSeq adapters and bisulfite 




1.2.3 Chromatin accessibility analysis 
There are several methods for the genome-wide analysis of chromatin accessibility. DNaseI-seq could be 
considered as the classical method, as it was widely used and is also part of full epigenome analysis, as 
outlined by large epigenome consortia such as ENCODE or IHEC. A more recent method, which is becoming 
increasingly popular, is ATAC-seq, the assay for transposase-accessible chromatin analysis using 
sequencing  (Buenrostro et al., 2013). Intact native chromatin is exposed to a Tn5 transposase pre-loaded 
with adapters compatible with Illumina next generation sequencing. The transposon cuts and simultaneously 
integrates the sequencing adapters into accessible DNA sites (Figure 8). Thus, after gap repair, accessible 





Figure 8: Chromatin accessibility analysis using ATAC-seq (modified after Buenrostro et al., 2013). Isolated nuclei are 
treated with the Nextera Tn5 transposase (Illumina), which simultaneously fragments and inserts Nextera sequencing 
adapters into the DNA of accessible chromatin regions. After gap repair, DNA fragments with adapters at 3’ and 5’ ends 
are enriched by PCR. The purified sequencing library yields a characteristic fragment size pattern that recapitulates 
nucleosome phasing. 
ATAC-seq offers a fast, straightforward workflow and, in contrast to DNaseI-seq, which requires enzyme 
titration, transposon concentrations are largely cell-type independent (Buenrostro et al., 2013). An important 
possible pitfall is, however, the isolation of clean nuclei with intact chromatin, which can be challenging from 
certain cell-types or tissues. Nuclei that are still attached to cytoplasm often result in an extensive number 
of reads mapping to the mitochondrial genome, as the transposon preferentially tagments the free 
mitochondrial DNA (Corces et al., 2017). Since this increases sequencing costs to obtain sufficient genomic 
coverage, nuclei should be as clean as possible. Relating to chromatin integrity, especially frozen samples 
represent a major challenge. Degraded chromatin leads to noisy data that are hard to interpret. In some 
cases this can be overcome by specialized protocols including a very gentle nuclei preparation (Corces et 
al., 2017). Thus, the proper establishment of nuclei isolation is of utmost importance when starting a new 
project (Kattler, Master thesis, 2015).  
Additionally, ATAC-seq can also be applied on single cells (Buenrostro et al., 2015; Cusanovich et al., 2015). 
However, single cell ATAC-seq yields extremely sparse data and due to the enrichment based nature of this 
method, the pure absence of a signal is not conclusive. Thus, the comprehensive analysis of single cell 
chromatin accessibility data represents an enormous bioinformatical challenge, which is currently mostly 




1.3 Liver and metabolic diseases 
1.3.1 Metabolic liver zonation 
Being the largest internal organ, the mammalian liver exhibits a multitude of essential biological functions 
including regulation of glucose metabolism, bile acid synthesis, fatty acid metabolism and detoxification. 
Some liver functions, such as gluconeogenesis and glycolysis, are contradictory to each other, which implies 
that specialized sets of hepatocytes might be involved in the respective processes to ensure their efficiency. 
The liver consists of four lobes, which are further structured into hexagonal-like hepatic lobules (Figure 9 A). 
At the borders of each lobule reside the portal triades (Figure 9 B), while the central vein is localized in the 
lobule’s center (Birchmeier, 2016; Rappaport, 1977). The portal triade comprises hepatic artery, portal vein 
and bile ducts. Oxygen-rich blood flows from the portal triad through the sinusoid capillaries towards the 
central vein, thereby creating a porto-central oxygen gradient (Kietzmann, 2017).  
In human, hepatocytes – the parenchymal liver cells – sit in rows of 15 to 25 cells (McEnerney et al., 2017) 
along the porto-central axis. Besides hepatocytes, liver tissue consists of a diverse set of non-parenchymal 
cells (NPCs, Figure 9 B). Cholangiocytes are specialized epithelial cells that frame the bile ducts and modify 
bile acids produced by hepatocytes (Tabibian et al., 2013). Discontinuous endothelial cells form the 
sinusoids between portal field and central vein, which harbor liver-resident macrophages, called Kupffer 
cells (Naito et al., 1997). More recently, several populations of innate lymphocytes such as liver resident NK 
cells (Peng and Sun, 2017) have been reported as well. Hepatic stellate cells reside in the space of Disse, 
which is located between sinusoids and hepatocytes. Apparently, they remain in a quiescent state during 
normal liver homeostasis, but, for instance, play a major role in extracellular matrix deposition during hepatic 
fibrosis (Eng and Friedman, 2000) as well as in the regulation of liver immunology (Weiskirchen and Tacke, 
2014). 
Although morphologically similar, hepatocytes are heterogeneous in respect to their metabolic enzymatic 
activity (Figure 9 B), depending on their localization within the hepatic lobule – a long known phenomenon 
termed as metabolic zonation (Jungermann and Sasse, 1978). Although metabolic pathways are subject to 
dynamic changes, due to blood contained factors including nutrients and hormonal stimuli, general gene 
expression profiles along the porto-central axis can be considered as rather stable zonation patterns 
(Gebhardt, 2014). During recent years, it was shown in multiple rodent studies that zonation is maintained 
by short-distanced morphogen gradients. In particular, pericentral Wnt-/β-catenin signaling, which is 
apparently established by the central vein’s endothelial cells (Preziosi et al., 2018), represents a master 
regulator of metabolic zonation profiles (Gebhardt, 2014). Moreover, the involvement of further signaling 
pathways such as fibroblast growth factor (FGF), transforming growth factor (TGF) beta, hepatocyte growth 
factor (HGF), Hedgehog and Notch signaling has been described (Gebhardt, 2014), indicating a complex 
crosstalk between different morphogen gradients. In addition, the porto-central oxygen gradient, which 
correlates with the number of mitochondria and oxidative properties, might exhibit modulatory functions, for 






Figure 9: Metabolic liver zonation. A – The mammalian liver consists of hexagonal hepatic lobules with a central vein 
and peripheral portal triades, consisting out of bile ductile, portal vein and hepatic artery. B – Oxygen-rich blood flows 
from the portal vein through sinusoids towards the central vein. The resulting oxygen gradient along the porto-central 
axis is accompanied by gradients of metabolic functions, such as periportal gluconeogenesis or pericentral glycolysis. 
This so called metabolic zonation is maintained by gradients of Wnt signaling pathway members (Birchmeier, 2016, 
modified). 
In human liver, the zonation of metabolic enzymes, including alcohol dehydrogenase (Sokal et al., 1993), 
fatty acid binding protein (Suzuki and Ono, 1987), glucose-6-phosphatase (Racine-Samson et al., 1996), 
glutamine synthetase (Racine-Samson et al., 1996) and several members of the cytochrome P450 family 
(Palmer et al., 1992; Sano et al., 1989) was already demonstrated by immunohistochemical stainings and 
activity measurements more than 20 years ago. Moreover, a study using laser capture microdissection 
coupled to RNA sequencing of normal liver from 3 human donors reported 139 transcripts with differential 
expression across the hepatic lobule (McEnerney et al., 2017), indicating an upregulation of Wnt signaling 
in pericentral hepatocytes as reported in mouse (Wang et al., 2015). These findings were recently 
supplemented by profiling of the human liver transcriptome on single cell level (MacParland et al., 2018). 
However, this study focused mostly on the classification of non-parenchymal cells, particularly revealing 
distinct macrophage subpopulations, and did not include a spatial reconstruction of hepatocytes along the 
porto-central axis, as was previously done in mouse by coupling scRNA-seq with single molecule 




more sophisticated studies are necessary to obtain a deeper understanding of principles of zonated 
morphogenic and metabolic control in human liver, both in normal homeostasis as well as during the 
development of complex metabolic liver diseases. 
 
1.3.2 Liver development 
The understanding of liver development during embryogenesis is crucial for the proper interpretation of 
experimental findings regarding hepatic regeneration in normal and diseased liver as well as in context of in 
vitro differentiation of hepatocyte-like cells. Generally, it is characterized by a complex interplay of a spatially 
distinct and sequentially orchestrated set of signaling pathways such as Notch, Wnt, FGF, and BMP 
signaling, which regulate a cascade of stage-specific transcription factors determining cell fate. 
In brief, hepatocytes, but also cholangiocytes, derive from endoderm, the inner germ layer of the early 
embryo. Definitive endoderm (DE), which in human develops from bipotential mesendodermal cells during 
the third week of gestation, is further segregated along the anterior-posterior axis by spatially distinct 
signaling from adjacent mesoderm (Gordillo et al., 2015). For instance, the posterior region of the gut is 
exposed to FGF4 and Wnt signaling, which results in an endodermal subpopulation expressing CDX2 that 
promotes the formation of the gastrointestinal tract (Stringer et al., 2012). Contrary, Wnt signaling is inhibited 
by secreted Sfrp5 in the ventral forgut endoderm, which thus gives rise to a population of bipotent hepato-
pancreatic progenitors (Russell and Monga, 2018). Bone morphogenic protein (BMP), which is inhibits the 
Notch signaling pathway, and low levels of fibroblast growth factor (FGF) signaling from cardiac mesoderm 
are essential for commitment to hepatic cell fate (Gordillo et al., 2015). The Wnt signaling pathway was also 
implied to have major impact on hepato-pancreatic cell fate specification (Rodriguez-Seguel et al., 2013). 
Resulting fetal hepatoblasts, expressing albumin (ALB) and α-fetoprotein (AFP), form the liver bud, which 
additionally contains endothelial cells, developing stellate cells and, as the fetal liver constitutes a transitional 
site of hematopoiesis until 11th week of human gestation (Tavian and Péault, 2005), also hematopoietic 
progenitors. Hepatoblasts, which have the potential to differentiate into hepatocytes or cholangiocytes, are 
kept in a proliferative stage by TBX3 expression (Suzuki et al., 2008). Moreover, β-catenin, a key factor of 
the Wnt signaling pathway, is also involved in hepatoblast proliferation and maturation (Tan et al., 2008). A 
major regulator of the hepatoblast cell fate decision is the Notch signaling pathway. Notch2-mediated 
signaling, resulting in SOX9 expression, is crucial for cholangiocyte differentiation (Zong et al., 2009), while, 
interestingly, Notch3 was reported to be involved in hepatocyte lineage decision (Ortica et al., 2014). 
However, detailed mechanisms of human hepatocyte differentiation are not fully understood (Russell and 
Monga, 2018). In summary, this underlines the complex spatiotemporal patterns of different signaling 
pathways during liver organogenesis. 
 
1.3.3 Hepatic regeneration  
The mammalian liver exhibits an outstanding regeneration capacity. For example, following partial 
hepatectomy of two thirds of tissue in rodent models, full original liver mass and function can be restored 




hepatocytes is actually in replication (Macdonald, 1961). Over the years, the question regarding the origin 
of hepatic regeneration has been discussed controversially, and several mechanisms have been proposed. 
The intense proliferation of periportal biliary ductal cells upon severe liver injury, which is referred to as oval 
cell response, has been studied extensively in different rodent models (Lemire et al., 1991; Petersen et al., 
1998; Sell et al., 1981) and was also reported in human (Roskams et al., 1998). Oval cells are atypical ductal 
cells expressing Epcam or Sox9, both proposed as liver progenitor markers (Dan et al., 2006; Furuyama et 
al., 2011), and have been considered as bipotent facultative progenitors that have the potential to 
differentiate into both hepatocytes and cholangiocytes (Kordes and Häussinger, 2013). However, several 
more recent mouse lineage tracing experiments reported that oval cells do not act as hepatocyte progenitors 
in common mouse models of chronic liver injury (Schaub et al., 2014; Tarlow et al., 2014). Thus, the oval 
cell response is now considered as an alternative regenerative mechanism in cases when all hepatocytes 
are chronically affected, for instance by toxins or viruses (Raven et al., 2017). Indeed, these studies also 
indicate mature hepatocytes as the predominant source of hepatic regeneration in chronic liver disease. 
Interestingly, the turn-over rate of mouse hepatocytes under normal conditions is rather low, and the 
replacement of the whole parenchyma takes about 1 year (Alison and Lin, 2011). Thus, the injury-induced 
massive proliferation of hepatocytes entails a coordinated cell-cycle entry of the remaining hepatocyte 
population (Corlu and Loyer, 2012). Earlier studies also refute a periportal to pericentral – or vice versa - 
hepatocyte streaming (Bralet et al., 1994; Kennedy et al., 1995), substantiating the hypothesis of stem cell 
activity independent hepatocyte self-renewal capacity.  
Still, substantial evidence for the existence of stem cell niches in the adult mammalian liver has been 
gathered (Kordes and Häussinger, 2013). Recent publications actually suggest two different types of hepatic 
stem cell niches with specific functionality. A lineage tracing experiment, using Wnt-responsive Axin2 
positive cells, in normal mouse liver revealed a subpopulation of diploid cells near the central vein expressing 
the early liver progenitor marker TBX3. These cells apparently feature a Wnt-signaling regulated self-
renewal capacity in homeostatic liver and differentiate into polyploid mature hepatocytes (Wang et al., 2015). 
Wnt signaling itself is probably maintained by endothelial cells of the central vein (Preziosi et al., 2018). In 
contrast, lineage tracing using cholangiocyte-enriched SOX9 identified a periportal hepatocyte 
subpopulation, apparently regulated by Notch signaling (Köhler et al., 2004), that starts extensive 
proliferation upon mild chronic liver injury and apparently has the potential to restore the entire liver 
parenchyma (Font-Burgada et al., 2015). Moreover, lineage tracing, using Mfsd2a as periportal zonation 
marker, showed that periportal hepatocytes do not contribute to normal adult liver homeostasis, but expand 
and replace pericentral hepatocytes during liver injury. Intriguingly, after recovery these periportal-like cells 
around the central vein can restore their pericentral metabolic functions, while remaining Mfsd2a positive 
(Pu et al., 2016). Taken together, these findings suggest – at least in the rodent models – a pericentral Wnt 
signaling controlled hepatic stem cell niche which is responsible for homeostatic self-renewal, as well as a 
periportal Notch regulated source of regeneration upon liver damage. While Wnt signaling has also been 
implied in human liver homeostasis (McEnerney et al., 2017), the situation in human hepatocyte 





1.3.4 Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is often referred to as a hepatic manifestation of the metabolic 
syndrome (Kim and Younossi, 2008). Major risk factors for the development of NAFLD are obesity and in its 
wake also type 2 diabetes mellitus (T2DM), and the combination of NAFLD and T2DM correlates with a poor 
prognosis (Cernea et al., 2017). Pathological overweight is generally defined as a body mass index (BMI) 
of more than 25, obesity of more than 30. The most fundamental cause of increasing body weight is a 
misbalance between calorie uptake and consumption, thus obesity correlates with a sedentary lifestyle as 
well as the calorie-rich western diet. The prevalence of obesity is increasing, not only in western countries, 
and was recently described by the World Health Organization as an “escalating global epidemic” (WHO, 
2018), as it is also considered as major risk factor for cardiovascular diseases and certain types of cancer. 
Of major concern is also the rapid increase of obesity, with all its implications, in children during recent years 
(Abarca-Gómez et al., 2017).  
The onset of NAFLD is defined as a liver steatosis (Figure 10), marked by the accumulation of fatty acids in 
lipid droplets in at least 5 % of hepatocytes (Benedict and Zhang, 2017). Bland steatosis without any 
inflammation is largely asymptomatic. However, in some cases it can progress to steatohepatitis (NASH), 
which is characterized by a pronounced infiltration of hepatic tissue with immune cells, particularly 
monocytes, granulocytes and innate lymphocytes (Narayanan et al., 2016). An additional hallmark of NASH 
is the so called hepatocyte ballooning, which denotes the appearance of enlarged, lipid droplet enriched 
hepatocytes that also feature cytoskeletal rearrangements and dilation of the endoplasmatic reticulum 
(Caldwell et al., 2010). Up to this stage, NAFLD has still the potential to fully recover to normal liver 
morphology and function, although elevated levels of certain liver enzymes, such as alanine transaminase, 
are already detectable, indicating a beginning impairment of liver functions (Cohen et al., 2011). Persistent 
inflammation in late NASH stages can then lead to deposition of excess extracellular matrix, forming fibrotic 
scar tissue. A widespread fibrosis, referred to as state 4 fibrosis, impacts and alters the normal liver 
morphology, resulting in a remodeled hepatic lobule architecture and vascularization. This 
pathophysiological alterations can lead to liver cirrhosis, which represents a severe condition, characterized 
by portal hypertension, that can eventually lead to liver failure (Schuppan and Afdhal, 2008). It is also 
frequently seen as a precondition for the development of hepatocellular carcinoma (Ramakrishna et al., 
2013). The only curative therapy of late cirrhotic stages is liver transplantation (Pais et al., 2016). Although 
several drugs are under consideration, to date, there is no approved pharmacological treatment of NAFLD 
available (Cernea et al., 2017). Indeed, the progression to cirrhotic stages can often be prevented by careful 
lifestyle adjustment and weight reduction. In severe cases with morbid obesity and T2DM, entailing a poor 
prognosis, bariatric surgery can markedly improve insulin resistance as well as liver histology (von Schönfels 





Figure 10: Histology of Non-Alcoholic Fatty Liver Disease progression (Cohen et al., 2011). Steatosis can develop from 
normal liver by accumulation of triglycerides in hepatocytes as lipid droplets (white) starting around the central vein. A 
bland steatosis can progress to steatohepatitis (NASH), which is characterized by invasion of inflammatory infiltrate, 
and further to cirrhosis with pronounced inflammation and fibrosis throughout the whole hepatic lobule. Collagen fibers 
are colored in light blue (Masson’s trichrome staining). 
Interestingly, although obesity is clearly associated with NAFLD, there are also obese donors that show  
normal liver histology and have no indication for fatty acid accumulation in hepatocytes (Machado et al., 
2006). Moreover, there are also lean patients that develop NAFLD. Although having a normal BMI, they 
show metabolic profiles comparable to those of obese patients (Kumar and Mohan, 2017). Insulin resistance 
is however reduced in lean NAFLD patients, suggesting a different pathophysiological disease development 




stimulate de novo lipogenesis, as well as genetic factors have been suggested as potential risk factors for 
non-obese NAFLD, but underlying mechanisms are not well understood (Kim and Kim, 2017). 
In human adults, the onset of non-alcoholic steatosis is mostly restricted to pericentral hepatocytes (Figure 
10, Cohen et al., 2011). In more progressed disease stages the accumulation of lipid droplets can spread 
throughout the whole hepatic lobule. Furthermore, the deposition of fibrotic tissue also starts around the 
central vein (Brunt et al., 1999). These observations argue for the zone-specific analysis of the development 
and progression of NAFLD. Remarkably, well established mouse models for steatosis or steatohepatitis 
feature differences regarding the zonal onset of fatty acid accumulation. While, for instance, in the leptin-
deficient ob/ob mouse lipid droplet accumulation starts in pericentral hepatocytes (Stacchiotti et al., 2016), 
the methionine/choline-deficient model is characterized by a periportal steatosis (Koteish and Diehl, 2001). 
Moreover, both widely used models apparently do not reflect the human NAFLD phenotype in a sufficient 
manner (Anstee and Goldin, 2006). There is also little overlap comparing differential gene expression during 
NAFLD progression in human and different mouse models (Teufel et al., 2016). Thus, regarding their 
application to human NAFLD development, findings derived from mouse studies should be considered with 
care. 
In contrast to NAFLD, alcoholic liver disease (ALD), which is the most prevalent type of chronic liver disease, 
is caused by excessive alcohol consumption for 1 to 5 years or more. Still, the development of ALD depends 
on many additional factors, including not only dose and duration of alcohol consumption, but also the type 
of alcohol, drinking patterns as well as further risk factors such as obesity or iron overload (Osna et al., 
2017). Beyond further metabolic effects, permanent ethanol uptake apparently stimulates lipogenesis, 
resulting in fatty acid accumulation in hepatocytes (Osna et al., 2017). Thus, the spectrum of ALD resembles 
the progression of NAFLD from steatosis to steatohepatitis, fibrosis, cirrhosis and finally the potential to 
develop hepatocellular carcinoma, suggesting similarities in pathogenic features (Rowell and Anstee, 2015).  
 
1.4 in vitro differentiation of hepatocyte-like cells 
One of the liver’s plethora of functions is the metabolism of xenobiotics including drugs, toxins and alcohol. 
Adverse drug effects are a main cause of hepatoxicity, which can lead to liver injury and eventually liver 
failure. Thus, for the development of new drugs it is of utmost importance to test effects on the human liver 
prior to clinical studies with human cohorts. Animal experiments for pharmacological drug assessment are 
still a compulsory part of clinical studies, but have been criticized for years, as rodents, but also larger 
mammals, do not reflect the human drug metabolism in a conclusive way (Akhtar, 2015; van Meer et al., 
2012). A promising road towards animal-free drug assessment is the use of in vitro cultured human 
hepatocytes. To date, there are different alternatives for in vitro culturing systems aiming to resemble human 
liver detoxification.  
The current gold standard for toxicological tests and pharmacological screenings are primary human 
hepatocytes (PHH), which can be maintained in spheroid culture for up to 5 weeks (Bell et al., 2016). In 
conventional cell culture PHH loose many hepatocyte related functions during hours, while sandwich 




al., 2018). However, their limited availability and inter-individual differences emphasize the need for the 
establishment of more reliable and versatile in vitro systems. 
Immortalized cell lines such as the well described hepatocyte-like HepG2 (Sassa et al., 1987) or HepaRG 
(Guillouzo et al., 2007) lines are readily available, can be maintained in culture over long periods at relatively 
low costs, and particularly HepaRG cells express many hepatocyte specific genes at levels comparable to 
PHH (Hart et al., 2010). Although, after induction with hepatotoxic drugs such as phenobarbital or rifampicin, 
fully differentiated HepaRG cells exhibit CYP activity comparable to PHH, both HepG2 and HepaRG show 
low predictivity for hepatoxicity assessment of drugs (Gerets et al., 2012). Thus, these cell lines can certainly 
be used to gain insight into intriguing questions of fundamental research, but do not represent an ideal tool 
for pharmacological or toxicological studies. 
 
Figure 11: Immunohistological stainings reveal drastic differences within HLC subpopulations as well as in comparison 
with primary human hepatocytes (PHH). HLCs and PHH were stained for colon-specific marker CDX2 (upper panel) 
and hepatocyte marker albumin (ALB, lower panel). Nuclei were stained with DAPI (blue) and cellular membranes with 
an antibody against the membrane-localized progesterone receptor (PR, red). Immunohistological stainings (10 x 
magnification) were provided by Dr. Patricio Godoy and Patrick Nell (IfADo). 
A promising alternative is the in vitro differentiation of induced pluripotent stem cells (iPSCs) to hepatocyte-
like cells (HLCs) that should resemble expression profiles of PHH. To this end, differentiation protocols 
based on various combinations of extracellular matrix components with exogenous factors such as 
cytokines, growth factors and small biologically active molecules have been established. Generally, human 
iPSCs are differentiated to definitive endoderm (DE) and then further to hepatoblasts and HLCs. However, 
HLCs generated by different protocols show variable degrees of final differentiation (Godoy et al., 2015). 
Standardized commercially available solutions such as the Cellartis iPS Cell to Hepatocyte Differentiation 
System (Takara Bio, Goteborg, Sweden), further on referred to as CEL protocol, might offer more reliable 
in vitro systems. A more cost efficient alternative might also be a detailed protocol, recently published by the 
group of David Hay, thus further on referred to as HAY protocol, describing a robust iPSC to HLC 




culture these cells were reported to exhibit a stable liver-like phenotype for more than one year and even to 
support compromised liver function in animal models (Rashidi et al., 2018), thus representing a promising 
in vitro system for human liver.  
Yet, gene expression profiles deviate severely from those of PHH (Bell et al., 2017; Godoy et al., 2018). 
Indeed, single cell RNA sequencing of 2D and 3D differentiated HLCs rather implies a fetal hepatoblast-like 
phenotype of HLCs (Camp et al., 2017). Moreover, a previous analysis of gene regulatory networks identified 
mixed HLC populations, particularly of liver, intestine, fibroblast and stem cell character (Godoy et al., 2015). 
This becomes also apparent in immunohistochemical stainings for certain marker genes. For instance, 
hepatocyte-marker albumin (Alb), which is highly expressed in PHH, is only detected in a subset of HLCs, 
while colon-specific marker CDX2 is highly abundant in most HLCs (Figure 11, kindly provided by Dr. Patricio 
Godoy and Patrick Nell, IfADo). Taken together, these findings highlight the need for further optimization of 
HLC culturing conditions towards a more homogenous PHH-like phenotype. 
Besides their potential for general in vitro assessment of hepatoxicity and liver disease modelling, iPSC 
based HLC systems show promise for personalized medicine (Figure 12). In principle, iPSCs can be 
generated from any somatic cell-type. Thus, patient-specific HLCs could be cultivated for individual drug 
screenings to identify the most promising treatment with reduced adverse effects, as was already 
successfully described for familial hypercholesterolemia (Cayo et al., 2017). 
 
Figure 12: Applications for in vitro differentiated hepatocyte-like cells (HLCs). Somatic cells from human donors can be 
reprogrammed into induced pluripotent stem cells (iPSCs), which can then be re-differentiated into HLCs. 
In addition, there are also advances towards tissue engineering (Figure 12). However, the liver is a complex 
organ with a plentitude of cell-types and structures. Thus, in vitro engineering of liver tissue would require 
extensive co-culturing of different cell-types. A further challenge would be the establishment of known 
oxygen and morphogen gradients that play important roles in the regulation of hepatocyte functions (chapter 
1.3.1). Still, there are already intriguing approaches. For example, 3D HLC bioprinting, which refers to the 




components, resulted in metabolically active cells. However, especially the construction of tissue 
microenvironment and the integration of different cell-types remain major challenges. Thus, it is a long road 
towards functional liver tissue engineering and the usage of HLC systems for personalized drug screenings 




This thesis focuses on the transcriptional and epigenetic characterization of human hepatocyte 
subpopulations in health and complex metabolic diseases as well as during in vitro differentiation of 
hepatocyte-like cells, and is based on the generation, analysis and integration of genome-wide sequencing 
data. Depending on their spatial location within the hepatic lobule, hepatocytes show remarkable metabolic 
heterogeneity. In rodents, this phenomenon, termed metabolic zonation, is regulated by interacting 
morphogen gradients that result in the establishment of gene expression gradients along the porto-central 
hepatic axis. Interestingly, the same morphogens were also implied to have major impact on hepatic 
regeneration during normal liver homeostasis and chronic liver disease. Particularly in human, the underlying 
regulatory mechanisms are not well understood. Thus, a major focus of this thesis, in close cooperation with 
the group of Prof. Dr. Jochen Hampe (TU Dresden), is the characterization of NGS based, zone-specific 
transcriptome and DNA methylome profiles of human hepatocytes from 3 hepatic zones captured by laser 
microdissection (LCM). This genome-wide dataset (3.1.1) comprises healthy human liver as well as the early 
spectrum of NAFLD and provides the first integrated spatial epigenomic map of the human liver, which can 
be queried regarding multiple fundamental questions of human liver biology including regulation of metabolic 
zonation and hepatic regeneration. Moreover, the onset of several metabolic liver diseases such as NAFLD 
or ALD is characterized by the accumulation of lipid droplets in a zone-dependent fashion. This observation 
strongly suggests the zone-specific analysis of fatty liver disease progression. To this end, the human cohort 
is extended to patients with more progressed steatohepatitis and severe fibrosis to elucidate the role of 
hepatic zonation in NAFLD progression, and also includes samples from cirrhotic livers with an alcoholic 
background representing the end-stage of fatty liver disease. The unique experimental set-up of a 
pathologically well defined human cohort in combination with sophisticated LCM coupled to NGS based 
genome-wide transcriptome and DNA methylome analysis of small numbers of isolated cells allows the first 
spatially resolved analysis of fatty liver disease progression (3.1.2). 
While single cell RNA sequencing is becoming more and more prominent, a major drawback is the loss of 
spatial tissue context. Still, as several studies imply gradient-like expression patterns in liver, single cell 
resolution, which is not feasible using standard LCM approaches, would contribute to a better understanding 
of many crucial questions. There are already promising bioinformatical advances regarding the modelling of 
single cell data into pseudotime. The same principles could be applied for spatial tissue reconstruction and 
might be further improved by the integration of spatial expression reference maps. Hence, the second part 
of this thesis demonstrates the spatial reconstruction of a single hepatocyte transcriptome dataset generated 
from human liver by making use of the reference maps described in chapter 3.1.1, and aims to identify 




Besides the elucidation of regulatory mechanisms of general liver biology in health and disease, the in vitro 
differentiation of hepatocyte-like cells, which are not only valuable tools for hepatoxicity assessment and 
disease modelling, but might one day become reliable tools for treatment of chronic liver diseases, is of 
major interest. Although during recent years considerable progress regarding the establishment of HLC 
culture systems has been made, there is still room for improvement. Previous studies mainly focus on gene 
expression analysis to characterize the HLC differentiation process and resulting phenotypes. Hepatic 
differentiation is a complex process, regulated by interacting signaling pathways and stage-specific 
cascades of transcription factors. Yet, the impact of epigenetic mechanisms remains largely elusive. So, the 
final part of this thesis deals with the integration of gene expression data with DNA methylation and 
chromatin accessibility data, with particular emphasis on distinct HLC subpopulations detected by single cell 
RNA-seq. This approach might lead to the identification of additional factors that could be modulated in order 





















2. Material and Methods 
2.1 Material 
2.1.1 Chemicals and reagents 
Component Company 
1, 4-Dithiothreit (DTT)  Carl Roth (Karlsruhe, Germany) 
AG 501-X8 resin  Bio-Rad Laboratories(Hercules, USA) 
Agencourt Ampure XP Beads  Beckman Coulter (Krefeld, Germany) 
ATP New England Biolabs (Frankfurt, Germany) 
Betaine Sigma-Aldrich (Taufkirchen, Germany) 
Biozym LE Agarose Biozym Scientific (Hessisch Oldendorf, Germany) 
Boric acid Carl Roth (Karlsruhe, Germany) 
Bromphenolblue Sigma-Aldrich (Taufkirchen, Germany) 
CaCl2*H2O Sigma-Aldrich (Taufkirchen, Germany) 
Chloroform VWR International(Darmstadt, Germany) 
Complete Protease Inhibitor Cocktail Tablets Roche Diagnostics (Mannheim, Germany) 
dATP Solis BioDyne (Tartu, Estonia) 
Desoxyribonucleotids (dNTPs)  Solis BioDyne (Tartu, Estonia) 
Dimethylformamide Sigma-Aldrich (Taufkirchen, Germany) 
EDTA Sigma-Aldrich (Taufkirchen, Germany) 
EGTA Sigma-Aldrich (Taufkirchen, Germany) 
Ethidiumbromide Carl Roth (Karlsruhe, Deutschland) 
EtOH (absolute)  Sigma-Aldrich (Taufkirchen, Germany) 
Fetal bovine serum (FBS) Sigma-Aldrich (Taufkirchen, Germany) 
Glucose Sigma-Aldrich (Taufkirchen, Germany) 
Glutamine Sigma-Aldrich (Taufkirchen, Germany) 
Glycogen VWR International (Darmstadt, Germany) 
HEPES ThermoSientific (Darmstadt, Germany) 
Isoamylalcohol VWR International (Darmstadt, Germany) 
K2HPO4  Merck (Darmstadt, Germany) 
KCl Merck (Darmstadt, Germany) 
MEM Non-Essential Amino Acids Solution ThermoSientific (Darmstadt, Germany) 
MgCl2  Solis BioDyne (Tartu, Estonia) 
Na2HPO4  Merck (Darmstadt, Germany) 
NaCl VWR International (Darmstadt, Germany) 
NaOAc Merck (Darmstadt, Germany) 
Nonident P-40 Carl Roth (Karlsruhe, Germany) 
nuclease-free water Qiagen (Hilden, Germany) 
PIPES VWR International (Darmstadt, Germany) 
Poly(vinylpyrrolidinone) Sigma-Aldrich (Taufkirchen, Germany) 
RNasIn (40 U / µl) Promega (Fitchburg, USA) 
Saccharose Sigma-Aldrich (Taufkirchen, Germany) 




Spermidine (free base)  MP Biomedicals(Santa Ana, USA) 
Sodium butyrate Sigma-Aldrich (Taufkirchen, Germany) 
Tris-HCl Carl Roth (Karlsruhe, Deutschland) 
Triton VWR International (Darmstadt, Germany) 
Ultrapure Phenol : Chloroform : Isoamylalcohol Invitrogen(Karlsruhe, Germany) 
Xylencyanol Sigma-Aldrich (Taufkirchen, Germany) 
 
 
2.1.2 Buffers and Solutions 
Buffer / Solution Composition 
1X TE (pH 8.0) 10 mM Tris-HCl 
  1 mM EDTA 
    
2X TD buffer 20 mM Tris-HCl 
 10 mM MgCl2 
 20 % Dimethylformamide 
    
5X TBE 890 mM Tris 
  20 mM EDTA 
  890 mM boric acid 
    
10X CutSmart Buffer  New England Biolabs (Frankfurt, Germany) 
    
10X PBS (pH 7.4) 43 mM Na2HPO4  
  14 mM K2HPO4  
  1.37 M NaCl  
  27 mM KCl  
    
Chloroform-Isoamylalcohol 24 x Chloroform 
  1 x Isoamylalcohol 
    
Dissociation Buffer 1 29 mM Glucose 
 10 mM NaCl 
 1.8 mM KCl 
 0.9 mM KH2PO4 (pH 7.4) 
 24 mM HEPES (pH 8.5) 
 14 % MEM Non-Essential Amino Acids Solution  
 4.5 mM Glutamine 
 0.5 mM EGTA (pH 7.6) 
  
Dissociation Buffer 2 31 mM Glucose 
 12 % MEM Non-Essential Amino Acids Solution 
 2.4 mM Glutamine 
 100 mM NaCl 
 2 mM KCl 




 25 mM HEPES (pH 8.5) 
 5 mM CaCl2*H2O 
  
ChIP lysis buffer 5 mM PIPES (pH 8) 
  85 mM KCL 
  10 mM sodium butyrate 
 0.5 % Nonident P-40 
  
DNA extraction B 10 mM EDTA 
  10 mM Tris-HCl (pH 8.0) 
  1 % SDS 
    
Gel loading dye 40 % Saccharose 
  0.05 % Bromphenolblue 
  0.05 % Xylencyanol 
    
Elution Buffer Qiagen (Hilden, Germany) 
    
Permeabilization Buffer A (pH 8.0) 60 mM KCl 
  15 mM Tris-HCl 
  15 mM NaCl 
  1 mM EDTA 
  0.5 mM EGTA 
  0.5 mM Spermidine (free base) 
  1 x PIC (Protease Inhibitor Cocktail Tablets) 
  
Qiagen PCR Buffer  Qiagen (Hilden, Germany) 
    
RRBS Lysis Buffer (pH 8.0) 10 mM Tris-HCl 
  5 mM EDTA 
    
Smartseq2 Lysis Buffer 25 µl RNasin (40 U / µl, Promega) 
 470 µl 0.2 % (v/v) Triton X-100 




Enzyme Cat.Number Company 
AluI (10 U/µl) R0137S New England Biolabs (Frankfurt, Germany) 
Lyophilized Collagenase Type 1 C2674-1G Sigma-Aldrich (Taufkirchen, Germany) 
HaeIII (50 U/µl) R0108T New England Biolabs (Frankfurt, Germany) 
HotStar Taq DNA Polymerase (5 U/µl) 203203 Qiagen (Hilden, Germany) 
Klenow Fragment (3`→5` exo-, 5 U/μl)  M0212S New England Biolabs (Frankfurt, Germany) 
Nextera Tn5 Transposase FC-121-1030 Illumina(San Diego, USA) 
Proteinase K 19133 Qiagen (Hilden, Germany) 




RNase-free DNase 79254 Qiagen (Hilden, Germany) 
Superscript II RT (200 U/µl) 18064071 Invitrogen(Karlsruhe, Germany) 
T4 DNA Ligase (2,000 U/µl) M0202T New England Biolabs (Frankfurt, Germany) 
 
2.1.4 Reaction kits  
Reaction Kit Name Cat. number Company 
Agilent High Sensitivity DNA Kit 5067-4626 Agilent Technologies (Santa Clara, USA) 
Direct-zol RNA MiniPrep Plus R2070 Zymo Research(Irvine, USA) 
ERCC RNA Spike-In Mix 4456740 Invitrogen(Karlsruhe, Germany) 
EZ DNA Methylation-Gold Kit D5006 Zymo Research(Irvine, USA) 
KAPA HiFi HotStart ReadyMix PCR Kit KK2602 Roche(Basel, Switzerland) 
MinElute PCR Purification Kit 28006 Qiagen (Hilden, Germany) 
NEBNext® High-Fidelity 2X PCR Master Mix M0541L New England Biolabs (Frankfurt, Germany) 
Nextera DNA Library Prep Kit FC-121-1030 Illumina(San Diego, USA) 
Nextera XT DNA Library Preparation Kit FC-131-1096 Illumina(San Diego, USA) 
Nextera XT Index Kit  FC-131-1002 Illumina(San Diego, USA) 
Nextera XT Index Kit v2 Set D FC-131-2004 Illumina(San Diego, USA) 
PerfeCTa® NGS Quantification Kit 733-2300 Quanta Biosiences(Gaithersburg, USA) 
Qubit® dsDNA HS Assay Kit Q32854 Invitrogen(Karlsruhe, Germany) 
TruSeq DNA Single Index Set A 20015960 Illumina(San Diego, USA) 
TruSeq DNA Single Index Set B 20015961 Illumina(San Diego, USA) 
TruSeq Dual Index Sequencing Primer PE FC-121-1003 Illumina(San Diego, USA) 
TruSeq PE Cluster Kit v3-cBot-HS  PE-401-3001 Illumina(San Diego, USA) 
TruSeq SBS Kit v3 - HS (200 Cycles) FC-401-3001 Illumina(San Diego, USA) 
TruSeq SR Cluster Kit v3-cBot-HS  GD-401-3001 Illumina(San Diego, USA) 
 
2.1.5 Oligonucleotides 
RP-HPLC purified and lyophilisated oligonucleotides (Table 1) were obtained from biomers.net GmbH (Ulm, 
Germany) with exception of the TSO which ordered from Eurogentec Proteomics (Cologne, Germany).  
Table 1: Oligonucleotide sequences (B = 5’ biotin, 7 = LNA g, 9 = RNA-G, V = A/C/G, N = any base, i5 and i7 = 8 index 
read bases as described in the Nextera xt index kit (Illumina)). 
Name Sequence [5' → 3'] 
Oligo-dT primer AAGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN 
TSO B-AAGCAGTGGTATCAACGCAGAGTACAT997 
IS PCR primer AAGCAGTGGTATCAACGCAGAGT 
V1 short TruSeq adapter 1 TCTTTCCCTACACGACGCTCTTCCGATCT 
V1 short TruSeq adapter 2 GATCGGAAGAGCAC ACGTCTGAACTCCAGTCAC 
V1 indexed TruSeq PCR 
primer i5 AATGATACGGCGACCACCGAGATCTACAC[i5]ACACTCTTTCCCTACACGACGCTCTTCCGAT 
V1 indexed TruSeq PCR 
primer i7 GATCGGAAGAGCACACGTCTGAACTCCAGTCAC[i7]ATCTCGTATGCCGTCTTCTGCTTG 
V2 TruSeq PCR primer 1 AATGATACGGCGACCACCGAGATCTACAC 





2.1.6 Primary human tissue and cells 
Clinical characteristics of primary human tissues used for laser capture microdissection experiments 
(chapter 3.1) are described in Table 2. Moreover, cryopreserved primary human hepatocytes from 3 male 
donors (DJJ, AFJ and IAN; Cat.Number: M00995-P) were obtained from BioreclamationIVT (Baltimore, 
USA) for single cell RNA-seq (chapter 3.3). 
Table 2: Classification of surgical liver samples obtained from human donors (donor, n=45) for laser capture 
microdissection of hepatic zones. Samples were grouped regarding their phenotype into normal controls (NC), healthy 
obese controls (HO), bland steatosis (STEA), early NASH with mild inflammation (EARLY), progressed NASH (NASH) 
and fibrotic NASH (FIB3). Moreover, cirrhotic samples from donors with alcoholic fatty liver disease (ACI) are included. 
The table also contains information about sex (f = female, m = male), NAS score (NAS), NAS ballooning score (Bal), fat 
content (Fat, in %), inflammation score (Infl), fibrosis grade (Fib), age and body mass index (BMI). Insulin (Ins [nmol/l] 
values were used to obtain HOMA indices to assess insulin resistance (IR = HOMA > 2.5). Diabetes refers to a known 
diabetes diagnosis. Initially sample 7522 was classified as cryptogen. Due to corresponding fibrosis grade and high 
RNA-seq data correlation it was assigned to FIB3 samples. 







54 22 0.0 0.3 
no 
no 
7173 54 26 0.0 0.7 
7373 3 57 20.6 0.0 0.6 
7213 
0 
44 NA 0.1 4.4 
yes 
7279 59 26.5 0.1 2.6 














0 31 45.6 0.0 0.9 




44 42.5 0.1 4.1 
6976 40 55.9 0.1 4.3 
7230 36 40.2 0.2 4.2 
7252 29 45.4 0.1 3.7 









46 46 0.1 9.1 
yes 
yes 
7172 1 35 53 61.9 0.4 16.8 
7181 3 70 46 43.5 0.1 4.2 
no 7468 2 60 29 62.1 0.2 6.3 
7484 
3 
70 37 38.9 0.1 3.8 
7137 
M 
90 1 67 33.2 0.1 9.3 yes 











0 51 45.1 0.1 3.1 
7344 0 50 58 51.2 0.3 20.3 
yes 
7425 0 60 45 42.4 0.7 30.9 
Nextera PCR Primer i5 AATGATACGGCGACCACCGAGATCTACAC[i5]TCGTCGGCAGCGTC 






1 50 41 59.7 0.1 5.2 
7157 4 1 
40 
1 44 40.3 0.1 7.4 
7415 3 0 0 19 55.8 0.1 2.5 no 
7185 
NASH F 
7 1 70 
0 
0 33 53.8 0.1 1.4 
no 
no 







51 69.1 0.0 0.4 yes 
7286 1 47 38.6 0.1 3.2 
yes 
no 
7299 1 70 
1 
51 57.5 0.5 36.8 
yes 
7319 1 80 39 46.8 0.1 8.7 
7203 
FIB3 




57 49.1 0.4 8.3 
yes 
NA 
7522 40 82 27.7 0.2 8.1 
7197 
M 
6 2 100 53 50.8 0.1 4.6 yes 










7479 0 64 
NA 
7490 10 51 
7259 
M 
NA 39 28.6 
7505 0 59 20.8 
7265 0 3 63 24.9 
7383 NA 0 2 NA 28.4 
 
 
2.1.7 Cultured Cells 
 
Cell culture (Table 3) was performed at the Leibniz Research Centre for Working Environment and Human 
Factors (IfaDo, Dortmund) by Patrick Nell and David Feuerborn. 
Table 3: Sample overview of in vitro differentiation from induced pluripotent stem cells (iPSCs) to definite endoderm 
(DE) to hepatocyte-like cells (HLCs). 
Cell-type 
Differentiation 
protocol Replicates Assay 
iPSC CEL 4 RNA-seq 
iPSC CEL 4 RRBS 
iPSC CEL 4 ATAC-seq 
DE CEL 4 RNA-seq 
DE CEL 4 RRBS 
DE CEL 4 ATAC-seq 
HCL CEL 4 RNA-seq 
HCL CEL 4 RRBS 
HCL CEL 4 ATAC-seq 
HCL CEL 3 scRNA-seq 
iPSC HAY 1 RNA-seq 
iPSC HAY 1 RRBS 







Besides general molecular biology equipment the following devices were used: 
Device Company 
Agilent 2100 Bioanalyzer Agilent Technologies(Santa Clara, USA) 
cBot Illumina(San Diego, USA) 
DynaMag Invitrogen(Karlsruhe, Germany) 
HiSeq 2500 Illumina(San Diego, USA) 
NanoDrop 2000c ThermoSientific (Darmstadt, Germany) 
Qubit Fluorometer Invitrogen(Germany, Karlsruhe) 
 
2.1.9 Software and Databases 
ChIPseek - chipseek.cgu.edu.tw 
Cytoscape - https://cytoscape.org 
DAVID - https://david.ncifcrf.gov 
deepTools - http://deeptools.ie-freiburg.mpg.de 
Draw Venn Diagram - http://bioinformatics.psb.ugent.be/webtools/Venn 
ENCODE at UCSC database - https://genome.ucsc.edu/ENCODE 
Galaxeast - galaxeast.fr 
Galaxy - https://galaxyproject.org 
GeneTrail2 - https://genetrail2.bioinf.uni-sb.de 
HOMER Motif Analysis - homer.ucsd.edu/homer/motif/ 
IGV browser - https://software.broadinstitute.org/software/igv 
jupyter notebook - https://jupyter.org  
Microsoft Office Standard 2013 -  
pathview - https://pathview.uncc.edu 
python (version 3.6) - https://www.python.org 
R (version 3.4.3) - http://www.R-project.org 
R studio - https://www.rstudio.com 
RegulatorTrail  - https://regulatortrail.bioinf.uni-sb.de/ 
DE HAY 1 RNA-seq 
DE HAY 1 RRBS 
DE HAY 1 ATAC-seq 
HCL HAY 1 RNA-seq 
HCL HAY 1 RRBS 
HCL HAY 1 ATAC-seq 




Sequence Read Archive (SRA) -  https://www.ncbi.nlm.nih.gov/sra 
Additionally, numerous R and python packages, detailed in chapter 2.2.2, were used. 
 
2.1.10 External Datasets 






2.2.1 Experimental methods 
2.2.1.1 Reduced representation bisulfite sequencing on laser capture microdissected material (LCM-RRBS) 
Laser capture microdissection of three zones along the hepatic proto-central axis was performed on human 
liver cryosections (Table 2, 2.1.6 Primary human tissue) by Luise Obermann in Jochen Hampe’s group (TU 
Dresden) as previously described (Brosch et al., 2018). Subsequently, microdissected cells were shipped 
on dry ice and stored at - 80 °C. A Reduced Representation Bisulfite Sequencing (RRBS) library preparation 
protocol (Schillebeeckx et al., 2013) was modified as described in Brosch et al. (2018) to prepare adequately 
concentrated Next Generation Sequencing libraries from the roughly 100 hepatocytes typically obtained by 
microdissection. Cell lysis was carried out directly in the caps of the capturing tubes. Cells were suspended 
in 8 μl lysis buffer (10 mM Tris-HCl, 5 mM EDTA) and 2 μl Proteinase K (diluted to 1 mg per ml in lysis buffer, 
Qiagen) and tubes were incubated upside down in a thermal shaker (200 rpm) at 55 °C for 3 hours. Then 
tubes were briefly centrifuged to collect the lysate at the bottom of the tubes. Proteinase K activity was 
inhibited with 0.5 µl Pefabloc (21 mM, Sigma) and incubation for 1 hour at room temperature. The CpG 
methylation insensitive enzymes HaeIII (25 U, NEB) and AluI (5 U, NEB) were used for DNA restriction in a 
double digest complemented with 1.5 μl CutSmart buffer (10X, NEB), 1 μl MgAce (5mM, Sigma) and 1 μl 
yeast tRNA (100 ng, ThermoFisher Scientific) at 37 °C for 18 hours. Restriction enzymes were heat-
inactivated at 80 °C for 20 min. A-Tailing of DNA fragments was performed by addition of 1 µl Klenow 
Fragment (3’ → 5’, exo −, 5 U per μl, NEB) and 1 μl dATP (10 mM, NEB) at 37°C for 30 min followed by 
enzyme inactivation at 75°C for 20 min. Ligation of methylated adapters was achieved with 1 µl adapter, 0.5 
μl T4 Ligase (2,000 U per μl, NEB) and 2 μl ATP (10 mM, NEB) at 16 °C for 22 hours. Initial samples (Donor 
IDs 7041, 7157, 7188, 7344, 6610, 6758, 6922, 7230, 7213, 7252, 7012, 7173, 7194, 7279, 6967, 7137, 
7172, 7181 and 7251) were ligated using short pre-annealed TruSeq compatible adapters (100 µM, 
V1_short_TruSeq_adapter_1 and 2, 2.1.5 Oligonucleotides) without index. Later samples were ligated with 
1 µl of original indexed TruSeq adapter (TruSeq DNA Single Index Set B, Illumina) diluted to 0.5 µM. After 
bisulfite conversion with the EZ DNA Methylation-Gold Kit (Zymo Research) DNA was eluted in 10 µl M-
elution buffer (Zymo Research). Enrichment polymerase chain reaction (PCR) of adapter ligated fragments 




and 0.5 μl Hot Start Taq (5 U/μl, Qiagen) in a 30 μl reaction. Initial samples (LCM-RRBS_1 to 57) were 
amplified with each 0.5 µl of indexed TruSeq primers (10 μM, V1 TruSeq_i5 and TruSeq_i7, 2.1.5 
Oligonucleotides), remaining libraries with each 0.5 µl non-indexed RRBS primers (10 µM, V2 
TruSeq_PCR_Primer_1 and 2, 2.1.5 Oligonucleotides). After initial denaturation at 95 °C for 15 min, thermo-
cycling was carried out for 22 cycles at 95 °C for 30 sec, 60 °C for 30 sec and 72 °C for 1 min, followed by 
final elongation at 72 °C for 7 min. Libraries were purified with 0.8 X Ampure XP Beads (Beckman Coulter) 
and eluted in 10 µl elution buffer (Qiagen). 
 
2.2.1.2 RRBS 
Genomic DNA was isolated by phenol chloroform isoamylalcohol extraction. It should be noted that only 
fixed frozen cell pellets, originally prepared for ChIP-seq, were available. Thus, a modified protocol was 
developed for proper isolation of intact genomic DNA from fixed material. 
Frozen cell pellets were thawed in 700 µl ChIP lysis buffer (without protease inhibitor cocktail) and 
resuspended on a vortexer. Then, 350 µl of the suspension were transferred into a separate tube and used 
for parallel chromatin preparation, which was however not used within the scope of the present thesis. The 
remaining 350 µl were used for extraction of genomic DNA. To this end, 350 µl DNA extraction buffer B were 
appended, mixed, supplemented with 3 µl RNase A (20 mg/ml, Qiagen) and samples were incubated at 37 
°C for 30 min. Protein digestion was performed using 14 µl Proteinase K (10 mg/ml, Qiagen) at 55 °C for 1 
hour and then 65 °C over night in a shaking device. For DNA extraction 700 µl Ultrapure Phenol-Chloroform-
Isoamylalcohol (PCI, 25:24:1, v/v/v, Invitrogen) were added. Samples were rotated for 15 min at room 
temperature and centrifugation was carried out at 13,000 rpm for 5 min. The aqueous phase was transferred 
to a new tube. PCI extraction was repeated, followed two times by extraction with Chloroform-Isoamylalcohol 
(24:1). For DNA precipitation the final aqueous phase was distributed into two 2 ml tubes, each appended 
with 775 µl ice-cold absolute ethanol and 33 µl 3 M NaOAc, inverted and stored at – 20 °C over night. Visible 
DNA threads were fished with a 10 µl tip, washed 3 times by dipping in 70 % ice-cold ethanol, dried at room 
temperature and solved in 100 µl 1 X TE at 50 °C for 5 hours. DNA quality was assessed by electrophoresis 
on a 1.5 % agarose gel in 0.5 X TBE stained with ethidium bromide solution. DNA concentration and purity 
was measured on a NanoDrop 2000c.  
RRBS library preparation was carried out similar as described for LCM-RRBS (2.2.1.1) with some 
modifications. In brief, at least 180 ng (183 to 458 ng) purified genomic DNA were digested using 1 µl HaeIII 
(50 U, NEB) in a 30 µl reaction supplemented with 3 µl 10 X CutSmart Buffer (NEB) at 37 °C. After 2 hours 
0.5 µl HaeIII (50 U/µl) were appended and incubation was completed for additional 16 hours. A-tailing was 
performed by addition of 1 µl Klenow Fragment (3`→5` exo-, 5 U/µl, NEB) and 1 µl 10 mM dATP at 37 °C 
for 30 min followed by enzyme inactivation at 75 °C for 20 min. Ligation of indexed methylated TruSeq 
adapters (10 µM, TruSeq DNA Single Index Set B, Illumina) was achieved by incubation with 2 µl adapter, 
1 µl T4 Ligase (2,000,000 U per μl, NEB), 1 µl 10 X Cutsmart Buffer (NEB) and 4 µl ATP (10 mM, NEB) at 
16 °C for 22 hours. Bisulfite conversion, enrichment PCR (15 Cycles) and final library purification were 





2.2.1.3 single cell RNA-seq  
Cryopreserved primary human hepatocytes (PHH) were thawed in a water bath at 37 °C, transferred into 5 
ml PBS supplemented with 10 % fetal bovine serum and carefully mixed by inversion.  
Adherent hepatocyte-like cells (HLCs) in matrigel culture dishes were washed twice with Dissociation Buffer 
1 and incubated for at least 15 min in Dissociation Buffer 2 containing collagenase (200 mg / ml, Sigma) at 
37 °C. As soon as the monolayer started to detach cells were carefully scraped with a cell scraper. Given 
that HLCs were rather clumpy the cell suspension was pipetted up and down about 10 times to reduce 
clumps. Finally, HLC suspensions were transferred to 1.5 ml tubes, centrifuged for 5 min at 300 g and 4 °C, 
washed twice in cold PBS and resuspended in PBS containing 0.1 % PVP. 
PHH and HLC suspensions were diluted in PBS containing 0.1 % PVP and single cells were manually 
isolated using a glass capillary into 2 µl Smartseq2 lysis buffer and stored at – 80 °C. cDNA preparation was 
performed as previously described (Picelli et al., 2013) with modifications. To each well 1 µl 10 mM dNTPs, 
0.5 µl Oligo-dT primer (2.1.5 Oligonucleotides) and 0.5 µl ERCC RNA Spike-In Mix (Invitrogen, diluted 
1:400,000) were added and samples were incubated at 72 °C for 3 min and immediately placed on ice. 
Reverse transcription was carried out using 0.5 µl SuperScript II RT (200 U / µl, Invitrogen) supplemented 
with 0.25 µl RNasin (40 U / µl, Promega), 2 µl Superscript II first-strand buffer (5 X), 0.48 µl 100 mM DTT, 2 
µl 5 M Betaine, 0.12 µl 0.5 M MgCl2, 0.1 µl 100 µM TSO (2.1.5 Oligonucleotides) and 0.25 µl nuclease-free 
water and incubation at 42 °C for 90 min, followed by 10 cycles of 50 °C for 2 min and 42 °C for 2 min. 
Enzyme deactivation was achieved by incubation at 70 °C for 15 min. cDNA was pre-amplified by addition 
of 12.5 µl KAPA HiFi HotStart ReadyMix PCR Kit (Roche), 0.25 µl IS PCR primer (2.1.5 Oligonucleotides) 
and 2.25 µl nuclease-free water with the following thermo-cycling conditions: 98 °C for 3 min, 18 cycles of 
98 °C for 20 sec, 67 °C for 15 sec, 72 °C for 6 min and final elongation at 72 °C for 5 min. cDNA was purified 
using 0.8 X Ampure XP Beads (Beckman Coulter) and elution in 7 µl elution buffer (Qiagen). After quality 
control of 11 randomly picked wells per replicate on an Agilent Bioanalyzer with the HS DNA Kit, in average 
450 pg of cDNA were used as input for dual-indexed Nextera XT library preparation (Illumina) following the 
manufacturer’s recommendations with 9 cycles for library amplification. All 96 individual single cell libraries 
per replicate were pooled in equal amounts prior to 1X Ampure XP Beads (Beckman Coulter) purification of 
100 µl pooled libraries with final elution into 15 µl elution buffer (Qiagen). 
 
2.2.1.4 RNA-seq 
RNA was extracted from approximately 1 million in vitro cultured cells stored at – 80 °C in 1 ml TRIzol 
(ThermoFisher) using the Direct-zol RNA MiniPrep Plus Kit (Zymo Research) including DNaseI treatment 
following the manufacturer’s recommendations. RNA concentration and purity was assessed by NanoDrop 
2000c (ThermoSientific). cDNA synthesis was carried out as described for single cells (2.2.1.3) but adapted 
for bulk RNA sequencing. Thus, 100 to 237 ng total RNA in 2.3 µl nuclease-free H2O were combined with 1 
µl 10 mM dNTPs and 1 µl of 10 µM Oligo-dT primer (2.1.5 Oligonucleotides), incubated at 72 °C and placed 
on ice. Reverse transcription and preamplification were carried out as described in chapter 2.2.1.3 except 
for applying only 5 cycles in the preamplification PCR. cDNA was quantified using the Qubit dsDNA HS 




Library Prep Kit, Illumina)  in 1 X TD Buffer and incubation at 55 °C for 10 min. Tagmented DNA was purified 
with the MinElute PCR Purification Kit (Qiagen) and final elution in 11 µl elution buffer (Qiagen). Libraries 
were amplified using 15 µl NEBNext® High-Fidelity 2X PCR Master Mix (NEB), 1 µl Nextera PCR Primer i5, 
1 µl Nextera PCR Primer i7 (2.1.5 Oligonucleotides) in a 30 µl reaction with the following thermo-cycling 
program: 72°C for 5 min and 98 °C for 30 sec, followed by 8 cycles of 98 °C for 10 sec, 63 °C for 30 sec, 72 
°C for 1 min and final elongation at 72 °C for 5 min. Final library purification was achieved with 0.9 X Ampure 
XP Beads (Beckman Coulter) and eluted in 10 µl elution buffer (Qiagen). 
 
2.2.1.5 ATAC-seq 
The assay for transposase-accessible chromatin using sequencing (ATAC-seq) on in vitro cultured HLCs 
and cryopreserved PHH was performed as described by Buenrostro et al. (2013) with modifications. After 
initial establishment of cell-type specific conditions nuclei preparation, tagmentation and following 
purification of HLCs was carried out by Patrick Nell at IfADo (Dortmund) and shipped on dry ice for further 
processing.  
Single cell suspensions in PBS were prepared as described for scRNA-seq (2.2.1.3). Prior to nuclei 
preparation centrifugation was carried out at 300 g and 4 °C for 5 min. For nuclei preparation cells were 
resuspended in 1 ml Permeabilization Buffer A (pH 8.0) supplemented with 0.05 % Nonident P-40 and 
incubated on ice for 10 to 15 min until isolated nuclei were visible by microscopic control. HLC nuclei were 
generally very clumpy, thereby not allowing proper counting. Thus, nuclei counts were estimated on the 
expected cell density of the used culture dish and aliquoted respectively to obtain approximately 50,000 
nuclei per reaction. PHH nuclei were counted in a Neubauer chamber and aliquoted accordingly. Nuclei 
were centrifuged, washed with 1 ml Permeabilization Buffer A, and finally resuspended in 50 µl tagmentation 
mix containing 2.5 µl Tn5 (Nextera DNA Library Prep Kit, Illumina) in 1 X TD buffer. Tagmentation was 
carried out at 37 °C for 30 min. Purification, amplification (9 cycles) and final library purification were 
performed as described for RNA-seq Nextera library preparation (2.2.1.4). 
 
2.2.1.6 Library quality control and Next Generation Sequencing 
Prior to sequencing libraries were quantified with the Qubit dsDNA HS Assay Kit (Invitrogen) and fragment 
size distribution for exemplary libraries was checked on the Agilent 2100 Bioanalyzer using the High 
Sensitivity DNA Kit (Agilent). Libraries of the same type (Nextera respective TruSeq) were pooled per flow 
cell lane according to required sequencing depth. Library pools were eventually quantified with the PerfeCTa 
NGS Quantification Kit (Quanta Biosiences) and normalized for clustering on a cBot (Illumina). LCM-RRBS, 
RRBS, ATAC-seq and RNA-seq libraries were sequenced on a HiSeq2500 (Illumina) using TruSeq SBS Kit 
v3 – HS Chemistry in single read runs with 94 bp read length. scRNA-seq libraries were sequenced 
accordingly, except for requiring dual index reads thereby limiting the read length to 88 bp. In case of Nextera 
sequencing (scRNA-seq, RNA-seq and ATAC-seq) read 1 primer hp8 was replaced by hp12. Final 





2.2.2 Bioinformatical methods 
2.2.2.1 Data processing 
Processing of raw FASTQ files was done by Dr. Karl Nordström. Initial raw data quality controls was 
performed using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were 
trimmed using Trim Galore! (v0.4.2) http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to 
remove 3’ ends with base quality below 20 as well as adapter sequences. RRBS reads were trimmed in 
RRBS mode. For the EpiTriO project, in the first round of analysis (V0.1, chapter 3.1.1), reads were aligned 
to the 1000 genomes version of the human GRCh37 reference and further processed as described below. 
For subsequent analysis of the extended EpiTriO dataset (V0.2, chapter 3.1.2), all samples (including V0.1 
samples) were re-processed and aligned to the more recent human genome reference GRCh38. All further 
datasets used in this thesis (chapter 3.2 and 3.3) were mapped to GRCh38, accordingly.  
RRBS reads were aligned with the BWA (Li and Durbin, 2009, v0.6.2) wrapper methylCtools (Hovestadt et 
al., 2014, v0.9.2). Samtools (Li et al., 2009, v1.3) and Picard tools (v1.115) 
(http://broadinstitute.github.io/picard/) was utilized for converting, merging and indexing of alignment files. 
Bis-SNP was used for SNP (dbSNP, v138, http://www.ncbi.nlm.nih.gov/SNP) aware realignment, quality 
recalibration and methylation calls.  
ATAC-seq reads were aligned with the GEM mapper (Marco-Sola et al., 2012, v1.376β), and samtools (Li 
et al., 2009, v1.3) were used to convert SAM to BAM format. MarkDuplicate (version 1.115) from Picard 
tools (http://broadinstitute.github.io/picard/) was used to mark PCR duplicates. ATAC-seq peaks were called 
using MACS2 (Feng et al., 2012, v2.1.0.20140616), applying the following parameters: --nomodel, --shift -
125, --extsize 250. Coverage files normalized for library size were generated using bamCoverage from 
deepTools (Ramirez et al., 2014, v1.5.9.1). Normalized read counts were counted using featureCounts (Liao 
et al., 2014, v1.5.0-p3) in 100 bp and 10,000 bp bins for subsequent analysis. 
Bulk RNA-seq reads were aligned using STAR (Dobin et al., 2013, v2.5.2a) with per sample 2-pass mapping 
strategy, that processes all reads in both passes as described in the tool vignette. PCR duplicates were 
detected using MarkDuplicate from Picard tools (version 1.115; http://broadinstitute.github.io/picard/). Reads 
aligned to GRCh37 were summarized to v19 Gencode gene models (Harrow et al., 2012) with featureCounts 
(Liao et al., 2014, v1.5.0-p3) counting primary alignments only. Gene and transcript-wise read counts for 
data mapped to GRCh38 were estimated based on Gencode release 30 (GRCh38.p12) using RSEM (Li and 
Dewey, 2011,  v1.3.1). Smartseq2 generated scRNA-seq reads were processed accordingly. For UMI based 
scRNA-seq reads obtained by the 10X Genomics Chromium Single Cell Gene Expression Solution, the 
zUMIs pipeline, including Star alignment to GRCh38, was applied as previously described (Parekh et al., 








2.2.2.2 NGS data analysis 
2.2.2.2.1 RNA-seq data 
RNA-seq data quality was judged by number of detected genes and transcripts per sample, and the 1000 
most variable genes, calculated based on expression values normalized as log CPM + 1 (counts per million), 
were used for Principal Component Analysis (PCA).  
The initial script for differential analysis (V0.1) of RNA-seq was provided by Dr. Karl Nordström and served 
as template for following analysis. EdgeR (Robinson et al., 2010, v3.16.5) was used to detect differentially 
expressed genes with significance thresholds of maximal FDR adjusted p-value of 0.01 and minimal 
absolute logFC of 1, based on gene wise negative binomial generalized linear models. For the EpiTriO 
project genes for which fewer than five samples had a CPM value above 0.5 were excluded. Inter-individual 
variance of expressed genes within groups was calculated based on log (CPM+1) after filtering of 
unexpressed genes using the matrixStats R package (https://github.com/HenrikBengtsson/matrixStats). 
After calculation of normalization factors, dispersion was robustly estimated using a model adjusting for 
phenotype, sex, age, BMI, donor and the prevalence of diabetes (V0.1). As for ACI samples no clinical data 
were available regarding the prevalence of diabetes, zonal comparisons including this phenotypic group 
were only adjusted for sex, age, BMI and donor (V0.2). For samples with missing clinical data (age or BMI), 
the value was set to the mean of the remaining samples in the respective group. Differential analysis 
between phenotypes was done without donor adjustment. In the StemNet dataset (chapter 3.3) genes for 
which row means of raw counts were below 1 were excluded, and DEG analysis was perfomed as described 
above, using a model without covariate adjustment.  
 
2.2.2.2.2 RRBS data 
General quality of DNA methylation data was analyzed by RnBeads (Assenov et al., 2014). Selection criteria 
for CpG sites analyzed by PCA are explained in respective figure legends. Differential DNA methylation 
analysis of the v0.1 EpiTriO dataset was performed by Dr. Karl Nordström using MethylKit (Akalin et al., 
2012, v1.3.1). All further analysis were performed accordingly. MethylKit was modified to treat missing sites 
as zero-covered sites in the aggregation step of tiled analysis. After merging both strands, calls were filtered 
to sites with at least 10X coverage. Then, the tiled dataset (500 bp tiles) was searched for differentially 
methylated regions (step-size: 500 bp), allowing for missing sites in no more than 75 % of samples per group 
(e.g. EpiTriO V0.1: 14 out of 19 samples need to be covered, StemNet: 3 out of 4 replicates need to be 
covered), with at least 3 CpGs, a maximum FDR adjusted p-value of 0.01 and minimal methylation difference 
of 5% (EpiTriO) or 20% (StemNet). Mitochondrial, X and Y chromosomes were excluded from the analysis. 
Resulting differentially methylated regions (DMRs) were annotated to closest genes and genomic features 
(promoter, exon, intron or intergenic) based on Gencode v19 (EpiTriO v0.1 samples) or Gencode release 
30 (GRCh38.p12) gene models (Harrow et al., 2012) using bedtools (Quinlan and Hall, 2010, v2.20.1) or 
GenomicRanges (Lawrence et al., 2013, v1.36.0). 
Genomic segmentation of RRBS data was performed by Abdulrahman Salhab with the R package 




Calculations of DMR enrichment and DNA methylation gradients at TFBS was performed by Alexander 
Hermann (TU Dresden). The detailed method is provided in our publication (Brosch et al., 2018). 
For the EpiTriO dataset, mitochondrial abundance was deduced from the ratio of mitochondrial versus 
genomic reads in the RRBS data. Significance of differences between hepatic groups was tested by 
Wilcoxon rank sum test with the wilcox.test function in R. P-values less than 0.05 were considered as 
significant. 
 
2.2.2.2.3 ATAC-seq data 
ATAC-seq quality was assessed by visual inspection of coverage tracks using the IGV browser (Robinson 
et al., 2011), by number of detected peaks and fraction of reads in peaks (FRiP score) as well as the ratio 
of mitochondrial reads. Bin-wise counts (generated using featureCounts as described in 2.2.2.1) were 
summarized as log (CPM + 1) and the 50,000 most variable 100 bp bins were selected for PCA. 
For differential chromatin accessibility analysis of ATAC-seq data, the mitochondrial chromosome and a set 
of mostly telomeric and centromeric blacklist regions with exceptionally high read counts (sum of all 18 
samples in the dataset > 10,000 reads / 100 bp) were excluded. Bin-wise counts (generated using 
featureCounts as described in 2.2.2.1) were summarized as log (CPM + 1). Differential analysis was then 
performed using csaw (Lun and Smyth, 2016, v1.16.1) combined with edgeR (Robinson et al., 2010, 
v3.16.5). To adjust background differences between samples, counts of 10,000 bp bins were used for 
calculation of normalization factors. After initial edgeR based differential analysis, windows belonging to the 
same peak region were merged, allowing a maximal peak size of 3,000 bp and a maximum distance of 
adjacent bins of 150 bp. Then, FDR for the merged window was calculated based on Benjamini Hochberg 
adjustment. Moreover, average log2 CPM values were calculated for merged windows. Annotation to the 
nearest gene was achieved as described for DMRs (chapter 2.2.2.2.2). 
 
2.2.2.2.4 Smartseq2 scRNA-seq data 
Quality of Smartseq2 single cell RNA-seq data was assessed as described for bulk RNA-seq (chapter 
2.2.2.2.1). In addition, the Ambion® ERCC Spike-In Control spike-in was used to assess expression profiling 
efficiency. The Smart-seq2 scRNA-seq dataset was extended by a compatible external dataset (Camp et 
al., 2017). Thus, batch effects were assessed by PCA visualization of the 1,000 most variable genes, PCA 
regression, average silhouette width calculation, and kBET rejection rate (Büttner et al., 2019) as outlined 
in the kBET vignette. In addition, batch correction was performed by mutual nearest neighbor correction 
(Haghverdi et al., 2018) and ComBat implemented within the R package Surrogate Variable Analysis (Leek 
et al., 2017). Corrected data were assessed again, but as no major batch effects were observed and 
corrections did not yield major improvements (Sup. Figure 12), original data were used for further analysis. 
Data were normalized as log (CPM + 1). 
Pseudotime analysis was performed using monocle2 (Trapnell, 2017) in semi-supervised mode with CDX2, 
ALB and AFP as marker genes for anchoring of the analysis as described in package vignette. Regulon 




and Clustering (SCENIC) workflow (Aibar et al., 2017), called pySCENIC 
(https://github.com/aertslab/pySCENIC). Regulons with activity scores above automatically assigned AUC 
score threshold in at least 30 % of single cells were considered as active in the respective cell cluster. 
Binarized regulon activities were used for hierarchical clustering and correlation based t-SNE visualization 
of single cells. Single cell variance was calculated using the R package matrixStats 
(https://github.com/HenrikBengtsson/matrixStats) with the function RowVars on normalized expression data 
after removal of unexpressed genes. 
 
2.2.2.2.5 High-throughput 10X Genomics scRNA-seq data – spatial reconstruction 
Single cell RNA-seq data generated by the high-throughput 10X Genomics platform were analyzed by 
SEURAT (Butler et al., 2018, v2.3.4). Cells were filtered by number of detected genes (500 – 2,000), UMI 
count (2,000 – 12,500) and percentage of mitochondrial reads (< 0.15). High confidence primary 
hepatocytes were identified by PCA on highly variable genes (HVGs), which was used to remove outliers. 
Further filtering was performed based on ALB (log2 normalized expression level > 4) and CD47 expression 
(log2 normalized expression level < 4). 
Spatial reconstruction of single high confidence hepatocytes was in principle performed by dimensionality 
reduction of highly variable genes (HVGs), which were detected by SEURAT using the function 
FindVariableGenes that controls for the high correlation between dispersion and average expression level. 
First, all HVGs detected in the dataset were subject to several dimension reduction algorithms. Diffusion 
maps were generated by the R package destiny (Haghverdi et al., 2015, v2.6.2), PCA and t-SNE were 
calculated within SEURAT. Uniform Manifold Approximation maps (UMAP) were generated in python using 
the UMAP package (Becht et al., 2019). Then, dimension reductions were performed on the 107 HVGs that 
featured zonated expression profiles in normal human liver tissue (Brosch et al., 2018). All dimension 
reduction plots were generated with the ggplot2 package (Wickham, 2009). 
As by visual inspection of marker gene distribution, diffusion maps showed the best performance, further 
analysis focused on diffusion map based spatial reconstruction. Several diffusion parameters, such as 
changing the local Gaussian kernel width sigma from local to an optimal global sigma of 2.9 or testing 
different numbers between 100 and 7,912 (number of cells – 1) for k, did not visibly impact the diffusion map 
results. Thus, all displayed diffusion maps were generated with destiny’s default parameters. It should be 
noted that strict filtering of low abundance transcript was not necessary, as the diffusion algorithm was 
apparently driven by highly expressed genes. 
For interspecies comparisons, a spatially reconstructed external mouse liver scRNA-seq dataset generated 
by MARS-seq (Halpern et al., 2017) was used. Reconstructed mouse zones 1 and 2 were considered as 
pericentral, zones 4 and 5 as intermediate and zones 8 and 9 as periportal. Spearman rank statistics of 
sequencing depth normalized mRNA expression levels (log(CPM+1)) were calculated for mouse single cell 
data (Halpern et al., 2017), human LCM-RNAseq data and human single cell RNA-seq data with one-to-one 
matching orthologues detected in all three datasets. The comparison was restricted to genes with high 
confidence expression values, corresponding to a CPM > 0 in the mouse dataset after background 




reconstructed scRNA-seq datasets was performed as described by Halpern et al. (2017), with Kruskal-Wallis 
test q < 0.2 between CV and PV considered as significantly zonated.  
 
2.2.2.2.6 Integrative data analysis 
Association of DMRs or DARs to DEGs was performed by annotating the closest genes as described above 
(chapter 2.2.2.2.2). The overlap of DMRs, respective DARs, was analyzed using bedTools (Quinlan and 
Hall, 2010) implemented on the GalaxEast Server (http://galaxeast.fr). Correlations between datasets were 
calculated with the R cor.test function. If not mentioned otherwise correlation values (r) are Pearson 
correlations. The use of Spearman rank statistics is specifically mentioned. 
Hg38 annotated bed files were lifted to genome version hg19 using LiftOver from UCSC 
(https://genome.ucsc.edu/cgi-bin/hgLiftOver) to allow the further annotation of genomic features and 
HOMER (Heinz et al., 2010) based TF motive enrichment analysis by ChIPseek (Chen et al., 2014).  
Gene ontology overrepresentation analysis was done using DAVID (Jiao et al., 2012) with at least 3 genes 
per GO term and p < 0.05. Gene Set Enrichment Analysis (GSEA) was performed by Kolmogorov-Smirnov 
Test with enrichment score > 0.5 and Benjamini-Yekutieli FDR adjusted p-value < 0.01 using Genetrail2 
(Stöckel et al., 2016). Interaction networks of differential genes were generated by String (Szklarczyk et al., 
2019) and visualized in using Cytoscape (v3.5.1, Shannon et al., 2003), using continuous mapping of 
additional parameters such as expression logFC or methylation difference for coloring. 
 
2.2.2.2.7 Data visualization 
In general, dimension reduction plots, scatterplots, violin plots, boxplots and volcano plots throughout this 
thesis were generated using the R package ggplot2 (Wickham, 2009). Bar diagrams and colored tables 
were generated in Microsoft excel. Pie charts were either produced in Microsoft excel or taken from the 
output of the ChIPseek online tool  (Chen et al., 2014). Venn diagrams of overlapping gene IDs were 
generated by DrawVennDiagram (http://bioinformatics.psb.ugent.be/webtools/Venn), while Venn diagrams 
of overlapping genomic regions were calculated using the R package GenomicRanges (Lawrence et al., 
2013). 
ATAC-seq coverage patterns were prepared using deeptools (Ramirez et al., 2014) based on normalized 
coverage tracks (bigwig) by the functions compute matrix in 4 kb windows around region centers as 
reference points and visualized by plotHeatmap. All other heatmaps were produced by the R package 
pheatmap (https://CRAN.R-project.org/package=pheatmap), with underlying values being either original 
values (if applicable, normalized to sequencing depth) or scaled z-scores. Clustered heatmaps were 
clustered either by euclidean, manhattan or canberra distance, as outlined in the respective figure legends.  
Genomic tracks of expression, DNA methylation and ATAC-seq data (bigwig), normalized by sequencing 
depth, were visualized in the IGV browser (Robinson et al., 2011). DNA methylation tracks were set to a 
range of 0 to 100, while DNA methylation coverage tracks, ATAC-seq and RNA-seq tracks were scaled to 




For illustration of expression levels of exemplary genes across three hepatic zones, expression data were 
normalized to the zone with the highest expression for each individual gene. Plots were generated in 
Microsoft excel. It should be noted that dashed lines are for visualization only.  
Bubble plots for GO term enrichment of hepatic zones were produced using the R package GOplot, while 
other GO term enrichment visualizations were achieved by bar-plots of enrichment scores using ggplot2. 
KEGG pathways were visualized using Pathview (Weijun Luo, 2017) with continuous mapping of expression 
logFC or methylation differences. Protein interaction networks, which were generated by String as described 
in chapter 2.2.2.2.6, were visualized by the java based application Cytoscape (v3.5.1, Shannon et al., 2003), 
using continuous mapping of expression logFC and methylation difference as fill and border colors to 
























3.1 Epigenomic analysis of microdissected human liver zones 
The transcriptional and epigenomic analysis of microdissected human liver zones was carried out in 
cooperation with the group of Prof. Dr. Jochen Hampe (TU Dresden) as part of the BMBF funded EpiTriO 
project (Figure 13). Laser capture microdissection of hepatocytes from three zones along the hepatic porto-
central axis (Figure 14, A) was performed on human liver cryosections by Luise Obermann, Fabian Reichel 
and Dr. Mario Brosch (TU Dresden), and shipped on dry ice for preparation of RRBS libraries. Moreover, 
RNA-seq data generated from adjacent cryosections was provided for integrated data analysis.  
 
Figure 13: Workflow for the generation of epigenetic reference maps from zonal hepatocytes. Hepatocytes from three 
hepatic zones (PV, IZ and CV) were isolated using laser capture microdissection (LCM) on cryosections of human liver 
samples. Microdissected cells from adjacent cryosections were used for RNA-seq and RRBS. PV: periportal zone, IZ: 
intermediate zone, CV: pericentral zone. 
During RRBS protocol establishment for low cell numbers it became apparent that RRBS using HaeIII as 
sole restriction enzyme yielded functional libraries (Figure 14, B), but CpG coverage was rather poor. In 
contrast, AluI/HaeIII double digested RRBS libraries resulted in high quality data with broad coverage of 
about 10 million CpGs per sample. As LCM of zonal hepatocytes yielded approximately 90 cells per sample, 
all LCM-RRBS libraries were generated based on AluI/HaeIII double digest, thereby allowing the 
comprehensive analysis of DNA methylation profiles. RRBS libraries were typically sequenced to at least 40 
million reads per library or an average CpG coverage of 5 (Sup. Table 1). Sequencing of RRBS libraries 
was carried out by Dr. Gilles Gasparoni and processing of raw RNA-seq and RRBS data was performed by 





Figure 14: A – Exemplary histological Cresyl Violet staining of a periportal (PV) and pericentral (CV) region (Brosch et 
al., 2018). B – Bioanalyzer tracks representing the typical fragment length distribution of HaeIII RRBS and HaeIII/AluI 
double digested RRBS on about 90 hepatocytes obtained from microdissection. 
 
The present study comprises a human cohort of surgical liver samples from 38 donors including normal lean 
(NC) and healthy obese controls (HO), together with NAFLD patients spanning the entire spectrum of non-
alcoholic fatty liver disease (NAFLD) from bland steatosis (STEA), early NASH (EARLY), progressed NASH 
(NASH) to NASH with fibrosis grade 3 (FIB3). As no NASH samples with higher fibrosis grade were 
available, we additionally included samples of 7 donors with an alcoholic cirrhosis of fibrosis grade 4 (ACI), 
representing the irreversible state of chronic steatohepatitis (Figure 15). Control samples (NC) were gained 
from patients undergoing liver resection for metastasis assessment, while NAFLD samples were obtained 
from bariatric surgery. Cirrhosis samples derive from surgical liver resections.  Importantly, all samples were 
flash frozen within less than 40 sec after surgery, ensuring high cellular integrity. Control and NAFLD 
samples were categorized by standard liver histological parameters (Kleiner et al., 2005) into phenotypic 
groups according to pathologically determined NAS scores. Donor information including sex, age, BMI, NAS 
score and further histological and clinical parameters are summarized in Table 2 (chapter 2.1.6). 
The first round of analysis (V.01, n = 19) focused on zonation signatures, thus it was limited to controls (NC, 
HO) and the early spectrum of NAFLD (STEA, EARLY) with low amounts of inflammatory infiltrate and no 
fibrosis. The main findings were recently published (Brosch and Kattler et al., 2018) and are presented in a 
more detailed fashion in chapter 3.1.1, with analysis produced by other co-authors specifically outlined. 
Already published figure panels are cited accordingly. In a second analysis (V.02, n = 45) we extended our 
dataset by further replicates of controls and early NAFLD samples to obtain more statistical power, but 
importantly also included donors with more progressed and fibrotic NASH (FIB3) as well as alcoholic 
cirrhosis samples (Figure 15). Here, the analysis was focused on zone-specific deregulation and its impact 






Figure 15: Human cohort (n = 45) comprising surgical liver samples of normal controls (NC), healthy obese controls 
(HO) as well as donors with bland steatosis (STEA), early NASH (EARLY), progressed NASH (NASH), fibrotic NASH 
(FIB3) and alcoholic cirrhosis (ACI). The first stage of analysis is based on 19 donors of controls and the early spectrum 
of NAFLD (V.01), in the second round (V.02) 26 additional donors including NASH, FIB3 and ACI were added.  Donor 
information including sex, age, BMI, histological factors such as NAS score and further clinical parameters are 
summarized in Table 2 (chapter 2.1.6). 
 
 
3.1.1 Hepatic zonation signatures in health and early NAFLD 
3.1.1.1 Transcriptional zonation profiles 
For the analysis of transcriptional zonation profiles of the human liver, full-length mRNA-seq was performed 
on hepatocytes (n = 19) isolated from pericentral, intermediate and periportal hepatic zones by laser 
microdissection (Table 2). The resulting RNA-seq dataset comprises normal controls (NC, n = 4), healthy 
obese donors (HO, n = 5), patients with bland steatosis (STEA, n = 5) and early steatohepatitis (EARLY, n 
= 5). Samples were sequenced to a mean depth of 20 million reads (Sup. Table 2). Raw fastq files were 
provided by Prof. Dr. Jochen Hampe’s group and analyzed as described in chapter 2.2.2.  
On average, 17,922 genes respectively 103,780 transcripts were expressed, and high intragenic (0.933) 
and particularly exonic rates (0.861) confirm high data quality with efficient expression profiling (Sup. Table 
2). Potential contamination with non-parenchymal cells such as immune cells, endothelial cells or fibroblasts 
was assessed by expression analysis of known cell-type marker genes (Sup. Figure 1 A) and revealed 
neglectable fractions of non-parenchymal cells, ensuring the predominant presence of hepatocytes. A 
principal component analysis (PCA) of the 1000 most variable transcripts (Figure 16 A) yielded significant 
correlations between hepatic zones and the first two principal components (PC1: r = 0.47, p= 2.0 × 10−4; 
PC2: r = 0.86, p < 2.2 × 10−16), explaining 91.78 % of total variability in the dataset (Sup. Figure 2 A). This 





Figure 16: Transcriptional zonation along the porto-central axis revealed by lcm-RNA-seq on microdissected hepatic 
zones of the human liver (n = 19). Pericentral (CV) is colored in green, intermediate (IZ) in grey and periportal (PP) in 
blue. The annotation legend with corresponding symbols displays controls (NC) in light blue, healthy obese (HO) in dark 
blue, steatosis (STEA) in red and early NASH (EARLY) in orange. A – Principal component analysis of the 1000 most 
variable transcripts (Brosch et al., 2018). B – Expression z-scores of zonated genes (805) at pericentral, intermediate 
and periportal zones determined by edgeR with |log2FC| > 1 and FDR < 0.01 between pericentral and periportal 
samples. The heatmap is clustered by Pearson correlation between genes (Brosch et al., 2018). C – Maximum 
normalized expression scores (including standard deviation) in human hepatic zones of exemplary genes with previously 
described strong zonation gradients in mouse liver (Halpern et al., 2017). Dashed lines are for visualization and do not 
necessarily reflect the actual transcriptional gradient between zones (Brosch et al., 2018). D – Comparison with a recent 
lcm-RNA-seq based study on pericentral and periportal hepatocytes from 3 human donors (McEnerney et al., 2017). 
The scatterplot displays the Pearson correlation of log2 fold changes of genes with zonal expression (120) detected by 
McEnerney et al.  
 
Differential expression analysis between zones was performed using edgeR with a paired model correcting 
for phenotype, sex, age, BMI, and diabetes diagnosis. In total, 805 genes were differentially expressed 
(|log2FC| > 1 and FDR < 0.01) between the periportal and the pericentral zone. Interestingly, we did not 
detect any genes with highest expression in the intermediate zone, but rather transcriptional gradients along 
the porto-central axis (Figure 16 B). While 317 genes showed upregulated expression around the central 




alternative splicing between zones (data not shown). Moreover, it should be noted that differential 
expression analysis using the HOMA index, a more precise measure for insulin resistance than mere 
diabetes diagnosis, as parameter for covariate adjustment results in the detection of 987 zonated genes, 
due to improved FDR correction. The subsequently presented analysis is, however, based on the set of 805 
zonated genes to ensure consistency with our already published findings (Brosch et al., 2018).  
In our human dataset, known zonation landmark genes described in mouse (Halpern et al., 2017) showed 
corresponding zonation profiles (Figure 16 C). A previous study, limited on 3 human donors, revealed 68 
genes with periportal and 52 genes with pericentral predominant expression (McEnerney et al., 2017). A 
comparison of our RNA-seq data showed high Pearson correlation (r = 0.73, p < 2.2e-16) between the log 
fold changes of the genes detected as zonated by McEnerney et al (Figure 16 D). However, our dataset 
tends to have higher fold changes, which might be due to more stringent microdissection of the hepatic 
zones. Moreover, our analysis extends the analysis of McEnerney et al. as we detected considerably more 
zonal genes due to higher statistical power.  
Reducing our dataset to samples with normal liver histology (NC, HO, n = 9) only 470 genes with statistically 
significant zonation profiles were detected. Comparing log2 fold changes of zonated genes in the limited (n 
= 9) and the full analysis (n = 19) including steatotic samples (STEA, EARLY), Pearson correlations from 
0.80 to 0.98 (all p < 2.2 x 10-16, Figure 17) were detected, indicating an impact of pairwise effect sizes on 
FDR cut-offs due to limited power in the reduced dataset, instead of biological variance between control and 
steatosis samples. It should be noted that differential expression analysis between steatotic and control 
samples for pericentral, intermediate and periportal zone revealed in total a deregulation of 467 genes (Sup. 
Figure 3), however largely irrespective of hepatic zone. Thus, although there are phenotype-related 
transcriptional differences, the relative zonation patterns apparently remain stable in the early phases of 
NAFLD (Figure 16, B), which will be described more detailed in chapter 3.1.2. 
 
Figure 17: Transcriptional zonation in the full dataset (including steatosis and early NASH) compared to zonation 
detected in normal lean and healthy obese controls only. Scatterplots of log2 fold changes of zonated genes detected 
in both comparisons (A), only in the full dataset (B) respective only in the control dataset (C) with according Pearson 






3.1.1.2 Epigenetic zonation profiles 
 
Figure 18: DNA methylation gradients along the porto-central axis detected by lcm-RRBS on microdissected hepatic 
zones of the human liver (Brosch et al., 2018). Samples (n = 19) are annotated as described in Figure 16. A – Principal 
component analysis of the 5000 most variable CpGs with coverage > 5 in all samples. B – Average methylation values 
at the top 1000 differentially methylated regions detected with methylkit (CpG coverage > 10, 500 bp tiles, at least 3 
CpGs, FDR adjusted p-value < 0.01) between pericentral and periportal that were also covered in the intermediate zone. 
Average CpG methylation differences between CV and PP range between 12.4% and 49.2%. Blue corresponds to low 
and red to high average methylation values per DMR. C – Genomic annotation of all 17,862 DMRs between CV and 
PV. 
AluI/HaeIII double digested RRBS libraries matching the RNA-seq dataset (chapter 3.1.1.1) were generated 
using adjacent cryosections to profile DNA methylation across hepatic zones. Libraries were at least 
sequenced to a mean CpG coverage of 5 (Sup. Table 1). Although less pronounced as for transcription, a 
PCA of the 5,000 most variable CpG sites showed separation by hepatic zone, with highly significant 
correlation of PC1 and zonation (r = 0.44, p = 6.7 x 10-4, Sup. Figure 2 A), indicating an impact of zonation 
on methylation patterns. Covariate adjusted analysis of differentially methylated regions (DMRs) using 
MethylKit (coverage > 10, ≥ 3 CpGs per 500 bp tile, chapter 2.2.2.2) between the pericentral and periportal 
zone yielded 17,862 DMRs with at least 5 % methylation difference (FDR < 0.01). Strikingly, only 23 
significant DMRs with the highest methylation difference in the intermediate zone were detected between 
PV or CV and IZ. The vast majority of DMRs exhibits a methylation gradient along the porto-central axis 




partially methylated domains no significant methylation differences were detected between zones (data not 
shown). Certainly also attributed to the restriction motives of the chosen restriction enzymes, the majority of 
DMRs was found in a gene-context, and only 18.7 % of DMRs were located in intergenic regions (Figure 
18, C).  
 
3.1.1.3 Integration of zonal gene expression, DNA methylation and transcription factor binding 
Particularly in case of pronounced anti-correlation between promoter CpG methylation and gene expression, 
there might be a decisive regulatory function of DNA methylation on expression levels. Moreover, intragenic 
or further distal regions featuring zonal DNA methylation patterns could impact gene expression in a more 
complex manner. To assess correlations between zonal gene expression and DNA methylation patterns, 
DMRs were annotated to their closest gene. DMRs related to differential expression (Figure 19 A) were 
predominantly located in introns (46.4 %), exons (18.7 %) and promoter regions (24.7 %, Figure 19 B). In 
total, 44.3 % (357) of zone-specific DEGs were associated with zonal DMRs (1094, Figure 19 A), in which 
205 DEGs corresponded to multiple DMRs. Gene expression and associated DNA methylation differences 
were largely anti-correlated (r = −0.37, p < 2.2 × 10−16). In the pericentral zone 132 genes showed 
transcriptional upregulation corresponding to 430 hypomethylated DMRs, while 139 periportal DEGs were 
associated with 291 hypomethylated DMRs. 
A representative example is the Wnt signaling pathway member Palmitoleoyl-Protein Carboxylesterase 
(NOTUM), which is exclusively expressed in pericentral hepatocytes and exhibits a cluster of six promoter 
DMRs with pronounced pericentral hypomethylation (Figure 19 C). Publicly available DNaseI-seq and 
ChIPseq data from the hepatocyte-like cell line HepG2 (ENCODE V3) indicate regulatory activity for these 
DMRs, suggesting a potential effect of DNA methylation in the regulation of zonal gene expression. Yet, we 
also detected 186 DEGs positively correlating with DNA methylation changes (Figure 19 A), and multiple 
DMRs associated with the same DEG did not necessarily behave similarly. A total of 99 DEGs exhibited 
mosaic DNA methylation patterns, suggesting differences in regulatory potential of DMRs, for example by 
affecting transcription factor (TF) binding dynamics.  
Indeed, subsequent in silico analysis of TF binding motives revealed enrichment of distinct sets of TFs for 
negatively and positively DEG correlating DMRs (Figure 19 D). The most significant TFs for hypomethylated 
DMRs corresponding to upregulated expression include hepatic nuclear factor 4a (HNF4α), involved in the 
regulation of numerous hepatic genes (Odom et al., 2004), TCF7L2, a key factor downstream of the Wnt 
signaling pathway (Yi et al., 2005), and Foxo1, which regulates metabolic homeostasis in response to 
oxidative stress and promotes gluconeogenesis in hepatocytes (Barthel et al., 2005). In contrast, binding 
motives of ligand-dependent Aryl Hydrocarbon Receptor (AHR), which plays a major role in the regulation 
of drug metabolizing enzymes such as cytochrome P450 (Ramadoss et al., 2005), and the C/EBP family, 
essential for many liver functions like nutrient metabolism and liver regeneration (Takiguchi, 1998), were 
enriched in hypomethylated DMRs associated with reduced gene expression. Interestingly, TCF7L2, HNF4α 
and C/EBP were enriched only in DMRs hypomethylated in the pericentral zone (Sup. Table 3), while AHR 
and Foxo1 were more strongly enriched in periportal hepatocytes (Sup. Table 4), suggesting potential 





Figure 19: Integration of gene expression and DNA methylation profiles across hepatic zones. A – Visualization of gene 
expression (purple) and DNA methylation (dark red) z-scores of 1094 DEG-associated DMRs and corresponding genes 
at pericentral (green), intermediate (red) and periportal zone (blue). Yellow heatmap values corresponds to low z-scores 
(reduced expression or DNA methylation) and navy to high z-scores (increased expression or DNA methylation). 
Negative or positive Pearson correlation between expression and methylation z-scores are annotated in blue and red, 
respectively. B – Genomic annotation of DEG-associated DMRs (Brosch et al., 2018).C – Exemplary genome browser 
representation of expression and DNA methylation signatures across hepatic zones (Brosch et al., 2018). Expression 
of the Wnt signaling pathway member NOTUM is restricted to the pericentral zone. The 5 kb promoter region features 
6 DMRs with methylation differences from 10.7 % to 36.5 % anti-correlated with gene expression. A representative 
healthy obese sample was used for visualization. Pericentral tracks are displayed in green, intermediate in red and 
periportal in blue. RRBS coverage tracks are colored in grey. Potential regulatory regions (purple) are illustrated by 
HepG2 ENCODE data for chromatin accessibility generated by DNase-seq and the histone modifications H3K4me1, 
H3K4me2, H3K4me3 and H3K27ac by ChIP-seq. DMRs are marked by black boxes with mean methylation difference 
between pericentral and periportal hepatocytes calculated from all samples (n = 19) considering only CpG sites with 
coverage > 10. D – In silico analysis of transcription factor binding motives in negatively (outlined in blue) and positively 
(red) expression correlated DMRs using HOMER. Presented are the 4 most significant TFs with p-value and respective 




Hence, together with Alexander Hermann and Prof. Dr. Jochen Hampe (TU Dresden), porto-central DNA 
methylation differences at experimentally verified TFBS of 59 TFs with publicly available ChIP-seq data for 
the hepatocyte-like cell line HepG2 (ENCODE V3) were analyzed to further substantiate these findings.  
 
Figure 20: DNA methylation gradient of transcription factor binding sites (TFBS) along the porto-central hepatic axis 
(Brosch et al., 2018). A – Bubble plot of 46 TFs displaying significant (p < 2.8 × 10−4) DNA methylation gradients at their 
binding sites. The y-axis depicts the average methylation difference, normalized for the mild genome-wide CV 
hypomethylation (-1.27 %), between pericentral (CV) and periportal (PV) at DMR overlapping TFBS, with negative 
values corresponding to CV hypomethylation. The x-axis depicts the log10 fold enrichment of DMRs among TFBS. 
Bubble sizes correlate with log10 p-values, calculated by Fisher’s exact test, with large bubbles referring to especially 
low p-values. Genome-wide TFBS are derived from HepG2 ChIP-seq data (ENCODE V3). B – Exemplary DNA 
methylation gradients of DMRs containing binding sites for TCF7L2. Plots are based on calculations of DMR enrichment 
and DNA methylation gradients at TFBS performed by Alexander Hermann. The detailed method is provided in our 
publication (Brosch et al., 2018). 
Indeed, 46 TFs showed highly significant (p < 2.8 × 10−4) DNA methylation gradients between pericentral 
and periportal hepatocytes at their binding sites (Figure 21 A). Intriguingly, these TFs were uniformly 
expressed along the porto-central axis, but their target genes frequently showed zonal expression patterns, 
which might be attributed to differential signaling efficacy of respective TFs. As certain TFs may have 
differing binding preferences for methylated and unmethylated DNA (Spruijt and Vermeulen, 2014), 
presumably contributing to the establishment of TF binding dynamics, information regarding binding 
preferences of the 46 TFs showing DNA methylation gradients (Figure 21 A) was gathered from current 
literature (Sup. Table 5). For several TFs only in silico predicted data were reported, thus these findings 
were validated by analyzing average DNA methylation at respective TFBS in HepG2 using publicly available 
WGBS data (DEEP), indicating the same binding preferences as previously reported (Sup. Table 5). While 
most of the analyzed TFs preferentially bind unmethylated DNA, there are several TFs, such as RXRa and 
CEBPB, specifically binding methylated CpGs. Both RXRa and CEBPB binding sites are enriched in DMRs 




A), thus suggesting an increased periportal binding efficiency. RXRa is a key factor for the activation of fatty 
acid oxidation (Hardwick et al., 2009), which is known to be localized in periportal hepatocytes (Figure 9). 
Likewise, periportal hypermethylation of CEBPB binding sites is in accordance with its involvement in hepatic 
liver regeneration (Jakobsen et al., 2013), which is probably driven by a periportal hepatocyte subpopulation 
(Font-Burgada et al., 2015). Contrary, TFs binding unmethylated DNA would be expected to be enriched in 
hypomethylated DMRs. For instance, TCF7L2, which actually features the most pronounced zonal 
methylation gradient (Figure 21, B) and is strongly enriched in hypomethylated DMRs correlating with 
upregulated gene expression (Figure 20 D and Figure 21 A), strongly indicates higher pericentral signaling 
efficiency. This is in line with the detected pericentral expression of alleged TCF7L2 target genes such as 
AXIN2, LGR5, CYP1A1 or OAT (Norton et al., 2014). Taken together, these observations indicate that DNA 
methylation gradients may elicit the zonated activity of otherwise uniformly expressed TFs by regulating 
differential binding efficiency. 
 
3.1.1.4 Morphogen gradients regulating hepatic zonation 
 
Figure 21: Mitochondrial, metabolic and morphogen zonation. A – Mitochondrial abundance gradient deduced from the 
fractions of mitochondrial reads in the RRBS data (n = 19) in pericentral (green), intermediate (grey) and periportal (blue) 
zones (Brosch et al., 2018). Significant differences between zones detected by Wilcoxon test are marked by asterisks 
(p < 0.001). B – Mitochondrial expression gradient identified by the ratio of lcm-RNA-seq reads mapping to mitochondrial 
genes. Differences between zones were not significant (NS). C – Visualization of significantly enriched GO terms (p < 
0.05) of genes with zonated expression signatures (Brosch et al., 2018). Negatively scored GO terms (green) correspond 
to pericentral GO enrichment, positive scores reflect periportal GO terms (blue). The circle size represents the number 
of zonated genes related to the respective term. Exemplary GO terms are labelled. The full GO enrichment analysis is 





Besides gradients of gene expression and DNA methylation, a significant mitochondrial gradient along the 
porto-central hepatic axis, deduced from the ratio of mitochondrial reads in the RRBS data, was observed 
(Figure 21 A). In line with the known oxygen gradient and resulting oxidative capacity, mitochondrial 
abundance is highest in the periportal zone and decreases towards the pericentral zone. A trend to zonation 
is also evident in mitochondrial gene expression (Figure 21 B) and likely reflects zonal metabolic activity 
(Figure 21 C), identified by gene ontology enrichment analysis of zonal expression and DNA methylation 
patterns (Sup. Table 6 and 7).  
Moreover, zone-specific enrichment of signaling pathways was detected (Figure 21 C). In the periportal zone 
an accumulation of Notch signaling pathway related genes was observed (e.g. GO:0007219, p = 1.7 × 10−4, 
Figure 23 A), while there was a strong enrichment of Wnt signaling among the pericentrally upregulated 
genes (e.g. GO:0016055, p = 5.7 × 10−4, Figure 22 A). Notch and Wnt signaling pathways are of major 
interest regarding regulation of hepatic zonation as well as liver regeneration. Both on the transcriptional 
and epigenetic level, networks of key pathway members showed zonal differences (Figure 22 A, Figure 23 
A), while other morphogen pathways relevant for hepatocyte functions, such as FGF, TGF beta, HGF and 
BMP were neither epigenetically nor transcriptionally zonated (FDR < 0.01). 
 
Figure 22: Wnt signaling pathway. A – Expression and DNA hypomethylation signature of the Wnt signaling KEGG 
pathway. Genes colored in green are associated with pericentrally hypomethylated DMRs, while blue corresponds to 
hypomethylated DMRs in the periportal zone. Accordingly, genes framed in green are pericentrally expressed and blue 
frames illustrate periportal expression. B – Expression z-scores of Wnt signaling pathway genes (GO:0016055, 
GO:0090263 and GO:0030178) along the porto-central axis (Brosch et al., 2018). The annotation legend displays 
hepatic zones and phenotypes as described in Figure 16.  
Classical Wnt agonists such as WNT3A or WNT3 as well as genes of the export machinery like PORCN1 
or WLS do not show zonated expression profiles. Instead, Wnt signaling enhancers RSPO2, RSPO3 and 
LGR5 are almost exclusively expressed in pericentral hepatocytes, and negative Wnt regulators including 
AXIN2, NOTUM, NKD1, RNF43 and ZNRF3 are also strongly upregulated in the pericentral zone (Figure 22 




such as a pericentral hypomethylation of DMRs associated to AXIN2 (Δmeth = 5.0–29.3%), NOTUM 
(Δmeth = 10.7–36.5%, Figure 19 C) and LGR5 (Δmeth = 9.2%). Yet, several Wnt signaling pathway 
members, which do not exhibit zonal expression profiles, show still zonated DNA methylation. Moreover, 
binding sites of the key downstream effector of Wnt signaling TCF7L2 show a more than 5 fold enrichment 
at pericentral DMRs (Figure 20 B). Taken together, these gradients of zonated Wnt signaling members 
suggest the sensitization of pericentral hepatocytes for canonical Wnt signals in a tightly controlled signaling 
environment, presumably representing a key regulatory mechanism for the establishment and maintenance 
of hepatic zonation. 
 
Figure 23: Notch signaling pathway. A – Expression and DNA hypomethylation signature of the Notch signaling KEGG 
pathway annotated as described in Figure 23. B – Expression z-scores of Notch signaling pathway genes (GO:0007219) 
along the porto-central axis (Brosch et al., 2018). 
Interestingly, LGR5 (logFC = 7.15, FDR = 4.88 × 10−26), which shows the strongest pericentral zonation 
profile, and AXIN2 (logFC = 2.24, FDR = 6.17 × 10−5) expression are strongly correlated with expression of 
the fetal liver progenitor marker TBX3 (pairwise expression correlation to AXIN2: r = 0.51, p = 5.36 × 10−5 
and LGR5: r = 0.86, p < 2.2 × 10−16, Figure 24 A). The genomic landscape associated to TBX3 displays 11 
pericentrally hypomethylated DMRs (Δmeth = 6.9–43.6%), reflecting the highly significant pericentral 
upregulation of TBX3 expression (logFC = 2.26, FDR = 4.1 × 10−59, Figure 24 A). These observations are in 
line with previous reports in mouse, suggesting AXIN2 and LGR5 positive hepatocytes as potential source 
of homeostatic regeneration (Wang et al., 2015).  
Periportal Notch signaling was also apparent on transcriptional and epigenetic level (Figure 23 A and B). 
For example, NOTCH ligand JAG1 (logFC = 2.03, FDR = 1.64 × 10−5, Δmeth = 5.3 to 10.0%) displayed 
pronounced upregulation that correlates with hypomethylation of associated DMRs in periportal hepatocytes 
(Figure 24 A). Moreover, the liver stem cell marker EPCAM, potentially marking a periportal hepatic 
progenitor cell niche (Yoon et al., 2011), showed a particularly strong periportal expression (logFC = 5.42, 





Figure 24: Morphogen gradients and resulting regulatory networks along the porto-central axis. A – Transcriptional and 
DNA methylation profiles of LGR5, AXIN2, TBX3, EPCAM and JAG1, projected against principal component 2 as a 
measure for zonation (Figure 16, A). For better visualization the PC2 axis was inverted. Transcription values are depicted 
as maximum normalized scores. Methylation (%) refers to the DMR with the strongest absolute average methylation 
difference between pericentral and periportal. Green corresponds to pericentral (CV), grey to intermediate (IZ) and blue 
to periportal (PV) samples. B – String interaction network of LGR5, AXIN2, TBX3, EPCAM and JAG1 and their direct 
interaction neighbors with zonated transcription. The color gradient refers to zonal expression profiles with green 
illustrating predominant pericentral expression and blue corresponding to periportal upregulation. Key morphogens are 
highlighted by black boxes. 
Integrating zonal expression of Wnt and Notch signaling pathway members in a network based on known 
protein interactions (Figure 24 B) suggests an intricate interplay of both pathways and underlines their 
presumable importance for the maintenance of liver zonation in the human. 
In summary, the zonal expression and DNA methylation analysis of liver samples with normal histology as 
well as with bland steatosis and early steatohepatitis revealed pronounced, largely anti-correlated 




alcoholic fatty liver disease show consistent gene expression differences corresponding to the severity of 
the disease across all zones, the relative zonated gene expression and DNA methylation patterns remain 
unchanged. Prominent gradients of DNA methylation at binding sites of uniformly expressed transcription 
factors suggest a zonally differential binding efficiency of those TFs, representing an epigenetic layer in the 
regulation of hepatic zonation. Moreover, zonation patterns are probably established and maintained by the 
interplay of Wnt and Notch morphogen signaling pathways, which might also play a role in hepatic 
regeneration. The pericentral epigenetic and transcriptional Wnt signature supports the concept of a 
pericentral hepatocyte regeneration pathway under steady-state conditions, while a periportal Notch 
signaling might be indicative of a stem cell niche activated by chronic liver injury. To further substantiate 
these findings, the second part of this project (V0.2) is dedicated to the analysis of more progressed NASH 
and cirrhosis samples, which might contribute to the better understanding of Wnt and Notch signaling 




























3.1.2 Hepatic zonation in progressed NASH, fibrosis and alcoholic cirrhosis 
In an attempt to unravel hepatic zonation in progressed NASH and alcoholic cirrhosis, the dataset (V0.2) 
was extended with zonal samples from donors with inflammatory steatohepatitis (NASH), steatohepatitis 
with grade 3 fibrosis (FIB3), and from patients with severe alcoholic cirrhosis (ACI). Moreover, additional 
replicates of controls and earlier NAFLD stages were included to obtain higher statistical power (Figure 15). 
Samples from more progressed disease stages turned out to be rather challenging regarding the preparation 
of RRBS sequencing libraries. Filtering of low quality samples yielded in total 139 zonal transcriptomes (Sup. 
Table 2) and 106 DNA methylomes (Sup. Table 1), resulting in 104 matching samples with high data quality. 
Differential gene expression analysis was based on the full transcriptome dataset (n = 139) to ensure a 
sufficient number of replicates. Integrative epigenomic analysis was then performed on the core set of 104 
matching samples. 
 
Figure 25: Exemplary histological Cresyl Violet staining of a periportal (PV) and pericentral (CV) region in cirrhotic liver 
tissue. Microdissected regions are marked in red. Images were kindly provided by Dr. Mario Brosch and Fabian Reichel. 
It should be noted that fibrotic and cirrhotic liver tissues exhibit fibrous septa, which consist out of type I 
collagenous fibrotic material and are infiltrated with different cell-types such as fibroblasts and immune cells. 
In fatty liver diseases, they are accumulated around the central vein, but can also bridge across the hepatic 
lobule in progressed stages (Younossi et al., 2018). To ensure the analysis of hepatocyte signatures, the 
fibrotic material itself was excluded from microdissection. Thus, only hepatocytes bordering fibrous septa 
close to central vein (CV) or portal field (PV) were sampled for NGS library preparation of FIB3 and ACI 
samples (Figure 25). 
Potential contamination with non-parenchymal cells was again estimated based on expression levels of 
known cell-type marker genes (Sup. Figure 1 A, V0.2). Most NPC markers showed comparably low 
expression levels as in the first round of data generation (V0.1). However, higher expression of the 
macrophage marker CD68 was observed, which was apparently attributed to a random increase of 
macrophage contamination in few libraries comprising NC, EARLY and ACI samples (Sup. Figure 1 B). In 
addition, expression levels of cholangiocyte markers, and to a lesser extent also fibroblast markers, were 




(Sup. Figure 1 C). On the other hand, during severe liver injury hepatocytes have the potential to 
transdifferentiate into cholangiocytes (Michalopoulos et al., 2005), which may explain the observed 
cholangiocyte signatures in the microdissected hepatocytes. Nevertheless, marker gene expression levels 
were still in an acceptable low range, allowing the analysis of predominant hepatocyte signatures across all 
phenotypes in the dataset. 
Principal Component Analysis (PCA) of the 1000 most variable transcripts in the full dataset (V0.2) revealed 
a pronounced separation of cirrhosis samples from controls and NAFLD samples (Figure 26 A). While in 
controls and NAFLD clustering by hepatic zone was still perceivable, cirrhosis samples did not show any 
separation by zonation. Thus, in this setting (V0.2), the phenotype was identified as a major driver of 
transcriptional variance (Sup. Figure 2 B). To obtain a more precise impression regarding hepatic zonation 
in individual phenotypic groups, separate group-wise transcriptome PCAs were performed (Sup. Figure 4). 
Indeed, principle components of controls (NC, HO) and NAFLD samples (STEA, EARLY, NASH) showed 
significant correlations with hepatic zones, although correlations were already reduced in inflammatory 
NASH. Contrary, principle components of fibrotic NASH (FIB3) and cirrhosis samples (ACI) correlated only 
with donors, indicating a deregulation of hepatic zonation patterns in progressed fatty liver disease (Sup. 
Figure 4). 
 
Figure 26: Principal Component Analysis of the 1000 most variable transcripts (A, n = 139) respective 3,621 CpGs with 
coverage above 5 in all samples (B, n = 106) detected in zonal hepatocytes isolated by LCM from human donors 
spanning the whole spectrum of fatty liver disease from healthy controls to cirrhosis. Hepatic zones (CV, IZ and PV) are 
depicted as symbols. The annotation legend displays controls (NC) in light blue, healthy obese (HO) in dark blue, non-
alcoholic steatosis (STEA) in red, early NASH (EARLY) in orange, progressed NASH (NASH) in dark red, fibrosis (FIB3) 
in black and alcoholic cirrhosis (ACI) in grey. In panel B a steatotic outlier (donor 7137) is marked by arrows. 
As PCA only considers data points present in all samples, it was restricted to the 3,621 CpGs with coverage 
above 5 in all 106 samples of the DNA methylation dataset. It showed a separation of fibrosis and cirrhosis 
samples from controls and NAFLD samples without obvious relation to hepatic zone (Figure 26 B). The first 




phenotype and less pronounced with donor, age, HOMA index as indicator for type 2 diabetes, and also 
slightly with CpG coverage and batch (Sup. Figure 2 B). Due to experimental setup, batches (V0.1 and V0.2) 
themselves correlated with phenotype (r = 0.531, p = 1.8 x 10-11). As correlations between PCs and batches 
were considerably lower, there are probably no major batch effects, both in transcriptome and methylome 
datasets (Sup. Figure 2 B). Thus, no batch corrections were performed prior to more detailed data analysis.  
It should be noted that steatotic donor 7137, which was already found to be an outlier in the initial methylome 
analysis (Figure 16 A), clustered with fibrotic and cirrhotic samples. Based on liver pathology and clinical 
data (Table 2), this sample was clearly defined as bland steatotic. Interestingly, even though there were no 
signs of inflammation, it exhibited a mild fibrosis (grade 1). However, several EARLY and NASH samples 
also featured a fibrosis grade 1 and still did not cluster with the more progressed fibrotic samples (grade 3). 
Thus, clustering of the outlier 7137 is probably not explained by fibrosis grade. Taken together, both on 
transcriptional and epigenetic level, PCAs suggest that progressed stages of fatty liver disease contribute 
more to variability than hepatic zonation and further indicate a fibrosis associated disruption of hepatic 
zonation profiles.  
 
Figure 27: Group-wise expression and DNA methylation heatmaps of genes (A) and DMRs (B) zonated in normal liver 
tissue. A – Clustered expression z-score heatmap (manhattan clustering distance). The row annotation (Signature) 
relates to predominant pericentral (CV: green) or periportal (PV: blue) expression in healthy liver. B – The heatmap 
shows average methylation of the 1000 most variable zonal DMRs (500 bp tiles) and is sorted by average pericentral 
methylation. Columns are sorted by hepatic zone. DMRs not covered in all samples of the displayed group are excluded. 
Prior to more detailed analysis of progressed fatty liver disease it should be noted that differential gene 
expression analysis between pericentral and periportal samples of the combined dataset (V0.1 and V0.2), 
excluding FIB3 and ACI samples to prevent disease associated variability, yielded due to higher statistical 
power a total of 1,073 zonated genes. Fold changes were highly correlated with the original analysis of 
dataset V0.1 (r = 0.953, p < 2.2 x 10-16). To ensure consistency with previous findings, the original set of 
zonally expressed genes (Brosch et al., 2018) was used for further analysis of hepatic zonation in 





Figure 28: Zone-specific expression levels of the top 20 pericentrally (A) and periportally (B) zonated genes during fatty 
liver disease progression from normal controls (NC) to cirrhosis (ACI). Expression levels are displayed as log (CPM + 
1). The analysis is based on the zonated gene list described in chapter 3.1.1 (805 genes). 
To obtain a first impression regarding the impact of fatty liver disease progression on hepatic zonation 
signatures, expression patterns of the genes previously detected as zonated in normal liver tissue (V0.1), 
as well as DNA methylation patterns at zonated DMRs (V0.1), were visualized for individual phenotypes 
(Figure 27 A and B). Expectedly, this analysis confirmed stable expression and DNA methylation zonation 
patterns in steatosis and early steatohepatitis. Intriguingly, it also suggests a progressive loss of 
transcriptional and epigenetic zonation signatures in fibrosis and cirrhosis. In this context, especially genes 
with pronounced expression differences between hepatic zones exhibit considerably deregulated 
expression across zones in late disease stages (Figure 28). From late NASH to fibrosis and most 
pronounced in alcoholic cirrhosis a progressive loss of pericentrally expressed genes was detected (Figure 
28 A). Simultaneously, an upregulation of periportal genes in these pericentral hepatocytes was observed 
(Figure 28 B). Though less pronounced these effects were also found when assessing all 806 zonated genes 




fatty liver disease pericentral hepatocytes might become more similar to periportal hepatocytes. This 
phenomenon was termed portalization of pericentral hepatocytes.  
 
Figure 29: Pearson correlation based comparison of zonated gene expression (A) and DNA methylation (B) between 
fatty liver disease stages and healthy liver tissue. Displayed Pearson correlation coefficients (r, p < 8.2 x 10-6) were 
calculated for logFC of genes zonated in healthy liver. DEGs and DMRs colored in red were detected as significantly 
zonated both in healthy liver and the displayed phenotypic group, while those only zonated in the original healthy liver 
tissue analysis (V0.1) are colored in black. In addition, zonated DEGs and DMRs detected uniquely in the phenotype-
specific analysis between pericentral and periportal hepatocytes are illustrated in grey. 
To provide more systematical evidence for the progressive loss of transcriptional zonation, zonal expression 
log fold changes in normal liver (V0.1) were correlated with those detected individually in each phenotypic 
group (Figure 29 A). While controls (NC, HO) and early stages of NAFLD (STEA, EARLY) showed high 




0.87) to FIB3 (r = 0.33) and further to ACI (r = 0.24). In NASH, 75 genes with zonated expression between 
CV and PV hepatocytes were detected, while in FIB3 and ACI no zonal gene expression was observed 
anymore.  
Likewise, zonal DMR methylation patterns of individual phenotypes featured high correlations with normal 
liver (V0.1) in controls and early NAFLD (r = 0.69 – r = 0.77) and decreased correlation in progressed NASH 
(r = 0.37), while in FIB3 (r = -0.06) and ACI (r = -0.11) zonated DNA methylation profiles did not correlate 
with epigenetic zonation in normal liver (Figure 29 B). Contrary to transcriptional zonation, also in late 
disease stages a considerable amount of significantly zonated DMRs was shared with normal liver (NASH 
= 1,317, FIB3 = 292, ACI = 2,026). Interestingly, in NASH 21.0 %, in FIB3 54.6 % and in ACI 58.2 % of these 
shared DMRs showed zonation profiles opposed to normal liver. Pericentral hypomethylation in healthy 
tissue turned into periportal hypomethylation in progressed disease, and vice versa, which indicates a 
pronounced epigenetic remodeling of zonation profiles during the progression of fatty liver disease. 
Moreover, in all analyzed phenotypes additional zonated DMRs were detected (NC = 5,797, HO = 5,797, 
STEA = 8,653m EARLY = 14,578, NASH = 29,156, FIB3 = 4,121, ACI = 10,139), which were not found in 
the original zonation analysis (V0.1). These DMRs showed low overlap between samples (9 % - 25 %), 
which is only partially explained by variability of CpG coverage in the RRBS libraries. Furthermore, it should 
be noted that the phenotype-specific zonal DMRs might represent low confidence DNA methylation 
changes. However, the standard deviations of these DMRs were not higher than of the DMRs shared 
between phenotypes. As a rather limited amount of replicates was available for DNA methylation analysis 
(n = 2 – n = 7, Figure 31) and DNA methylation patterns in human are subject to inter-individual variability 
(Gunasekara et al., 2019), increasing replicate numbers and also higher sequencing depth might lead to a 
better overlap of zonal DMRs between phenotypes. In summary, the analysis of zonation signatures in 
normal liver in comparison with early and late stages of fatty liver disease reveals a progressive loss of 
transcriptional zonation, together with a pronounced deregulation of zonal DNA methylation patterns. 
In addition, zone-wise differential analysis was performed between disease phenotypes and samples with 
normal liver histology in order to assess also phenotype-specific differences not necessarily directly related 
to hepatic zonation patterns. Normal lean controls (NC) were mostly obtained from colon cancer patients. In 
contrast, besides from being severely obese, healthy obese donors (HO) did not suffer from any diagnosed 
disease. Both NC and HO donors showed normal liver histology, and clinical parameters such as ALT, AST 
(alanine- and aspartate aminotransferase) and ὙGT (γ-glutamyltransferase) were in a normal range. 
Differential expression analysis between HO and NC revealed in total 102 DEGs in any of the three zones. 
The majority of these genes did not exhibit zonated expression profiles (89.2 %), and for zonated genes (11) 
such as SAA1 the relative zonation profiles across the hepatic lobule were stable between the two groups 
(Sup. Figure 6 D). Significantly enriched GO terms (p < 0.05) include liver function associated terms such 
as xenobiotic metabolic process, canonical glycolysis, steroid metabolic process and response to nutrient, 
but also the inflammatory related terms acute-phase response and immune response. These observations 
confirm previous findings, reporting low-grade upregulation of inflammation associated genes in liver tissue 
of obese patients whit normal liver histology (Bertola et al., 2010). However, in NC several genes such as 
ZNF667-AS1, FGL1 and TM4SF5, which were implicated to play a role in tumor and metastasis development 




NC samples were mostly derived from colon cancer patients, and up to 35 % of them develop liver 
metastasis (Valderrama-Trevino et al., 2017), an impact of colon cancer on normal liver homeostasis cannot 
be fully excluded, even though in NC donors no hepatic metastasis were detected yet.  
 
Figure 30: Volcano plots of zone-specific differential expression analysis between HO and the other phenotypic groups 
(NC, STEA, EARLY, NASH, FIB3 and ACI). The x-axis visualizes expression log2 fold changes (logFC), while the y-axis 
depicts negative log10 of FDR adjusted p-values. Significantly upregulated (|logFC|>1, FDR < 0.01) genes and 
respective Venn diagrams are colored by corresponding group (NC = light blue, HO = dark blue, STEA = red, EARLY = 
orange, NASH = dark red, FIB3 = purple, ACI = grey). Venn diagrams show the overlap of DEGs detected in pericentral 
(CV, green line), intermediate (IZ, grey line) and periportal (PV, blue line) zones. 
Thus, both NC and HO do not represent an ideal healthy state. However, due to ethical reasons, it is not 
possible to obtain surgical liver samples from human donors without any medical necessity. As the impact 




obese as well, HO was considered as best control group for zone-wise differential analysis of disease 
phenotypes (Figure 30 and 31). Yet, it should be noted that ACI samples were derived from lean patients, 
which could potentially bias the analysis. Thus, ACI samples were also compared to NC as control group, 
which yielded highly similar log2 fold changes of genes significantly deregulated in ACI (r = 0.937, p < 2.2e-
16), suggesting a negligible impact of obesity associated gene expression differences in the comparison of 
histologically normal liver with cirrhotic tissue. Hence, further analysis focused on HO based differential 
analysis of disease phenotypes (Figure 30 and 31). As this analysis consists of a complex set of multiple 
comparisons, first an overview of phenotype-specific transcriptome and methylome changes is described, 
which is then followed by a more detailed assessment of individual phenotypes. 
Comparing the full range of fatty liver disease including alcoholic cirrhosis, the 18 zone-specific 
transcriptome comparisons between phenotypes yielded in total 2,845 significant DEGs (|logFC| > 1, FDR 
< 0.01) with 1,673 genes detected in multiple comparisons (Figure 30). The number of DEGs increased with 
disease progression. In addition, DEG counts of individual zones indicate more pronounced changes in the 
pericentral region. However, it should be noted that the difference in DEG counts might arise from mere 
FDR adjusted p-value cut-off based statistical effects due to different replicate numbers and inter-sample 
variability of individual comparisons. Canberra clustering of log fold changes of all DEGs detected in the 
dataset, without consideration of FDR adjusted p-values, confirms the increase of differential gene 
expression in progressed disease states (Sup. Figure 6 A). Furthermore it indicates phenotype related 
changes to be more similar in pericentral and intermediate hepatocytes than in periportal hepatocytes. 
Moreover, differential gene expression was more similar between the zones of a phenotypic group than 
between phenotypes (Sup. Figure 6 A), suggesting besides the loss of transcriptional zonation also a 
dominant lobule-wide deregulation of gene expression. Out of all DEGs, 205 genes were previously found 
to have zonated expression profiles in normal liver tissue (V0.1). Thus, 25.4 % of zonated genes were 
detected as differentially expressed during fatty liver disease progression. Along with the overall number of 
DEGs, the number of DEGs that show zonated expression patterns in healthy liver increased with 
progressing disease stage from NASH to fibrosis and finally to cirrhosis (Figure 32 A). Interestingly, most 
zonation-related expression changes were detected in the pericentral zone. As was already indicated in 
Figure 28, they constitute predominant upregulation of genes with strong periportal expression in healthy 
liver as well as a strong downregulation of pericentral genes. Thus, in cirrhosis expression patterns of these 
genes are rather similar across hepatic zones, while they show strong zonated expression in healthy liver 
(Figure 32 B). These findings add further evidence to the hypothesis of progressive portalization of 
pericentral hepatocytes. 
The complementary differential analysis of zone-wise DNA methylation patterns during fatty liver disease 
showed an increase of DMR counts in late disease stages, together with considerably higher effect sizes 
(Figure 31). No major differences regarding the number of hypomethylated and hypermethylated DMRs 
were observed. Interestingly, also standard deviations of significant methylation differences were higher in 
FIB3 and ACI than in controls and NAFLD samples (Sup. Figure 7 A). It should ne noted that overlap of 
DMRs between zones was low (Figure 31), which was frequently explained by differences in CpG coverage 
between samples. The genomic annotation of DMRs was similar across all comparisons with the majority of 




Figure 7 B). In line with transcriptional deregulation (Sup. Figure 6 A), differential methylation levels in 
pericentral hepatocytes and intermediate hepatocytes seem to be more similar than in periportal  
hepatocytes (Sup. Figure 7 C), even though intermediate and periportal hepatocytes share more significant 
DMRs (Figure 31). Moreover, correlations of covered DMRs between individual zones within a distinct 
phenotype were rather low (r = 0.63 – 0.73), which suggests zone-specific differences on the epigenetic 
level and is in line with the phenotype-specific zonation patterns of DNA methylation described in Figure 29. 
 
 
Figure 31: Volcano plots of zone-specific differential analysis of DNA methylation between HO and the other phenotypic 
groups (NC, STEA, EARLY, NASH, FIB3 and ACI). The x-axis visualizes the methylation difference (%), while the y-
axis depicts negative log10 of FDR adjusted p-values. Significant DMRs (|Δ methylation| > 5%, FDR < 0.01) and 
corresponding Venn diagrams are colored by the hypomethylated group (NC = light blue, HO = dark blue, STEA = red, 
EARLY = orange, NASH = dark red, FIB3 = purple, ACI = grey). Venn diagrams show the overlap of DMRs detected in 






Figure 32: Impact of fatty liver disease progression on zonated genes and DMRs. A – Stacked barplot of zone-specific 
DEG counts derived from the comparisons between ACI, FIB3 or NASH with healthy obese (Figure 30) of genes with 
zonal expression profiles in normal liver tissue. P_up (blue) refers to upregulation in disease of genes with periportal 
expression pattern in healthy liver, C_up (red) equivalently to upregulation of pericentral genes in disease, while C_down 
(green) and P_down (yellow) mark respective zonal genes downregulated in disease. B – Exemplary expression z-score 
heatmap of zonal DEGs between ACI_C (grey) and HO_C (dark blue) across all three zones. Red corresponds to high 
expression levels, blue to low or no expression. Pericentral samples are labelled in green, intermediate in grey and 
periportal in blue. Heatmap rows represent genes with periportal (blue) or pericentral (green) expression profiles in 
healthy liver tissue (Zonation). Rows are clustered using manhattan distance metrics. C – Stacked barplot of zone-
specific DMR counts derived from the comparisons between ACI, FIB3 or NASH with healthy obese (Figure 30) of 
regions with zonal methylation signatures in normal liver tissue. ACI_hypo_P (blue) refers to hypomethylation in disease 
of regions with periportal hypomethylation in healthy liver, ACI_hypo_C (red) equivalently to pericentral hypomethylation 
in disease of regions with pericentral hypomethylation in healthy liver, while ACI_hyper_C (green) and ACI_hyper_P 
(yellow) mark respective zonal regions hypermethylated in disease. D - Exemplary methylation z-score heatmap of zonal 
DMRs between ACI_C and HO_C across all three zones, annotated as outlined in panel B. 
Out of 37,635 significant DMRs in ACI in any zone, 29,968 were covered by all comparisons. In total, 1,239 
DMRs were associated with genes with zonated expression in healthy tissue. However, the strongest DNA 
methylation differences were apparently not directly associated with zonated gene expression, but were 
rather detected uniformly across all hepatic zones (Sup. Figure 7 D and E). Still, few selected zone-specific 
DNA methylation differences might exhibit a decisive regulatory potential. Thus, phenotype-specific DMRs, 
which overlapped zonated DMRs in healthy liver (V.01), were assessed in more detail. The most intriguing 
differences were observed in regions hypomethylated in pericentral hepatocytes of normal liver tissue. In 




partially also featured increased hypomethylation in intermediate and periportal zones (Figure 32 C). These 
observations entail the disruption of normal zonated methylation signatures in progressed fatty liver disease 
(Figure 32 D) as already described in Figure 29 B. 
It should be noted that even though high numbers of DEGs and DMRs were detected within the pairwise 
comparisons between HO controls and progressed disease stages (Figure 30, Figure 31), the majority of 
these DMRs (98.6 %) was not annotated to DEGs (Sup. Figure 7 F). Thus, only 22.1 % of DEGs were 
associated with differential DNA methylation. Contrary, in zonation of healthy liver 44 % of DEGs show also 
DNA methylation differences. Possible implications of this observation are discussed in chapter 4.1.2.  
Taken together, this overview of phenotype-specific zone-wise deregulations during fatty liver disease 
progression supports the hypothesis of a progressive disruption of hepatic zonation, both on transcriptional 
and epigenetic level. In the following, the observed disease associated deregulations (Figure 30, Figure 31) 
are characterized for individual phenotypes in more detail, to allow the interpretation of observed DEG and 
DMR patterns also in a more functional context. 
Consistent with previous results (Sup. Figure 3), in bland steatosis (STEA) and early steatohepatitis 
(EARLY) the expression of 413 genes was deregulated. It should be noted that the comparison between 
STEA and HO of the intermediate zone yielded considerably higher DEG counts than for the other zones 
(Figure 30). This can be explained by the lower inter-individual variability observed within this sample group 
(Sup. Figure 6 B), presumably due to differences in technical variability. Differential expression in early 
NAFLD stages (STEA, EARLY) only affected 13 genes with zonated expression profiles, such as SAA1 or 
CYP2C19, which were consistently deregulated across hepatic zones and stages of fatty liver disease (Sup. 
Figure 6 C). In line with our previous findings (Brosch et al., 2018), the relative zonation of these genes 
remains stable in early stages of NAFLD.  
In more progressed steatohepatitis (NASH) zone-specific GO term enrichment analysis of differential gene 
expression revealed for instance liver function related terms such as triglyceride catabolic process (p-
value_CV = 0.014, p-value_PV = 0.012) and lipid transport (p-value_CV = 0.020), which indicate deregulation of 
fatty acids. Moreover, immune response related terms like acute phase response (p-value_CV = 0.03, p-
value_IZ = 0.03, p-value_PV = 0.014) and type I interferon signaling pathway (p-value_CV = 0.009) underline 
the inflammatory state of progressed steatohepatitis. Interestingly, the canonical Wnt signaling pathway was 
significantly downregulated in the intermediate zone (p-value_IZ = 0.005).  
Likewise, in fibrotic samples (FIB3) the regulation of lipid metabolic processes (p-value_CV = 0.010, p-value_IZ 
= 0.016, p-value_PV = 0.025) was deregulated in all hepatic zones, while the disruption of triglyceride 
homeostasis (p-value_CV = 0.010, p-value_IZ = 0.049) was only detected in pericentral and intermediate 
hepatocytes. In line with the progressed disease state, positive regulation of inflammatory response (p-
value_CV = 0.037, p-value_PV = 0.012) and acute phase response (p-value_CV = 5 x 10-5, p-value_IZ = 1.8 x 10-
4, p-value_PV = 0.002) were upregulated across all zones. 
Further detailed analysis focused on alcoholic cirrhosis samples (ACI), as they represent the most severe 
phenotype analyzed in this dataset and showed the most pronounced transcriptional and epigenetic 
differences compared to HO controls (Figure 30, Figure 31). Figure 33 displays the top GO terms either up- 
or downregulated in ACI by individual zone. Several GO terms, including steroid hormone mediated 




DEGs (Figure 33 B). The most upregulated GO term, both in pericentral and periportal hepatocytes, was 
the tumour necrosis factor mediated signalling pathway, which was previously shown to play a role in hepatic 
stellate cell mediated fibrogenesis by remodelling of the extracellular matrix (Tarrats et al., 2011). However, 
more frequently, top GO terms upregulated in ACI were distinct for hepatic zones.  
 
Figure 33: Zone-specific GO enrichment of DEGs detected between ACI and HO. Z-scores represent relative GO 
enrichment, with negative values corresponding to downregulation and positive values to upregulation in ACI. The 20 
GO terms with the strongest enrichment in the pericentral (A) and periportal (B) zone are displayed for all three zones 
with CV colored in green, IZ in grey and PV in blue. The full table of GO terms is shown in Sup. Table 8. Terms enriched 
in DMR associated genes as well are highlighted in red. C – Scatterplot of pericentral and periportal expression logFC. 
Genes with |logFCACI_CV| more than 1 fold change higher than |logFCACI_PV| are defined as pericentral specific DEGs, 
highlighted in green. Accordingly, periportal specific DEGs are marked in blue. GO terms of interest enriched (p < 0.05) 
in zone-specifically deregulated genes are displayed. D – Fraction of mitochondrial reads per zone (pericentral = C, 
intermediate = I, periportal = P) and phenotype (NC = light blue, HO = dark blue, STEA = red, EARLY = orange, NASH 
= dark red, FIB3 = black, ACI = grey). Significant differences detected by Wilcoxon test are marked by asterisk (p < 
0.05). 
Intriguingly, extracellular matrix organization and inflammatory response were uniquely detected in 
pericentral hepatocytes. Moreover, the canonical Wnt signalling pathway was downregulated in pericentral 
and intermediate zones. Even though few enriched GO terms (Sup. Table 8) were shared between DEGs 
and DMRs (Figure 33), matching terms included top terms such as the pericentral depletion of Wnt signaling 
pathway and enrichment of extracellular matrix organization (Figure 33 A). Taken together, GO analysis 




In order to substantiate zone-specific differences, only DEGs with |logFCACI_CV| more than 1 fold change 
higher than |logFCACI_PV| were considered for pericentral specific GO enrichment analysis, and vice versa 
for periportal (Figure 33 C). Indeed, this analysis confirmed the pericentral downregulation of canonical Wnt 
signalling, along with the upregulation of cell proliferation, extracellular matrix organization and inflammatory 
response. DEGs specific for periportal hepatocytes in ACI were enriched for cellular response to tumour 
necrosis factor (Figure 33 C), which was however also identified in the pericentral zone (Figure 33 A).  
In addition, the analysis of mitochondrial abundance, deduced from RRBS coverage, revealed a significant 
difference between HO and ACI in the pericentral zone (Wilcox test p < 0.05). In line with previous findings 
in healthy liver (Figure 21 A), HO samples exhibit a mitochondrial gradient along the porto-central axis. In 
contrast, the ratio of mitochondrial reads was equal across zones in ACI (Figure 33 D), i.e. in cirrhosis 
pericentral hepatocytes apparently resemble periportal hepatocytes on the level of mitochondrial abundance 
as well. 
The observed deregulation of the Wnt signalling pathway in ACI is of particular interest, as we and others 
identified Wnt signaling as an important regulator of pericentral hepatic zonation in normal human liver tissue 
(Brosch et al., 2018; McEnerney et al., 2017). Interestingly, in pericentral hepatocytes derived from cirrhotic 
tissue, several upstream regulators of Wnt signalling such as LGR5, NOTUM and RSPO2 are strongly 
downregulated, while further downstream regulators including β-catenin and Frizzled are upregulated, which 
could potentially be seen as a compensatory effect (Sup. Figure 8 A). Although most DEGs detected in ACI 
were not associated with differential DNA methylation (Sup. Figure 7 F), the Wnt signaling pathway is highly 
enriched for DMRs in pericentral hepatocytes, and especially key regulators such as WNT, AXIN2 and LGR5 
show pronounced DNA methylation differences in ACI (Sup. Figure 8 A). In periportal hepatocytes, which 
show only low expression of Wnt signaling pathway members in normal liver, Wnt signaling is even further 
downregulated, accompanied by differential DNA methylation of several pathway members (Sup. Figure 8 
B). These observations highlight the importance of the Wnt signaling pathways in hepatic zonation, and 
suggest the downregulation of Wnt signaling to play a major role in the loss of hepatic zonation in progressed 
fatty liver disease. 
In contrast, the Notch signaling pathway, which is enriched in periportal hepatocytes of normal human liver 
tissue (Brosch et al., 2018), and was described to be involved in hepatic regeneration upon partial 
hepatectomy (Köhler et al., 2004), was not significantly deregulated in ACI. Yet, a trend towards pericentral 
and intermediate upregulation of NOTCH3 was observed (HO.I vs ACI.I: FDR = 0.014, logFC = - 4.6, HO.C 
vs ACI.C: FDR = 0.030, logFC = -3.7, Sup. Figure 9). The Notch ligand JAG1, which is periportally zonated 
in normal tissue, was also not significantly deregulated, but showed higher inter-individual variability (Figure 
34 A). SOX9, which interacts with Notch signaling in a positive feedback loop (Leung et al., 2016), was 
significantly upregulated in pericentral and intermediate hepatocytes of cirrhotic tissue, with expression 
levels resembling those in periportal hepatocytes (Sup. Figure 9, Figure 34 A). Moreover, the liver progenitor 
marker EPCAM was strongly upregulated in the pericentral zone as well (logFC = 9.8, FDR = 1.9 x 10-6, 
Figure 34 A). Together with the loss of pericentral zonation signatures of Wnt signaling pathway members 
such as LGR5 and AXIN2, and the overall downregulation of liver progenitor marker TBX3 (Figure 34 A), 
the pericentral upregulation of several morphogens, which show periportal expression profiles in normal liver 





Figure 34: Morphogen gradients and resulting regulatory networks in fatty liver disease. A – Transcriptional profiles of 
LGR5, TBX3, AXIN2, EPCAM, JAG1 and SOX9. The x axis represents fatty liver disease progression: NC, HO, STEA, 
EARLY, NASH, FIB3 and ACI. Transcription values are depicted as log (CPM + 1). Green corresponds to pericentral 
(CV), grey to intermediate (IZ) and blue to periportal (PV) samples. B and C – String interaction networks of LGR5, 
AXIN2, TBX3, EPCAM, JAG1 and SOX9 with their direct interaction neighbors with deregulated expression in pericentral 
ACI. Fill colors represent pericentral, border colors periportal hepatocytes. B – Expression illustrated as logFC between 
pericentral ACI and pericentral HO samples. Blue corresponds to downregulation and grey to upregulated expression 
in ACI. C – Methylation difference of associated DMRs. Hypomethylation in ACI is depicted in grey, hypermethylation in 




In order to assess this further, morphogens of interest (LGR5, TBX3, AXIN2, EPCAM, JAG1 and SOX9) as 
well as direct interaction partners which featured both transcriptional (Figure 34 B) and epigenetic (Figure 
34 C) deregulation in pericentral hepatocytes of cirrhotic tissue, were visualized as interaction network. This 
network highlights the intricate interplay between Wnt and Notch signaling, but also includes important 
factors of other signaling pathways such as Sonic Hedgehog signaling, which is described as a pro-
fibrogenic pathway in fatty liver disease (Rangwala et al., 2011).  
In summary, the zonal analysis of steatohepatitis, fibrosis and cirrhosis revealed the progressive loss of 
transcriptional and epigenetic zonation in late stages of fatty liver disease. In particular the portalization of 
pericentral hepatocytes, which is seen on the level of gene expression, but also in zonal mitochondrial 
abundance, might present an important feature of disease progression. In addition, on epigenetic level 
phenotype-specific zonation patterns were detected, which were apparently not directly associated with 
zonated gene expression. These deregulations of hepatic zonation might be associated with the pericentral 




























3.2 Spatial reconstruction of single cell transcriptomes into tissue context 
Multiple observations on hepatocytes microdissected from different zones (3.1) indicate a gradient-like 
regulation of hepatic zonation along the porto-central axis. In particular differential gene expression between 
pericentral and periportal hepatocytes revealed an expression gradient (Figure 16 B), contradicting the 
notion of distinct hepatic zones. This is in line with previous findings from bioinformatical spatial 
reconstruction of single cell RNA sequencing data of hepatocytes from mouse liver (Halpern et al., 2017). 
The inherent low resolution of our microdissection approach limits however the more detailed analysis of 
expression gradients in our human dataset. To this end, spatial reconstruction of high throughput single cell 
RNA sequencing data of a human liver was pursued as complementary approach.  
 
3.2.1 Pseudospace inference of human hepatocytes 
Raw single cell transcriptome data of hepatocytes isolated from human liver were provided by Dr. Mario 
Brosch and Prof. Dr. Jochen Hampe (TU Dresden). Data were generated using the commercial 10X 
Genomics Chromium Single Cell Gene Expression Solution, which is a droplet based high-throughput single 
cell RNA sequencing approach comparable to the Drop-seq method (Macosko et al., 2015). Data were 
processed by Dr. Karl Nordström and gene-wise UMI counts for 14,949 detected barcodes were provided 
as sparse matrix for further analysis. In principle, each individual barcode identifies a single cell. However, 
particularly in high-throughput single cell RNA-seq datasets there is a high amount of technical noise. Thus, 
rigorous quality filtering has to be applied prior to data analysis. The chosen filtering criteria are based on 
recommendations by several state of the art scRNA-seq data analysis packages (Macosko et al., 2015; 
McCarthy et al., 2017; Wolf et al., 2018). During initial filtering, cells with unique UMI count below 2,500 
were excluded (Sup. Figure 10 A) to remove cells with low coverage. To reduce drop out rates, cells covering 
less than 500 genes were excluded as well. Additionally, cells with more than 2,000 genes and or 12,500 
UMIs were filtered out to remove potential cell duplets. Cells with more than 15 % of reads mapping to the 
mitochondrial genome were also excluded, as high amounts of mitochondrial reads indicate dead or 
damaged cells. Thus, initial filtering yielded in total 8,181 single cells with sufficient data quality.  
It should be noted that no filtering of low-abundance genes was performed, as genes such as LGR5 or 
TBX3, which are only expressed at low levels in a small subset of cells, are of major interest regarding liver 
zonation. Instead, the average expression of each gene across all cells was taken into account for 
calculation of highly variable genes (HVGs, Macosko et al., 2015), which were then used for downstream 
analysis. Principal Component Analysis (PCA) of HVGs (Sup. Figure 10 B) showed a dense cluster of cells 
and several outliers. Based on expression levels of marker genes, most outliers were identified as non-
parenchymal cells (NPCs) such as immune cells and cholangiocytes (Sup. Figure 10 B and C). Additional 
filtering by marker gene expression as well as based on principal components (Sup. Figure 10 B and C) 






Figure 35: Dimensionality reduction by PCA (A, E), t-SNE (B, F), UMAP (C, G) and diffusion map (D, H), colored by 
pericentral CYP3A4 expression with yellow representing intermediate and orange high expression levels. The plots are 
either produced on all HVGs (A – D) in the dataset or on 107 HVGs with known zonal expression patterns in human 
liver (E – H). For t-SNE plots different perplexities from 1 to 100 were tested. Presented plots (B, F) are based on a 
representative perplexity of 20 and 11 principle components derived from PCA (A).  
Expression analysis of microdissected hepatocytes from three hepatic zones revealed zonation as a major 
driver of variance in healthy liver (Sup. Figure 2 A). Thus, it was reasoned that HVGs in the single cell 
expression dataset should contain spatial information. Expression variability of single hepatocytes was 
calculated based on average expression and corresponding dispersion for each gene as outlined in the 
SEURAT package (Macosko et al., 2015), yielding 3,633 HVGs. Subsequently, several approaches for 
dimensionality reduction and visualization were considered for pseudo-spatial clustering of cells. To this 
end, resulting plots were colored by single cell expression of strong zonation markers such as the pericentral 
marker CYP3A4 (Figure 35). All findings were validated by using at least 10 pericentral and 10 periportal 
marker genes, ensuring CYP3A4 profiles to be representative of actual zonated expression (data not 
shown). Based on all HVGs in the dataset, PCA (Figure 35 A) did not reveal any obvious clustering of single 
cells by zonation markers. As t-distributed stochastic neighbor embedding (t-SNE) depends heavily on the 
chosen perplexity, which can be considered as a score for the number of expected direct neighbors, several 
reasonable perplexities between 2 and 100 were tested without yielding any obvious zonal clustering. Figure 
35 B displays a representative t-SNE (perplexity = 2). Uniform Manifold Approximation and Projection 
(UMAP), a more recent non-linear algorithm featuring more consistent clustering and preservation of 
continuous expression profiles than t-SNE (McInnes et al., 2018), indicated a slight accumulation of 
pericentral hepatocytes, although no gradient-like patterns were observable (Figure 35 C). As the expected 




diffusion map algorithm, which is a spectral non-linear method relying on continuous diffusion-like dynamics 
and was originally proposed for pseudotime inference (Haghverdi et al., 2015), might serve as reasonable 
tool for pseudo-spatial reconstruction along the hepatic porto-central axis. Indeed, a diffusion map, on all 
HVGs detected in the dataset (Figure 35 D, parameters detailed in chapter 2.2.2.2) showed the best 
separation of hepatic zones of all tested dimensionality reduction approaches. Yet, the separation appeared 
to be rather noisy and did not reveal a clear zonation profile along the diffusion component 1 (DC1), which 
generally represents the strongest source of variation.   
 
Figure 36: Diffusion map based on 107 HVGs with known zonal expression patterns in human liver colored by periportal 
marker HAL (A) and pericentral marker CYP3A4 (B, same plot as Figure 35 H). C – Table with Pearson Correlations 
and corresponding p-values between diffusion component 1 (DC1) and marker genes expression levels for diffusion 
maps generated from all HVGs, zonated HVGs and the subset of zonated genes with the highest expression level in 
the single cell RNA-seq dataset. Counts in brackets display the number of genes in the respective analysis. D – 
Scatterplot of Pearson correlations between DC1 and single cell expression levels of the zonated HVGs used for 






Thus, further analysis was limited on HVGs with significant zonation patterns in the laser capture 
microdissection (LCM) RNA-seq dataset (3.1.1) as reference gene set, thereby reducing other sources of 
variation and focusing the analysis on spatial variability. Indeed, this approach markedly improved 
separation of hepatic zones (Figure 35 E – H). While particularly t-SNE, but also UMAP did not yield 
adequate spatial reconstruction, both PCA and diffusion map resulted in a clear separation of pericentral 
and periportal hepatocytes, suggesting a gradient-like expression pattern (Figure 35 E and H). However, 
hepatocytes of the intermediate zone were not well represented in the PCA. Contrary, the diffusion map 
revealed a striking separation of the three hepatic zones in a gradient along DC1 (Figure 35 H). Thus, further 
validation of pseudospace inference focused on the diffusion map approach. 
For visualization of zonation, a combination of the representative marker genes CYP3A4 (pericentral) and 
HAL (periportal) was selected, which showed clear separation of hepatic zones along DC1 in the diffusion 
map generated on HVGs with zonated expression signatures (Figure 36 A and B). Contrary, DC2 showed 
high Pearson correlations with expression levels of the tumor metastasis markers CXCL1 (r = - 0.830, p < 
2.2e-16) and CXCL2 (r = - 0.780, p < 2.2e-16, Acharyya et al., 2012), even though seemingly healthy liver 
tissue was analyzed. As the sample was derived from a colon cancer patient undergoing screening for liver 
metastasis with negative metastasis diagnostic, expression of these two markers might be explained by 
early stage metastasis development, not yet detectable by standard diagnostic liver biopsy assessment. As 
DC1 already showed a convincing spatial separation, DC2 was not further considered in this context. 
To assess the performance of diffusion map based pseudospace inference, Pearson correlations between 
DC1 of diffusion maps generated on different subsets of HVGs and single cell expression levels of these 
marker genes were assessed (Figure 36 C). As already suggested by diffusion map plots (Figure 35 D and 
H), the diffusion map calculated on all 3,633 HVGs resulted in correlations between DC1 and single cell 
expression levels of HAL (r = - 0.558) and CYP3A4 (r = 0.473) considerably lower than the approach using 
only zonated HVGs. Highly significant Pearson correlation coefficients (p < 2.2e-16) between DC1 of 
zonated HVGs and single cell expression levels of the marker genes (rHAL = - 0.814, rCYP3A4 = 0.906) 
demonstrate the high correlation of DC1 with expression patterns of these strongly zonated genes (Figure 
36 C). Interestingly, limiting the set of HVGs for diffusion map calculation on the 34 genes with the highest 
average expression level and lowest drop-out rate (average normalized log2 expression > 0.1) yielded 
almost the same correlation values as when using all zonated HVGs (Figure 36 C), which indicates that the 
diffusion map is mostly driven by HVGs with high average expression. Presumably, this can be explained 
by low-abundance genes being more susceptible to technical noise, thereby limiting their utility in retrieving 
spatial information from their expression variability across single cells. Further reducing the diffusion map 
on only two genes with high average expression and strong zonation profiles (e.g. CYP3A4 and HAL) still 
yielded a separation by spatial localization. Even though correlations between DC1 and expression levels 
of marker genes were lower than when using all zonated HVGs (rHAL = - 0.636, rCYP3A4 = 0.685), the 
performance was still better than when using all HVGs in the dataset, underlining the robustness of the 
reference gene set based diffusion map approach. Moreover, a systematic analysis considering correlations 
between DC1, generated from all 107 zonated HVGs, and the expected zonation patterns, derived from the 
LCM RNA-seq dataset (chapter 3.1.1), of zonated HVGs confirmed that particularly genes with strong 




between DC1 and log2 expression fold changes of all zonated HVGs is highly significant (cor = - 0.67, p-
value = 3.526e-15) and in a reasonable range, which indicates the validity of this approach. However, 
including also lowly expressed genes apparently does not compromise diffusion map generation (Figure 36 
C). Thus, the diffusion map generated on all zonated HVGs detected in the dataset without filtering of low-
abundance genes with high drop-out rates was selected for dimensionality reduction based pseudospace 
reconstruction of single cell transcriptomes. 
To this end, DC1 coordinates were used to relate single cells to their probable spatial origin. In principle, 
DC1 could be used to assign each cell to a discrete localization in pseudospace. However, to achieve a 
more robust modelling for subsequent zone-specific data analysis, DC1 values were rather considered as 
the probability of a cell to originate from a certain hepatic zone. For this purpose, DC1 thresholds for zone 
definition were selected manually by inspection of the expression patterns of all 107 zonated HVGs. 
Although the underlying diffusion map was calculated on actual normalized expression values, imputed 
expression values were used for visualization to obtain a more interpretable result for lowly expressed genes 
with high drop-out rates. Hence, in total 5,395 cells were assigned to the periportal zone, 1,750 cells to the 
intermediate zone and 768 cells to the pericentral zone (Figure 37 A). Interestingly, this approach yielded 
also a more detailed subdivision within zones (Figure 37 B), which might resemble layers of hepatocytes in 
the anatomy of the hepatic lobule (Figure 9 B). Previously, a study on zonation of the mouse liver lobule, 
which features up to 15 rows of hepatocytes along the porto-central axis, defined 9 hepatic layers (Halpern 
et al., 2017). In the human liver, hepatocytes reside in rows of 15 to 25 cells along the porto-central axis 
(McEnerney et al., 2017). Thus, it was reasoned that subdividing the diffusion map into 10 layers, on average 
containing each two rows of hepatocytes, might reflect a reasonable additional classification. Visualization 
of normalized expression levels as scaled average log2 (CPM + 1) values across these pseudo-spatial layers 
1 to 10 of genes detected as zonated in LCM RNA-seq indeed suggests that these layers might represent 
meaningful hepatic subzones (Figure 37 C). Expected expression profiles of strongly zonated genes 
including GLUL, HAL and H19, as well as genes with less pronounced zonation patterns such as APOLD1 
and FNIP2 are accordingly detected in a gradient-like fashion. Contrary, expression patterns of several 
genes such as ADAMTS1, CMYA5, HMGB3, DMKN and PLIN1 indicate non-monotonic gene expression. 
However, these genes exhibit low average expression levels (log2 (CPM + 1) < 0.5). Thus, scaled relative 
expression levels might overestimate actual differences between layers and should be considered with care. 
For an additional validation of zonal cell assignment, the percentage of reads mapping to mitochondrial 
genes was assessed between zones. Indeed, single cells mapped to the periportal zone showed a 
significantly higher percentage (Wilcox test < 0.001) of mitochondrial reads than those assigned to the 
intermediate or the pericentral zone (Figure 37 D). This finding independently confirms the porto-central 
mitochondrial gradient detected from the fraction of mitochondrial reads in the LCM-RRBS dataset (Figure 
21 A), and indicates an appropriate single cell assignment to hepatic zones.  
To assess whether it is also possible to detect accurate zonation signatures of genes not used for diffusion 
map generation, pericentral CYP2E1 and periportal H19 were removed from the set of 107 zonated HVGs. 
DC1 of the resulting diffusion map was then used as spatial covariate to determine pseudospatial expression 
profiles of both genes (Figure 37 E and G), which revealed striking concordance with their corresponding 




genome-wide reference maps are not available and additional spatial expression patterns should be inferred 
from the single cell dataset. Moreover, patterns of genes with uniform expression along the porto-central 
axis such as VMP1 were confirmed (Figure 37 F), indicating that the diffusion map approach is not prone to 
overestimation of zonated gene expression.  
Finally, diffusion map based pseudotime inference was validated in an independent dataset, comprising a 
small number of deeply sequenced single cell transcriptomes of cryopreserved primary human hepatocytes 
from 3 donors (286 cells, in average 1.8 million reads per cell). Using all 444 HVGs in the dataset resulted 
in a diffusion map capturing mostly inter-individual differences between donors (Sup. Figure 11 A – B). In 
contrast, the diffusion map on the 38 HVGs with zonated expression profiles in healthy liver tissue, yielded 
a separation of hepatic zones along DC1 comparable to the previous analysis of sparse data (Figure 36 A). 
Inter-individual variability was only detected along DC2, allowing the assignment of hepatocytes from 
different donors into hepatic zones (Sup. Figure 11 C – D). Taken together, these results suggest the 
suitability of diffusion map based pseudospace inference and embedding of single cells into hepatic zones 







Figure 37: Reconstruction of hepatic zonation signatures from single cell transcriptomes. A – Cells are assigned to the 
periportal (blue), intermediate (grey) and pericentral (CV) zone based expression of zonation marker genes along DC1. 
For determination of zonal DC1 thresholds, expression profiles of all 107 HVGs were considered. The displayed plot is 
colored by exemplary CYP3A4 expression. B – Frequency histogram of cells assigned to the three with further 
subdivision into smaller layers (1 – 10). C – Heatmap displaying normalized expression levels as scaled average log2 
(CPM + 1) values across pseudo-spatial layers 1 to 10. The heatmap comprises genes detected as zonated in LCM 
RNA-seq with average log2 (CPM + 1) > 0.1 in the reconstructed single cell dataset. Blue corresponds to increasing 
expression in relation to other subzones. Layers are annotated by corresponding hepatic zone and genes are clustered 
by correlated expression. D – Mitochondrial abundance gradient deduced from the ratio of scRNA-seq reads mapping 
to mitochondrial genes [%] in cells assigned to PV, IZ and CV. Significant differences between zones detected by 
Wilcoxon test are marked by asterisks (p < 0.001). E, F and G – Proof of principle: Scatterplots of DC1 from a diffusion 
map generated on zonated HVGs, omitting randomly chosen periportal H19 and pericentral CYP2E1, versus normalized 
single cell expression levels of H19 (E), equally expressed VMP1 (F) and CYP2E1 (G). Grey represents no or very low 





3.2.2 Interspecies comparison of liver zonation between human and mouse 
based on spatial reconstruction of single cells 
The transcriptional zonation of the mouse liver lobule has recently been studied systematically by 
bioinformatical modelling of single cell RNA-seq data (Halpern et al., 2017). This approach combined single 
cell transcriptome data generated by MARS-seq with sm-FISH of 6 zonation landmark genes to infer spatial 
information, thereby defining 9 hepatic zones. To enable an interspecies comparison between human and 
mouse, merged zones 1 to 2 of the mouse data were considered as pericentral, zones 4 to 5 as intermediate, 
and 8 to 9 as periportal. One-to-one matching orthologues were then compared to our human LCM RNA-
seq dataset (3.1.1) and to our human spatially reconstructed scRNA-seq data (3.2.1), yielding 12,179 genes. 
To obtain a deeper impression on methodical bias and the accuracy of pseudospace inference, the human 
single cell RNA-seq dataset was compared to the zonal LCM RNA-seq dataset as well.  
Expression values of all datasets were normalized as log2 (CPM + 1). In reconstructed single cell datasets 
normalized expression values of single cells were averaged across assigned zones. On global transcript 
level high Spearman correlations between datasets were obtained, indicating an overall comparability of the 
datasets (Figure 38 A and B). Correlations between methodically different human datasets were higher (0.84 
– 0.85) than between mouse and human (LCM: 0.74 – 0.75, sc: 0.69 – 0.70), suggesting a higher impact of 
species than of technical variability. Out of the 805 zonated genes detected in the human LCM RNA-seq 
dataset, 575 genes featured one-to-one orthologues in the mouse. Of these, 313 were sufficiently covered 
in the mouse dataset and including the human scRNA-seq dataset reduced the number of covered zonated 
genes further to 299. Compared to global transcript levels, these zonated genes yielded lower Spearman 
correlations (Figure 38 C). The expression of zonated genes still showed considerably high Spearman 
correlations between the human datasets (0.58 – 0.71), indicating a reasonable spatial reconstruction of the 
single cell data. Contrary, correlations of zonated genes between human and mouse were heavily reduced 
(0.29 – 0.40), which suggests differences in hepatic zonation profiles between species.  
In this analysis, the LCM RNA-seq approach was considered as the gold standard for the detection of 
zonated genes expression, as it preserves information regarding the spatial origin of microdissected cells 
and does not rely on bioinformatical pseudospace inference. However, it is also possible to determine 
zonated genes in the reconstructed single cell datasets. To this end, Halpern et al. (2017) considered genes 
with average expression differences between pericentral layer 1 and periportal layer 9 that featured a 
Kruskal-Wallis q-value < 0.2 as zonated. This approach yielded in total 3,496 zonated genes, representing 
about 50 % of expressed genes in the dataset.  
Adapting this approach, the human single cell dataset yielded 1,479 genes with Kruskal-Wallis q-value < 0.2 
of the average expression difference between single cells assigned to the pericentral and periportal zone. 
Yet, the overlap of zonated genes detected in the individual datasets was rather low (Figure 39 A). Only 21 
genes, comprising highly expressed genes with strong zonation profiles such as CYP2E1, CYP1A2, HAL 
and SDS were detected as zonated in all three datasets. Despite high correlations between expression 
profiles of zonated genes (Figure 38 C), both human datasets showed only an overlap of 51 zonated genes. 
The high number of genes only detected as zonated in the single cell dataset (1,472), which did not show 




questions the suitability of the method used by Halpern et al. (2017) for differential expression detection in 
reconstructed single cell data. The 754 zonated genes not detected as zonated by the reconstructed scRNA-
seq approach were not sufficiently covered in the single cell dataset (Figure 39 C). 
 
Figure 38: Comparison of zonal expression in human and mouse, detected by LCM (human) or by spatial single cell 
reconstruction (human and mouse). A – Spearman correlation heatmap of global one-to-one orthologue expression 
levels for individual zones in human LCM RNA-seq, human reconstructed scRNA-seq and mouse reconstructed scRNA-
seq. Dark red corresponds to high correlation. B – Exemplary scatterplots with spearman correlation and corresponding 
p-values of expression levels normalized as log (CPM + 1) of human LCM RNA-seq versus human scRNA-seq (1), 
human LCM RNA-seq versus mouse scRNA-seq (2) and mouse scRNA-seq versus human scRNA-seq (3) in the 
periportal zone. Genes with significant zonation in human detected by LCM RNA-seq (|logFC > 1, FDR < 0.01) are 
highlighted in green (pericentral) and blue (periportal). C – Spearman correlation heatmap of one-to-one orthologues 
detected as zonated in the human LCM RNA-seq dataset.  
Between mouse and the human LCM RNA-seq dataset 113 genes with conserved zonation signatures, 
including highly expressed zonation landmark genes, but importantly also morphogens such as LGR5 and 
SOX9, were observed. The 692 zonated genes uniquely detected in the human comprise 230 genes that 
do not feature one-to-one matching orthologues in mouse and 262 genes not sufficiently covered in the 
mouse dataset. The remaining 202 genes zonated in human, comprising important Wnt signaling pathway 
members like RSPO2, were not detected as zonated in the mouse. However, most non-corresponding 
genes showed considerably lower expression levels in the mouse single cell dataset as compared to the 
deeply sequenced human LCM RNA-seq dataset (Figure 39 D). Comparing zonation of spatially 




not detected as significantly zonated by the LCM RNA-seq approach and corresponding log2 fold changes 
of these genes did not show any indication for zonal expression differences (Figure 39 B). 
 
Figure 39: Comparison of zonated genes detected by LCM RNA-seq and by spatially reconstructed scRNA-seq data in 
human and mouse. In human LCM RNA-seq data, genes with |logFC > 1 between CV and PV (FDR < 0.01) were 
considered as zonated. In spatially reconstructed scRNA-seq data, genes with Kruskal-Wallis test q < 0.2 between CV 
and PV (human), respective between layer 1 and 9 (mouse, Halpern et al., 2017) were considered as zonated. A – Venn 
diagram displaying the overlap of zonated genes. B – log2 fold changes in the LCM RNA-seq dataset of genes detected 
in all datasets (all), only in human LCM RNA-seq and mouse scRNA-seq (human lcm & mouse sc), only in human and 
mouse scRNA-seq (human sc & mouse sc), only in human datasets (human lcm & human sc) or uniquely in human 
scRNA-seq (human sc only), mouse scRNA-seq (mouse sc only) and human LCM RNA-seq (human lcm only). C – 
Boxplot of gene expression levels of genes detected in both human datasets and genes zonated in LCM RNA-seq, but 
not in the human single cell dataset. D – Boxplot of gene expression levels of genes with conserved zonation patterns 
(113) and of genes detected as zonated in human by LCM RNA-seq (200), but not in the mouse single cell dataset. The 
pericentral zone is illustrated in green, the intermediate in grey and the periportal in blue. 
Interestingly, the 3,221 genes detected uniquely as zonated in the mouse dataset comprised 65 genes that 
were not found as zonated in the human LCM RNA-seq dataset, even though log2 fold changes suggested 




a corresponding FDR adjusted p-value of more than 0.01, presumably caused by high inter-individual 
variation. Thus, with higher replicate number, which increases statistical power, these genes might be 
detected as being zonated in the human as well. However, the vast majority of genes uniquely zonated in 
the mouse did not feature any zonal expression differences in the human datasets (Figure 39 B).  
In summary, these results identify an, at least, partial conservation of hepatic zonation signatures between 
human and mouse. Additionally, they illustrate differences between the detection of zonated gene 
expression in LCM RNA-seq data and spatially reconstructed scRNA-seq data, which might include an 











3.3 Epigenomic and transcriptional characterization of in vitro differentiated 
hepatocyte-like cells 
The epigenomic and transcriptional characterization of in vitro differentiated hepatocyte-like cells (HLCs) 
was performed in cooperation with Prof. Dr. Jan Hengstler’s group at the IfADo (Dortmund) as part of the 
BMBF and DLR funded project StemNet. The aim of this project is the improvement of HLC differentiation 
towards a phenotype more closely resembling adult primary human hepatocytes (PHH), which represent 
the current gold standard for in vitro toxicological and pharmacological experiments. To gain a more 
profound understanding of in vitro differentiation as basis to develop reasonable interventions, the 
differentiation from iPSCs over definitive endoderm (DE) to HLCs was characterized on transcriptional level 
by RNA-seq, and on epigenetic level by RRBS for DNA methylation analysis and ATAC-seq for chromatin 
accessibility profiling (Figure 40). Resulting data were compared to corresponding PHH data. While ATAC-
seq was also performed for PHH from three donors, transcriptome and methylome comparisons are based 
on comparable PHH data, previously generated within the German Epigenome Project (DEEP). Moreover, 
a complementary analysis of HLCs in comparison to PHH by deep single cell RNA-seq was included. 
 
Figure 40: Workflow for the transcriptional and epigenomic characterization of in vitro cultivated hepatocyte-like cells in 
comparison to primary human hepatocytes. Bioanalyzer tracks (red) illustrate typical fragment size distributions of quality 





The project was performed in close cooperation with Patrick Nell and David Feuerborn (IfADo), who 
performed all cell culture experiments and provided fresh, frozen or fixed frozen cells for the individual 
assays. Manual isolation of single cells for scRNA-seq was achieved with kind support from Dr. Konstantin 
Lepikhov. Sequencing was performed by Dr. Gilles Gasparoni and processing of raw data was done by Dr. 
Karl Nordström (RNA-seq and scRNA-seq) and Abdulrahman Salhab (ATAC-seq and RRBS).   
 
Figure 41: In vitro differentiation process from induced pluripotent stem cells (iPSC) to definite endoderm (DE) to 
hepatocyte-like cells (HLC) following the commercial CEL (Takara Cellartis) protocol and the published HAY protocol 
from David Hay's lab (Wang et al., 2017). The white bar represents 200 µm. Pictures were provided by Patrick Nell and 
David Feuerborn (IfADo). Microscopic pictures were provided by Dr. Patricio Godoy (IfADo).  
We analyzed two 2D culture systems – the commercially available Cellartis iPS Cell to Hepatocyte 
Differentiation System (Cellartis, Takara Bio Europe AG, Goteborg, Sweden), further on referred to as CEL 
protocol, as well as a protocol published by David Hay’s group (Wang et al., 2017), referred to as HAY 
protocol. The detailed components of the CEL protocol are confidential. The HAY protocol relies on human 
recombinant laminins as extracellular matrix (ECM) in combination with serum-free differentiation (Wang et 
al., 2017). In both protocols, iPSCs are pre-cultured for 4 days to achieve a pure, pluripotent stem cell 
population (Figure 41). This is followed by differentiation to DE for 5 (HAY) or 7 days (CEL). For 
differentiation to HLCs, DE cells are transferred to an ECM and cultured further for 13 (HAY) or 18 days 
(CEL) to obtain fully differentiated HLCs (Figure 41). Instead of using the proprietary Cellartis ECM, an 
optimized mixture of Laminin 521 and Laminin 111 was used as HLC differentiation matrix for both protocols. 
Moreover, it should be noted that CEL and HAY iPSC populations originate from different human donors, 
which might contribute to variability between both protocols. Based on preliminary results from the first 
replicate of scRNA-seq, it was decided to focus on the CEL protocol, as HAY cells apparently remained in 
a less differentiated state than CEL HLCs (Figure 43, Figure 44 and Figure 46). Thus, bulk transcriptomic 
and epigenomic analysis were performed in 4 replicates of CEL, but only 1 replicate of HAY. The scRNA-
seq experiment was done in 3 replicates of CEL HLCs, 3 replicates of PHH and 1 replicate of HAY HLCs, 




3.3.1 Transcriptional profiling of HLC subpopulations at single cell level 
Besides inter-individual and circadian variability, hepatocytes in primary liver tissue exhibit pronounced 
heterogeneity depending on their localization along the porto-central axis (Brosch et al., 2018). In order to 
gain deeper insights into the heterogeneity of in vitro cultured hepatocyte-like cell (HLC) populations, which 
was already indicated by immunohistological stainings (Figure 12), scRNA-seq was performed on 3 
replicates of CEL HLCs and 1 replicate of HAY HLCs, and compared to primary hepatocytes from 3 human 
donors (PHH). As dissociation of HLCs did not yield pure single cell suspensions and contained high 
numbers of duplets, clumps and extracellular matrix particles, theses samples did neither qualify for FACS 
assisted single cell isolation nor for droplet-based high-throughput scRNA-seq methods. Thus, for each 
replicate 96 single cells were manually collected, ensuring the proper isolation of single cells. NGS libraries 
were prepared using a modified version of the Smartseq2 protocol (Picelli et al., 2013), yielding in total 672 
single cell RNA-seq libraries. As external RNA control the Ambion® ERCC Spike-In Control, consisting of 
92 polyadenylated artificial transcripts with a length of 250 to 2000 nucleotides, was used. The spike-in 
allows determination of the dynamic range of expression profiling in single cells and can be used to assess 
the general performance between experiments.  
 
Figure 42: Quality metrics of in-house StemNet and external single cell RNA-seq datasets from Camp et al., 2017. A – 
Read counts. B – Number of detected genes. C – ERCC spike-in detection rate of StemNet (orange) and Camp (yellow) 
data, illustrated by concentrations (attomol / µl) versus average RPKM values across single cells of all 92 ERCC spike-
in transcripts. D – PCA of the 1000 most variable transcripts. Cells are colored by sample annotation (black – external 
adult PHH (Camp et al., 2017), external fetal PHH – shades of red, CEL HLCs – shades of green, HAY HLCs – orange, 
PHH – shades of blue). 
A recent single cell RNA-seq study by Camp et al. (2017) generated data on the Fluidigm C1 platform using 
a comparable Smartseq2 workflow compatible to our single cell dataset. Besides a low number of adult 




which represent a valuable additional resource for the comprehensive analysis of HLCs at single cell level. 
In addition, the 82 adult PHH contained in the Camp dataset were used to control for batch effects. Raw 
external data were downloaded from SRA and processed according to our single cell data workflow (chapter 
2.2.2.1) to minimize batch effects. 
Our single cell dataset was sequenced to a mean depth of 1.7 million reads per single cell, while the Camp 
dataset featured a mean coverage of 0.76 million reads per cell (Figure 42 A). The number of detected 
genes varied between datasets and also between sample groups (Figure 42 B). Internal PHH yielded an 
average of 4,389 covered genes per cell. Contrary, in Camp PHH a mean of 2,311 genes was detected, 
which might be explained by the lower sequencing depth of the Camp dataset, but could also reflect the 
quality of used PHHs. In vitro cultured HLCs generally showed higher average gene counts between 6,723 
(CEL R3) and 7,991 (CEL R1) detected genes, while gene counts of fetal hepatocytes ranged between HLC 
and PHH samples. It should be noted that in fetal hepatocytes hardly any reads mapped to ERCC spike-in 
transcripts, which might, for instance, be attributed to a dilution error during sample preparation. Thus, ERCC 
spike-in counts were not used for data normalization, but rather as an additional quality parameter to assess 
comparability between the two datasets. Due to their low ERCC spike-in coverage, fetal hepatocyte samples 
were not considered for this particular analysis. While the detection of highly abundant spike-in transcripts 
was achieved with high accuracy in both datasets, the detection of low abundance transcripts was more 
efficient in our in-house dataset with a lowest detection limit of 0.028 attomol per µl, compared to 0.229 
attomol per µl in the Camp dataset. This technical difference might, at least in part, be explained by the 
lower sequencing depth of the Camp dataset (Figure 42 A). Still, the overall ERCC spike-in detection rates 
in both datasets suggest the comparability of the expression profiling efficiency of the external and our in-
house single cell RNA-seq data (Figure 42 C), therefore allowing the integrated analysis of both datasets. 
During initial quality control, cells with less than 300,000 reads and or less than 1,000 detected genes were 
excluded, resulting in 873 high quality cells (Figure 42 A – B). In order to maintain as much information as 
possible for downstream analysis, only a very mild gene expression filtering criterion of an average read 
count above 1 was chosen, yielding 15,020 genes covered across the dataset.  
In a PCA of the 1,000 most variable transcripts, single cells from our 3 internal PHH donors clustered 
together with external adult PHH (Figure 42 D), suggesting no major batch effects between datasets. Fetal 
hepatocytes of week 10 and 17 formed wide-spread clouds, indicating a rather high variability within these 
populations. Interestingly, CEL HLC replicates 2 and 3 were well-mixed, while replicate 1 formed an 
individual cluster closer to HAY HLCs. As PCA visualization would only display batch effects on the first 2 
principal components, PCA regression was performed to assess batch effects on additional principal 
components. This identified potential batch effects on PC5, PC12 and PC15, which were however driven by 
few outliers.  
Although the data cluster by cell-type and not by dataset, a more sensitive batch effect assessment was 
performed using a k-nearest neighbor batch effect test (kBET, Büttner et al., 2019, Sup. Figure 12 A), which 
is based on Pearson’s chi squared test between replicates. Indeed, this analysis yielded high rejection rates 
in the combined dataset (Sup Figure 12 A), suggesting the presence of batch effects. However, kBET is 
very sensitive to any kind of bias, including the variation between CEL HLC replicates, which are most likely 




(Figure 43). Thus, the average silhouette width, which estimates the average distance between batches, 
was calculated in addition. Together with the PCA based visualization of the dataset (Figure 42 D and Sup. 
Figure 12 B), the low silhouette score of 0.199 suggests, at most, minor batch effects between the external 
Camp dataset and our StemNet dataset. As even small batch effects might impact downstream data 
analysis, several batch correction methods were applied, and corrected data were evaluated again by 
visualization of dimensionality reduction, kBET and silhouette width (Sup. Figure 12). Mutual nearest 
neighbor correction (MNN) was considered as the most appropriate approach for our single cell dataset, as 
it does not rely on equal population composition and requires only a subset of phenotypes to be shared 
between batches (Haghverdi et al., 2018). Thus, MNN correction was anchored on adult PHH, the only 
phenotype shared between both datasets. It yielded slightly changed clustering with fetal hepatocytes of 
week 17 cells overlapping the CEL HLC R1 cluster, though clustering of adult PHH appeared to be very 
similar to clustering without any batch correction (Sup. Figure 12 C). Although average silhouette width was 
slightly reduced, observed rejection rates were even higher than before batch correction (Sup. Figure 12 A). 
Hence, MNN correction apparently did not improve batch effects in the dataset. Contrary, batch correction 
with ComBat, which is based on empirical Bayes frameworks for correction of known covariates, yielded 
both reduced rejection rates as well as the smallest average silhouette width of all tested normalization 
methods (Sup. Figure 12 A). While adult PHH still clustered together similarly as before correction, 
especially fetal hepatocytes of gestational week 10 formed a denser cluster partially overlapping CEL 
HLC replicate 2 and 3. In addition, CEL HLC replicate 1 and HAY HLC cells formed an overlapping 
cluster (Sup. Figure 12 D). However, due to the unbalanced distribution of phenotypes within both 
batches, ComBat correction might be prone to overestimation of batch effects (Nygaard et al., 2015). 
The used workflows for downstream analysis including pseudotime reconstruction and TF network 
activity analysis intrinsically handle data normalization (monocle2) or rely on a robust scoring system 
(SCENIC), which is able to overcome batch effects (Aibar et al., 2017). Thus, it was decided to proceed 
without batch correction for further analysis. 
To obtain a first impression of cellular heterogeneity, normalized expression levels of several marker genes 
were visualized (Figure 43). The hepatocyte lineage marker HNF4α (Odom et al., 2004) was highly abundant 
in in-house PHH as well as in both CEL and HAY HLCs. However, it was not detected in a subset of external 
adult PHH, which, in line with the lower number of detected genes (Figure 42 B), indicates a higher drop-
out rate in the Camp dataset. Moreover, HNF4α was not expressed in fetal hepatocytes of gestational week 
10, but was detected at low levels in a subpopulation of week 17 fetal hepatocytes (Figure 43 A). The colon 
marker CDX2 drives intestinal endoderm development, is thus highly expressed in colon (Stringer et al., 
2012), and should not be expressed in hepatocytes. Indeed, it was not detected in fetal and adult PHH, but 
subpopulations of both CEL and HAY HLCs expressed CDX2 in variable ranges (Figure 43 B). Albumin 
(ALB), the most abundant transcript in mature hepatocytes (Sup. Figure 1 A), was detected at high levels in 
all PHH cells. Interestingly, ALB was only expressed in a small subpopulation of CEL HLC replicate 1 and 
HAY HLCs. In contrast, ALB expression was detected in all single cells of CEL HLC replicate 2 and 3, albeit 
expression levels were mostly not as high as in primary hepatocytes, but rather resembled ALB expression 
levels in fetal hepatocytes (Figure 43 C). Moreover, the hepatoblast marker α-fetoprotein (AFP) 




in HLCs than in fetal hepatocytes (Figure 43 D). Taken together, marker gene expression levels suggest 
that in some aspects HLCs resemble fetal hepatocytes more closely than mature PHH, and in addition might 
display gene expression programs not desired in hepatocytes. Besides a considerable intra-sample 
heterogeneity, there is also variability between HLC replicates that suggest both CEL HLC replicate 1 and 
HAY HLCs to be less differentiated than CEL HLC replicates 2 and 3. 
 
Figure 43: Single cell expression levels (normalized as log (CPM + 1)) of the marker genes HNF4α (A), CDX2 (B), ALB 
(C), and AFP (D). Cells are colored by sample annotation (black – external adult PHH (Camp et al., 2017), external fetal 
PHH – shades of red, CEL HLCs – shades of green, HAY HLCs – orange, PHH – shades of blue). 
Pseudotime analysis of single cells represents a powerful tool to reconstruct cellular lineages and to track 
differentiation processes. To this end, pseudotemporal ordering of single cells by monocle2 (Trapnell, 2017) 
was applied in a semi-supervised mode, in which marker genes are used as anchors for cell clustering. 
Thus, the clustering is not simply based on highly variable genes, but specifically on genes that co-vary with 
the marker genes, making the approach more robust against drop-out effects. Using CDX2, ALB and AFP 
as anchors for pseudotime inference identified 6 individual differentiation states (Figure 44 A). State 1, 4 
and 5 are fetal hepatocytes of week 10 and 17. State 2 refers to CEL HLCs (R1, R2 and R3), while state 3 
marks HAY HLCs. Both in-house and external PHH form a dense cluster as terminally differentiated state 6 
(Figure 44 A – B). State 1 is detected as the root state (Figure 44 A). The first major branching event (1) is 




in vitro branch segregates then further into CEL and HAY HLCs (2). As already suggested by PCA and 
marker gene expression, CEL HLC replicate 1 builds a separate cluster at the top of the in vitro branch, 
which suggests a less mature differentiation state. The in vivo branch from fetal to adult primary hepatocytes 
shows a linear differentiation, but also an additional branch (3) with a subset of fetal hepatocytes deviating 
from the major branch. This subpopulation consists mainly of fetal hepatocytes of gestational week 10, which 
express considerable levels of fetal liver erythropoiesis markers such as KLF1 and TAL1 (Sup. Figure 13 A 
– B). Moreover, it should be noted that in pseudotemporal ordering fetal hepatocytes of week 17 appeared 
to be less mature than fractions of week 10 hepatocytes and showed a considerable heterogeneity. 
According to Camp et al. (2017), week 17 fetal hepatocytes were rather clumpy and contained many blood 
cells. Therefore, these cells were cultured for 12 hours to obtain clean fetal hepatocytes (Camp et al., 2017), 
which might have impacted gene expression profiles and could explain why these cells do not appear more 
differentiated than week 10 fetal hepatocytes. In summary, pseudotemporal clustering revealed two major 
branches, segregating in vivo and in vitro differentiation, which suggests differences in the underlying gene 
regulatory networks.  
 
Figure 44: Pseudotemporal ordering of single cells using monocle2 in semi-supervised mode with CDX2, ALB and AFP 
expression as anchors for cell clustering. A – Reduced dimension map with correlation spanning tree (black) with 3 
branching events. In total, 6 different states were identified in the single cell dataset. B – Annotation of pseudotemporal 
ordering by groups.  
In order to pursue this hypothesis further, single cell regulatory network inference and clustering (SCENIC) 
analysis of HLCs, fetal hepatocytes and adult PHH was carried out as previously described (Aibar et al., 
2017). In brief, modules of transcription factors (TFs) and corresponding co-expressed genes were 
determined to identify potential TF target genes. In order to remove indirect target genes, modules were 
filtered for those genes that were associated with significant binding motive enrichment of the respective TF. 
The resulting modules, each consisting of an upstream TF and its putative direct target genes, are further 
on referred to as regulons. Subsequently, regulon activities for all TFs expressed in the dataset were 




each regulon. Binarized activity scores were then used for hierarchical clustering of regulons (Figure 45 A) 
and correlation based t-SNE (Figure 45 B) to identify regulons which discriminate cellular subpopulations.  
 
Figure 45: Regulon activity analysis. A regulon is defined as a transcription factor with corresponding genes. A – Binary 
regulon activity heatmap rows clustered by manhattan distance with active regulons displayed in red. B – Correlation 
distance based tSNE plot of regulon activity levels, colored by cell annotation as described in Figure 47. 
In total, 451 TF regulons with variable activity in the dataset were observed (Figure 45 A). However, it should 
be noted that the majority of regulons only featured significant activity in few cells, not yielding any relevant 
information. Thus, only the 176 regulons which showed significant activity in more than 30 % of single cells 
in at least 1 group were considered. The visualization of t-SNE embeddings of binarized regulon activities 
shows clear separation of cell-types (Figure 45 B). All adult PHH derived from 4 individual donors cluster 
together, suggesting no major contribution of batch effects in this analysis. Fetal hepatocytes segregate by 
gestational week, although a subpopulation, which consists mostly of week 17 hepatocytes, clusters 
separately. In addition, CEL HLC R1, which is characterized by absent ALB expression in most cells (Figure 
46), forms a distinct cluster between HAY HLCs and CEL HLC R2 and R3, confirming the less differentiated 
state of CEL HLC R1 already suggested by pseudotime analysis (Figure 44). Contrary, CEL HLC R2 and 
R3 cells are well-mixed, highlighting their similar differentiation state also on basis regulon activity. 
Interestingly, HLC clusters share more active regulons with fetal hepatocytes (28 regulons) than with adult 
PHH (14 regulons), which indicates a more fetal-like phenotype in HLCs. 
Indeed, 24 regulons, comprising among others PXR (NR1|2), CAR (NR1|3), RXRA, and RXRB, which are 
known regulators of a multitude of hepatocyte specific functions (Hardwick et al., 2009; Tien and Negishi, 
2006), were detected as active uniquely in PHH (Figure 46). Interestingly, FXR (NR1H4) and PPARA were 
identified to be active both in ALB expressing HLCs and adult PHH, but not in HLC CEL R1 or HAY HLCs. 




regulon activity was only detected in in vitro cultured cells (Figure 46). As ALB is a major hepatocyte marker, 
Spearman correlations between ALB expression and regulon activities were calculated in order to identify 
regulons which might contribute to a more favorable HLC differentiation. In total, the activity of 29 regulons 
correlated with ALB expression levels in the dataset (r > 0.5, Sup. Table 13), confirming major candidates 
for the regulation of a hepatocyte-like cell fate such as PXR (r = 0.81), CAR (r = 0.81), FXR (r = 0.67), 
PPARA (r = 0.61) and RXRA (r = 0.57).  
 
Figure 46: Activity of selected regulons in relation to ALB and CDX2 expression at single cell level. Expression levels 
are colored in green, regulon activities in red. For cell-type annotation refer to Figure 45 B.  
In addition, Spearman correlations between regulon activities and colon marker CDX2 as well as hepatoblast 
marker AFP revealed major putative regulators of unfavorable expression signatures in HLCs. CDX2 




of the correlation based approach. While most regulons showed similar correlation with CDX2 and AFP 
expression (Sup. Table 13), SOX9 regulon activity was exclusively identified as a major regulator of AFP 
positive hepatoblast signatures (r = 0.64), which is in line with SOX9 being a marker for bipotent liver 
progenitor cells with the potential to differentiate into hepatocytes or cholangiocytes (Furuyama et al., 2011; 
Tarlow et al., 2014). Further TFs which might be involved in the regulation of unfavorable expression patterns 
were among others FOSL2 (Figure 46, rAFP = 0.68, rCDX2 = 0.71), KLF5 (rAFP = 0.63, rCDX2 = 0.69), KLF6 (rAFP 
= 0.77, rCDX2 = 0.67), and SOX4 (rAFP = 0.67, rCDX2 = 0.65). These factors are not described to play a role in 
hepatocyte differentiation, but seem to be involved in other cellular lineages. For instance, KLF5 is 
associated with a colon phenotype (Liu et al., 2017), FOSL2 was reported to play a role in colon cancer 
metastasis (Li et al., 2018), and SOX4 regulates bile duct development (Poncy et al., 2015). Thus, 
downregulation of these TFs might have a beneficial effect on HLC differentiation. Taken together, this 
approach revealed several TF regulons that might play a major role in the differentiation process of HLCs, 
and thus represent interesting targets for interventions. 
In summary, the combination of pseudotemporal inference and TF regulon activity analysis of the single cell 
RNA-seq dataset revealed the less differentiated state of HLCs, rather resembling fetal hepatocytes than 
adult PHH. Moreover, a set of several major candidates such as the nuclear receptors PXR, CAR and FXR, 
which might be decisive for proper hepatocyte cell fate specification, was identified. However, the number 
of candidates for cell culture interventions, such as knock-down of unfavorable TFs or over-expression of 
PHH specific TFs, is still rather high (Sup. Table 13). Thus, the additional integration of epigenetic data was 
used to provide more insights into the regulation of in vitro differentiation, which would allow a better informed 
choice of the most promising regulators for cell culture interventions. 
 
3.3.2 Epigenomic characterization of the HLC in vitro differentiation process 
In addition to single cell RNA-seq of HLCs and PHH, the bulk transcriptome during differentiation from iPSCs 
to DE to HLCs was assessed by RNA-seq of 4 CEL replicates and 1 HAY replicate. Libraries were generated 
by a modified Smartseq2 protocol for high input of isolated RNA (chapter 2.2.1.4), and sequenced to a mean 
depth of 69.2 million reads, covering in total 37,664 genes (Sup. Table 10). In addition, RNA-seq data of 3 
male and 3 female primary hepatocyte samples, generated within the DEEP project 
(http://epigenomesportal.ca/tracks/DEEP, EGA accession: EGAD00001002527), were used for comparison.  
In a PCA of the 1,000 most variable transcripts in the dataset, PC1 apparently represents the differentiation 
state, while PC2 might reflect a cultivation effect over time (Figure 47 A). Both iPSC and DE samples cluster 
together, while CEL HLCs and PHH form separate clusters, indicating major expression differences between 
DE and HLCs, but also between HLCs and PHH. Moreover, the HAY HLC sample clusters more closely to 
DE samples than to CEL HLCs, indicating a less mature differentiation state of HAY HLCs, which is in line 
with pseudotime analysis of the single cell dataset (Figure 44). Hierarchical clustering by euclidean distance 
of expression z-scores of all expressed genes in the dataset suggests massive expression differences 
during in vitro differentiation from iPSCs to DE to HLCs, between CEL and HAY protocols, and also between 
terminally differentiated HLCs and PHHs. As already suggested by PCA, HAY HLCs appeared to be more 




should be noted that for some differentiation marker genes variability between CEL HLC replicates was 
observed (Sup. Figure 14), which is not reflected on a genome-wide scale (Figure 47 B), but indicates 
variation in the differentiation stage of individual CEL HLC cultures. As the apparently less promising HAY 
protocol was performed only in 1 replicate, HAY samples were not considered for more detailed analysis.  
 
Figure 47: Transcriptome analysis by bulk RNA-seq reveals major expression differences during in vitro HLC 
differentiation and between HLCs and PHH. iPSCs are colored in brown, DE in red, HLCs in olive and PHH in blue. The 
annotation legend with corresponding symbols displays CEL samples (n = 4) in green, HAY samples (n = 1) in orange, 
female PHH (n = 3) in pink and male PHH (n = 3) in light blue. A – Principal component analysis of the 1000 most 
variable transcripts. B – Expression z-scores of genes with average CPM > 0.5 clustered by euclidean distance. 
Replicates are annotated in white, light grey, grey and black. C – Exemplary volcano plot for differential analysis between 
PHH and CEL HLCs using edgeR. Genes upregulated in PHH (logFC > 1, FDR < 0.01) are displayed in blue, genes 
upregulated in HLCs (logFC < -1, FDR < 0.01) in green. D and E – Overlap of significant DEGs (|logFC| > 1, FDR < 
0.01, average logCPM > -2.2) detected by edgeR during CEL differentiation process from iPSCs to DE to HLCs (D), 
respective between CEL samples and PHH (E). HAY samples were excluded from differential analysis. F – Gene set 
enrichment analysis (Kolmogorov-Smirnov test, enrichment score > 0.5, Benjamini-Yekutieli adjusted p-value < 0.01) of 





Differential expression analysis of CEL differentiation confirmed major expression differences (Figure 47 C). 
Out of 18,799 expressed genes in the dataset, 15,375 were differentially expressed throughout in vitro CEL 
differentiation (Figure 47 D), and 16,152 DEGs were detected when comparing CEL iPSC, DE and HLC 
samples with PHH (Figure 47 E). Gene set enrichment analysis (GSEA) of genes upregulated in PHH in 
comparison to CEL HLCs (Figure 47 H) yielded hepatocyte-specific terms including exogenous drug 
catabolic process and epoxygenase P450 pathway, but also immune system related processes known to 
be important in liver such as complement activation (Qin and Gao, 2006). Interestingly, GSEA of genes 
upregulated in HLCs did not result in significant enrichment of any particular biological processes, 
suggesting a rather unsystematic upregulation of gene expression in HLCs.  
Even though CEL HLC expression profiles seem to emulate PHH transcriptomes (Figure 43), they express 
most hepatocyte-specific genes at levels significantly lower than in PHH (Figure 47 B). Moreover, they 
partially maintain the expression of stemness markers such as KLF4 and TBX3, and also express aberrant 
genes such as colon-specific CDX2 and KLF5. Taken together, these findings support the single cell 
transcriptome based observation that in vitro differentiated CEL HLCs remain in a less mature differentiation 
state than PHH. 
Transcriptome analysis of the CEL in vitro differentiation process revealed an immense gene expression 
difference in HLCs compared to PHH (Figure 47 B). Thus, epigenetic profiling of DNA methylation and 
chromatin accessibility was carried out on iPSCs, DE and HLCs. The obtained data were then compared to 
the epigenome of PHHs in order to gain a better understanding of the in the in vitro differentiation process. 
DNA methylation analysis of the differentiation process was achieved using HaeIII based RRBS covering in 
average 7 million CpGs per sample with a mean depth of 11.5 (Sup. Table 11). In addition, PHH DNA 
methylation data generated by whole genome bisulfite sequencing (DEEP: 
http://epigenomesportal.ca/tracks/DEEP, EGA accession: EGAD00001002527) were downsampled to the 
regions sufficiently covered also in the RRBS dataset.  
PCA of the 5,000 most variable CpGs (Sup. Figure 15 A) showed a similar clustering as the PCA on the 
transcriptome data (Figure 47 A), with iPSC and DE clustering closely together and CEL HLCs and PHH 
forming distinct clusters. The HAY HLC sample clustered between CEL HLCs and DE samples, indicating 
a less differentiated phenotype also on the level of DNA methylation. Intriguingly, differential analysis using 
Methylkit revealed major DNA methylation differences in the dataset (meth.diff > 20 %, FDR < 0.01, Figure 
48 A). Throughout the CEL in vitro differentiation from iPSCs to DE to HLCs, in most DMRs the level of DNA 
methylation is increasing, with the highest overall DNA methylation level in HLCs. In addition, up to 10 fold 
more hypomethylated regions were detected in PHH than in cultured cells (Figure 48 A). The majority of 
DMRs of iPSCs, DE and HLCs versus PHH overlap (Figure 48 B), indicating systematic regulatory 
differences between in vivo derived PHH and the artificial in vitro HLC differentiation system, which result in 
pronounced DNA methylation differences between HLCs and PHH (Figure 48 C). As the restriction enzyme 
HaeIII was used for RRBS library construction, which leads to an enrichment of CpG-rich sequences 
associated to putative regulatory regions and gene bodies in the resulting sequencing library (Martinez-
Arguelles et al., 2014), the majority of DMRs was annotated to a gene context (Figure 48 D). Interestingly, 
DMRs hypermethylated in HLCs were more frequently localized in intergenic regions (40%), which might 





Figure 48: Differential DNA methylation analysis by RRBS reveals pronounced DNA methylation changes during in vitro 
HLC differentiation and between HLCs and PHH. A – Volcano plots of relevant DNA methylation comparisons. The x-
axis visualizes the methylation difference (%), while the y-axis depicts negative log10 of FDR adjusted p-values. 
Significant DMRs (|Δ methylation| > 20%, FDR < 0.01) are colored by the hypomethylated group: iPSCs are colored in 
brown, DE in red, HLCs in olive and PHH in blue. Corresponding DMR counts are depicted as well. B – Overlap of 
significant DMRs during CEL differentiation process from iPSCs to DE to HLCs and between CEL samples and PHH. C 
– Heatmap of average CpG methylation levels in DMRs between HLCs and PHH that are also covered in DE and iPSC 
samples. Red corresponds to high methylation, blue to unmethylated regions. D – Genomic annotation of DMRs 




In addition, a genome segmentation into large domains, defined by different overall DNA methylation levels 
as previously described by Salhab et al. (2018), revealed also major differences on a genome-wide scale. 
In this context partially methylated domains (PMDs), which are characterized by reduced average DNA 
methylation levels, are of particular interest, as changes in PMDs are hallmarks of cell differentiation (Salhab 
et al., 2018). While iPSCs feature the highest number of PMDs, it drops towards DE and is lowest in HLCs, 
which show a strong gain in highly methylated domains (Sup. Figure 15 B). It should be noted that the 
number of PMDs in fully differentiated PHH ranks between DE and HLCs. Moreover, the average DNA 
methylation level in PMDs decreases from iPSCs to HLCs, and is lowest in PHH (Sup. Figure 15 C). These 
observations support the pronounced hypermethylation effect during HLC in vitro differentiation detected by 
differential analysis on local level (Figure 48 A), and indicate an undirected deregulation of DNA methylation 
also on a genome-wide level.  
In summary, DNA methylation analysis revealed an increasing hypermethylation from iPSCs to DE to HLCs 
as well as a pronounced hypermethylation of cultured cells in comparison with PHH, both on local and global 
level. Intriguingly, in vitro cultured cells showed a pronounced transcriptional upregulation of the DNA 
methyltransferases DNMT1, DNMT3A and DNMT3B as well as of the methyl-cytosine dioxygenase TET1 
(Sup. Figure 16). Expression levels were highest in iPSCs and decreased over DE to HLCs (Sup. Figure 
16), which is in line with the progressive hypermethylation observed throughout in vitro differentiation (Figure 
48 A). 
Chromatin accessibility profiling by ATAC-seq was performed in 4 CEL replicates and 1 HAY replicate. 
Within the DEEP project PHH chromatin accessibility was analyzed by DNase-seq, which is a similar 
approach for chromatin accessibility profiling. However, a detailed comparison between ATAC-seq and 
DNase-seq revealed assay specific features (Nordström et al., 2019). Thus, ATAC-seq was additionally 
performed on PHH from 3 male donors (DJJ, AFJ and IAN) to avoid technical bias in differential chromatin 
accessibility analysis. Libraries were sequenced to a mean depth of 49 million reads (Sup. Table 12). In 
general, CEL and HAY samples had acceptable ratios of mitochondrial reads (Sup. Table 12), which resulted 
in 11 to 31 million uniquely mappable reads. Most samples featured rather high fraction of reads in peaks 
scores (FRiP score, in average 0.17, Sup. Table 12), which indicate low background signals across the 
genome. Only the first replicate of CEL HLC was excluded due to high background, which impaired proper 
peak calling (7,344 peaks, 0.016 FRiP). It should be noted that PHH samples exhibit a substantially higher 
amount of mitochondrial contamination, probably due to less stringent washing of the very fragile hepatocyte 
nuclei (chapter 2.2.1.5), which resulted in higher duplication rates and ultimately in a low amount of uniquely 
mappable reads (4 to 7 million, Sup. Table 12). Only up to 45,610 peaks were called using MACS2 in PHH. 
However, at least for donors DJJ and AFJ the fraction of reads in peaks score (FRiP score, Sup. Table 12) 
was in an acceptable range, and previous PHH DNase-seq data (DEEP) yielded similar peak counts. Thus, 
despite their low number of uniquely mappable reads, PHH DJJ and AFJ ATAC-seq data were of sufficient 
quality. PHH donor IAN only yielded 14,639 peaks and a low FRiP score (0.049), which indicates a rather 
high background in this sample. However, it was reasoned that for subsequent differential analysis, which 
includes a background normalization step, using the third replicate would still yield superior results than only 





Figure 49: Differential accessibility analysis reveals major changes of chromatin structure during in vitro HLC 
differentiation. A – Heatmap illustrating the sequencing depth normalized ATAC-seq coverage of representative samples 
in a ± 2 kb window around the centers of all differentially accessible regions (DARs, |logFC| > 1, FDR < 0.01) detected 
in the dataset using csaw as outlined in chapter 2.2.2.2.3. HAY samples were excluded from differential analysis. Purple 
implies open chromatin, missing values or zero coverage are displayed in white. B – Overlap of significant DARs (|logFC| 
> 1, FDR < 0.01, average logCPM > -2.2) during CEL differentiation process from iPSCs to de to HLCs, respective 
between CEL samples and PHH. C – Genomic annotation of DARs. D – Diffusion map of chromatin accessibility based 
on log (CPM + 1) values reconstructing the CEL differentiation process. PHH are colored in blue, HLCs in green, DE in 
red and iPSCs in brown. HAY samples are marked by arrowheads. 
PCA of the 50,000 most variable 100 bp bins across the genome showed distinct clusters of iPSC and DE 
samples, but more widespread clustering of HLCs and PHH, indicating higher variability within these sample 
groups (Sup. Figure 17 A), which was also observable on the level of detected peak counts (Sup. Figure 17 
B). Overall, DE samples featured the highest number of peaks (86,897– 123,399), followed by HLCs (32,561 
– 103,601) and iPSCs (44,215 – 64,965), while PHH had the lowest number of peaks. There were no major 
differences across samples regarding peak length, which averaged around 392 bp (Sup. Figure 17 C). 
As can be taken from Sup. Figure 19, mere comparison of called peaks between samples is not conclusive. 
For example, the chromatin structure upstream and along the gene body of albumin (ALB) is more 
accessible in PHH, while in HLC there is only little ATAC-seq signal. The MACS2 peak calling identifies only 
few narrow peaks in the PHH samples, while manual assessment rather suggests a broad accessible region 
spanning the entire ALB gene. Thus, differential analysis using csaw (Lun and Smyth, 2016) was not 
performed based on ATAC-seq peaks, but rather on the sum of read counts in 100 bp windows with merging 
of differentially accessible windows, allowing different sizes of differentially accessible regions (DARs). 
Moreover, read counts in 10,000 bp windows were used for background normalization, as FRiP scores 
varied between samples and indicated different amounts of background. 
As already in transcriptome and DNA methylation analysis, differential analysis revealed major changes on 
the level of chromatin accessibility. On a genome-wide level, chromatin accessibility increased strongly from 




amount of open regions, indicating a more controlled chromatin structure than in in vitro cultured cells (Figure 
49 A). Most DARs detected in the pairwise comparisons in the dataset were attributed to the high amount 
of accessible regions in DE, but there were also pronounced differences between HLCs and PHH (Figure 
49 B). DAR length was similar between comparisons, with exception of the comparison between PHH and 
CEL HLC, which frequently tended to be larger (Sup. Figure 15 D). Moreover, the genomic annotation of 
DARs was similar for all comparisons, with 40 % of DARs located in introns, 44 % in intergenic regions and 
only 8 % in promoters (Figure 49 C). To allow a functional interpretation of chromatin accessibility changes, 
DARs were annotated to the closest gene. Geneset enrichment analysis using the same parameters as on 
genes upregulated in HLCs compared to PHH (Figure 47 F) did not yield any significantly enriched GO 
terms, indicating random changes in the epigenome during HLC differentiation. 
In addition, the diffusion map based pseudotemporal inference of ATAC-seq data comprehensibly modelled 
the HLC differentiation process, underlining the opening of chromatin from iPSCs to DE, followed by closing 
towards HLC, which however did not reach the even more closed chromatin state observed in PHH (Figure 
49 D). 
 
Figure 50: Exemplary genome browser view on the differentiation marker genes ALB, AFP, CDX2, HNF4A and NANOG. 
Displayed are gene expression (RNA-seq, black), chromatin accessibility (ATAC-seq, purple) and DNA methylation 
(RRBS) of a representative iPSC, DE, HLC, and PHH sample. Coverage tracks (ATAC-seq and RNA-seq) are 
normalized by sequencing depth. In RRBS tracks green corresponds to unmethylated CpGs, while red illustrates high 
methylation levels. 
Finally, the integration of single cell data with bulk transcriptome and epigenome data (Figure 50) additionally 
aimed to gain a better understanding of genome-wide deregulations in in vitro cultured HLCs. To this end, 
gene expression log fold changes between iPSCs and PHH, which represent the desired effect of 
differentiation, were plotted against log fold changes of HLCs vs. PHH, which reflect the remaining 
differences between HLCs and the desired differentiation state (Figure 51). Accordingly, positive values 
correspond to upregulation in iPSCs (x axis) or HLCs (y axis), negative values to upregulated expression in 




51 B). For instance, genes upregulated in PHH, but not during HLC differentiation, are located in the lower 
left quadrant of the scatterplot. To obtain a real PHH-like phenotype, these genes would have to be 
upregulated in HLCs accordingly. Interestingly, genes upregulated in HLCs (upper left quadrant), but not in 
PHH, are mostly not expressed in PHH (Figure 51 B), underlining the higher number of expressed genes in 
HLCs (Figure 42 B) and suggesting an aberrant deregulation of gene expression in HLCs (Figure 51 A). 
This is also reflected on the level of single cell expression variability (Figure 51 C and D), which was highly 
correlated with average bulk gene expression levels (rHLC = 0.85, rPHH = 0.82).  
 
Figure 51: Integrative analysis of bulk RNA-seq data with scRNA-seq, ATAC-seq, and RRBS data. Scatterplots depict 
bulk RNA-seq log fold changes of iPSC over PHH (x axis: desired differentiation) and HLC over PHH (y axis: remaining 
differentiation). Accordingly, positive values correspond to upregulation in iPSCs (x) or HLCs (x), negative values to 
upregulated expression in PHH. Average expression levels, single cell variance and epigenetic data are integrated as 
color. A and B – Average log (CPM + 1) of bulk RNA-seq in HLCs (A) and PHH (B). Darker grey corresponds to high 
expression levels. C and D – Variance of single cell expression in HLCs (C) and PHH (D). Darker orange color 
corresponds to higher variance. To reduce batch effect induced sources of variation, only in-house data were used for 
calculation of PHH single cell variance. E and F – Genes associated with chromatin regions more accessible in HLC (E) 
respectively in PHH (F) are highlighted in blue. G and H –Genes associated with hypomethylated regions in HLC (G) 
and PHH (H) are colored in red. Genes not associated with epigenetic changes are displayed in grey. It should be noted 
that scatterplots are prone to overplotting. As genes associated with chromatin accessibility (E and F) or DNA 
methylation (G and H) changes are highlighted on top, genes not associated with epigenetic changes are frequently 
hidden. 
Then, associated epigenetic changes on the level of chromatin accessibility and DNA methylation were 
integrated by color code, allowing the genome-wide assessment of complex epigenomic changes in relation 
PHH-like expression signatures and undesired expression patterns in HLCs (Figure 51 E – H). In this context 
it should be noted that frequently multiple regions with DNA methylation and or chromatin accessibility 
changes were observed per gene. As both hypomethylated and hypermethylated regions, respective more 




of epigenetic effects on gene expression remains a major challenge. Mere averaging of observed epigenetic 
effects per gene would not represent the actual biological meaning, as the effect of epigenetic changes 
depends also on the genomic localization and changes in both directions associated to the same gene would 
not be represented properly. Moreover, only considering the region with the largest effect size would also 
entail a loss of relevant information, as for instance already relatively small changes in chromatin 
accessibility could impact transcription factor binding dynamics and thereby also gene expression (Sup. 
Figure 18). To circumvent this problem, genes associated with regions more accessible or hypomethylated 
in HLCs (Figure 51 E and G) and PHH (Figure 51 F and H) were plotted separately.  
The resulting integrative visualization reveals several general features of epigenetic gene expression 
regulation during in vitro HLC differentiation. While increased chromatin accessibility in HLCs can be 
observed without obvious relation to gene expression deregulation (Figure 51 E), in PHH there is an 
enrichment of increased accessibility in genes with higher expression in PHH (Figure 51 F, lower left 
quadrant). Thus, more accessible chromatin is frequently indicative of an upregulated, favorable gene 
expression of PHH, but not in HLCs. In contrast, DNA methylation changes, which are predominantly 
characterized by a hypomethylation of PHH (Figure 48 A), do not reflect upregulated gene expression, 
neither in HLCs (Figure 51 G) nor in PHH (Figure 51 H).  
Taken together, this global analysis suggests a well controlled epigenetic landscape in PHH that is involved 
in the regulation of gene expression (Figure 51 F). In contrast, epigenetic changes in HLCs appear to be 
more aberrant. On a genome-wide scale, the majority of epigenetic changes, including the increase of 
chromatin accessibility and in particular the predominant hypermethylation of HLCs, do not reflect gene 
expression signatures in HLCs. 
In order to obtain a functional interpretation of the epigenetic changes that are associated with differentially 
expressed genes between HLCs and PHH, the overlap of DEGs and genes associated with DARs and or 
DMRs was calculated, without further regard to a direct overlap of DARs and DMRs. This identified 2,147 
genes featuring differential expression associated both with differential DNA methylation and differential 
chromatin accessibility (Figure 52 A), which were termed epigenetically marked DEGs. Hierarchical 
clustering of the resulting integrative z-score heatmap (Figure 52 B) revealed 8 gene clusters, characterized 
by different combinations of transcriptional and epigenetic changes (Figure 52 C). Clusters 1 to 4, which are 
underrepresented in comparison to the remaining clusters, are characterized by a hypomethylation in HLCs. 
Thus, the integrative analysis is dominated by a predominant hypermethylation in HLCs as well (clusters 5 
to 8, Figure 52 B). Cluster 8, which is characterized by upregulated gene expression associated with 
hypomethylation and higher chromatin accessibility in PHH, represents the favorable situation that should 
be achieved also in HLCs (Figure 52 C). Cluster 7 features also upregulated gene expression and DNA 
hypomethylation in PHH, but also reduced accessibility as compared to HLCs. In contrast, cluster 5 and 6 
are upregulated in HLCs, thus representing undesired gene sets. While cluster 5 shows higher chromatin 





Figure 52: Integrative epigenomic analysis reveals potential key transcriptional regulators of HLC differentiation. A – 
Overlap of genes featuring differential expression (DEGs, blue), differential DNA methylation (DMRs, red) and differential 
chromatin accessibility (DARs, orange) between HLCs and PHH. B – Clustered integrated z-score heatmap of 
expression, methylation and accessibility of DEGs associated with DMRs and DARs. Z-scores were calculated 
separately for each assay. Red heatmap color represents upregulated expression, hypermethylation and higher 
accessibility, while blue corresponds to downregulated expression, hypomethylation and closed chromatin. HLC 
samples are annotated in green and PHH in blue. The heatmap is clustered by manhattan distance, thereby identifying 
8 distinct clusters. C – Overview of DEG, DMR and DAR characteristics of the clusters detected in B. The number of 
differential regions and the count of associated genes are given as well. D – Key transcriptional regulators for each 
cluster as identified by REGGAE (Kehl et al., 2018) with adjusted p-value less than 0.05. The full list of TFs is provided 
in Sup. Table 14. 
Potential key transcriptional regulators of individual gene clusters were detected by making use of the 
REGGAE algorithm (Kehl et al., 2018), which is based on a novel overrepresentation analysis of ranked 
gene sets. Intriguingly, while in most clusters a high number of different transcription factors (59 – 418 TFs) 
was detected, indicating a broad unspecific deregulation in HLCs, clusters 5 and 8 yielded specific putative 
key regulators (Figure 52 D). SIX2 (p = 0.026) was detected as the sole master regulator of cluster 5, 
representing genes which should be downregulated in an improved HLC system. This TF plays a role in the 




differentiation or hepatogenesis so far (Ohto et al., 1998; Self et al., 2006, 2009). In contrast, key regulators 
of cluster 8, representing the genes that should be further upregulated in HLCs to obtain a PHH-like 
phenotype, are FXR (p = 0.003) and SMC1A (p = 0.022). While SMC1A was also found in other clusters, 
FXR is the only top regulator detected exclusively in a single cluster, underlining the specificity of this TF. 
Moreover, FXR was already identified by previous regulon analysis of single cell transcriptomes (Figure 46), 
which suggests FXR as a most promising candidate for cell culture interventions. 
Interestingly, regulators of clusters with epigenetic patterns that do not directly reflect gene expression, for 
instance upregulated expression together with hypermethylation and more closed chromatin structure 
(cluster 1 and cluster 6), were highly enriched for chromatin remodeling (p = 1.3 x 10-9), and in particular for 
positive regulation of histone H3-K4 methylation (p = 4.2 x 10-4), histone H3 acetylation (p = 5.6 x 10-4), 
negative regulation of histone H3-K9 methylation (p = 5.9 x 10-3), and regulation of DNA methylation (p = 
2.5 x 10-2). Finally, it should be noted that CDX2, a marker of undesired colon-like expression patterns in 
HLC (Sup. Table 13), was identified in cluster 1 to 4 as well (cluster 1: p = 4 x 10-3, cluster 2: p = 3.4 x 10-6, 
cluster 3: p = 4.8 x 10-2, cluster 4: p = 1.24 x 10-4), although not ranking in the top 50 displayed in Sup. Table 
14. 
In summary, the epigenetic analysis revealed pronounced differences on the levels of chromatin accessibility 
and DNA methylation, both during in vitro differentiation of HLCs and in comparison with PHH. Intriguingly, 
an increasing hypermethylation from iPSCs to HLCs was observed, which is in stark contrast with the 
massive upregulation of gene expression observed in HLCs, while PHH showed considerably lower DNA 
methylation levels. Yet, this hypermethylation effect is in line with the transcriptional upregulation of DNMTs 
in cultured cells. In addition, on a genome-wide scale chromatin accessibility increased in DE samples. 
HLCs exhibited again a more closed chromatin structure, but not reaching the even more closed state of 
PHH. While the analysis of the single cell RNA-seq dataset already revealed the less mature state of HLCs 
in comparison to PHH and yielded a set of putative regulators of hepatocyte differentiation (chapter 3.3.1), 
the integrative analysis of transcriptomic and epigenomic data narrowed this set of TFs to the most probable 
key regulators of the desired PHH differentiation state. In this setting, FXR was detected as major putative 
regulator of desired expression and epigenetic signatures. Moreover, SIX2 was identified as an additional 
putative regulator of unfavorable gene expression in HLCs, and undesired epigenetic patterns were 
associated with many epigenetic regulators. The presented integrative analysis represents the basis for the 
development of reasonable cell culture interventions, including the overexpression and posttranscriptional 











In the current era of single cell sequencing the study of cellular heterogeneity becomes more and more 
feasible and contributes to a better understanding of numerous intriguing questions of biology. However, 
there are still major challenges, including the spatial organization of single cells in tissues and integrating 
bulk epigenomic data into the analysis of single cell datasets. Based on the generation, analysis and 
integration of different types of genome-wide sequencing data, the present thesis aims to develop strategies 
to approach these challenges in order to achieve a better transcriptional and epigenomic understanding of 
hepatocyte heterogeneity in health and complex metabolic diseases as well as during in vitro differentiation. 
Regarding spatial heterogeneity of hepatocytes in the human liver, the first part presents a laser capture 
microdissection based approach to achieve the comprehensive transcriptional and epigenetic 
characterization of hepatic zonation in health (Brosch and Kattler et al., 2018) as well as in fatty liver 
diseases (chapter 4.1). In addition, the resulting transcriptional map of the human liver is used as reference 
for a novel pseudospace inference approach, which considerably improves spatial reconstruction of single 
cells into tissue context (chapter 4.2). Furthermore, the final part focuses on the assessment of hepatocyte 
heterogeneity during in vitro differentiation, and in particular demonstrates the integrative analysis of bulk 
epigenomic datasets with single cell transcriptome data. 
4.1 Epigenomic analysis of human liver zonation 
In recent years the field of epigenomics, which comprises the genome-wide mapping of different layers of 
epigenetic modifications by Next Generation Sequencing (NGS) based methods, fundamental 
achievements have been made. Especially large sequencing consortia like ENCODE and IHEC, including 
the German contribution DEEP, provide nowadays a plentitude of high quality epigenomic maps for a large 
number of tissues and cell-types, also related to different diseases for human and in part also for mouse 
(Stunnenberg et al., 2016). Although databases like the IHEC data portal (https://epigenomesportal.ca/ihec) 
are already highly valuable resources, it has become more and more apparent that for the proper 
understanding of tissue regulation it is of utmost importance to study isolated cell-types as well as different 
subpopulations of the same cell-type that could differ in their functions, which is reflected on the epigenetic 
level.  
Thus, more recent consortia such as the Human Cell Atlas (HCA) or the upcoming LifeTime consortium 
focus on single cell sequencing technologies. Also, the focus of epigenetic research shifts towards smaller 
cell numbers – even down to single cell level. While single cell RNA sequencing (scRNA-seq) has become 
more and more feasible and can be readily applied to profile up to millions of single cells in high throughput 
assays, the epigenetic analysis of single cells is still a challenge. To date, several protocols for single cell 
bisulfite sequencing as well as single cell chromatin accessibility analysis are published (Buenrostro et al., 
2015; Cusanovich et al., 2015; Guo et al., 2013; Smallwood et al., 2014). However, those methods only 
capture parts of the genome and require heavy bioinformatical preprocessing, including data aggregation 
and imputation to allow a meaningful analysis. Hence, the targeted analysis of well defined subpopulations 




Within the frame of the BMBF funded EpiTriO project, the goal of a joined endeavor between the groups of 
Prof. Dr. Jochen Hampe (TU Dresden) and Prof. Dr. Jörn Walter was the zone-specific transcriptional and 
epigenomic characterization of hepatocytes in the human liver. In principle, a spatial analysis could be 
obtained by recent single cell sequencing technologies, however this would come with two major drawbacks. 
The preparation of single cell libraries requires tissue dissociation resulting in the loss of spatial information. 
Indeed, it is possible to bioinformatically infer spatial information from single cell data (chapter 4.2), but 
published approaches rely on known marker genes (Achim et al., 2015; Satija et al., 2015), for example 
determined by single molecule FISH (Halpern et al., 2017). In addition, especially methods for single cell 
DNA methylation analysis yield extremely sparse data (Farlik et al., 2015), which do not allow a 
comprehensive in-depth methylome analysis. Thus, we developed a complementary approach based on the 
unique experimental set-up of a pathologically well defined human cohort in combination with sophisticated 
laser capture microdissection (LCM) coupled to next generation sequencing (NGS), which preserves spatial 
orientation and still provides deep genome-wide data of approximately 100 to 200 isolated cells. By using 
adjacent liver cryosections, it was even possible to obtain matching high-quality RNA-seq and RRBS data, 
thereby allowing the first integrative spatial analysis of transcriptomes and methylomes across three micro-
dissected zones along the porto-central axis of human liver (Brosch and Kattler et al., 2018). 
 
4.1.1 Hepatic zonation in healthy liver and early NAFLD 
The first integrated spatial epigenomic map of the human liver (chapter 3.1.1) comprises healthy human 
liver as well as the early spectrum of NAFLD, and can be queried regarding multiple fundamental questions 
of human liver biology such as the regulation of metabolic zonation and hepatic regeneration (Brosch and 
Kattler et al., 2018). 
Depending on their spatial location within the hepatic lobule, hepatocytes show remarkable metabolic 
heterogeneity, which is termed metabolic zonation (Jungermann and Sasse, 1978). Previous studies in 
rodents revealed that zonation is established and maintained by interacting morphogen gradients along the 
porto-central hepatic axis (Gebhardt, 2014). In particular, a pericentral Wnt-/β-catenin signaling is described 
as a master regulator of metabolic zonation (Preziosi et al., 2018). Interestingly, the same morphogens were 
also implied to have major impact on hepatic regeneration (Font-Burgada et al., 2015; Wang et al., 2015). 
In contrast, hepatic zonation and underlying regulatory mechanisms in human liver are not well understood. 
Most previous studies relied either on measurement of zonal enzyme activity (Sokal et al., 1989, 1991, 1993) 
or on immunohistochemical assays (Palmer et al., 1992; Ratanasavanh et al., 1991; Suzuki and Ono, 1987), 
which only provide information about zonation patterns of few selected metabolic enzymes. A recent study 
using a similar laser capture microdissection RNA sequencing approach on normal human liver reported 
139 transcripts with differential expression across the hepatic lobule (McEnerney et al., 2017). However, the 
analysis was limited to normal liver tissue from 3 human donors (2 females, 1 male) undergoing curative 
hepatectomy of liver metastasis. Albeit this study gives a first impression about zonal signatures and 
indicates an upregulation of Wnt signaling in the pericentral zone as shown in mouse, it lacks the statistical 
and methodological power to gain deeper insights into the principles of zonated morphogenic and metabolic 




our approach identified 667 additional genes with zonated expression profiles (Figure 16 B). Intriguingly, 
this pronounced transcriptional gradient was also reflected on functional and epigenetic levels. 
The detected mitochondrial gradient (Figure 21 B and C) reflects the known oxygen gradient as well as the 
resulting oxidative capacity and metabolic functions of each zone (Kietzmann, 2017), and is in line with 
microscopic findings in rat liver, reporting less mitochondria in pericentral hepatocytes (Loud, 1968). 
On the epigenetic level a methylation gradient with a predominant pericentral hypomethylation was observed 
(Figure 18 B). Differential DNA methylation and expression of associated zonated genes was largely anti-
correlated (Figure 19 A), although DMRs correlating with transcription were detected as well. In this context 
it should be noted that the regulatory effect of DNA methylation depends on its genomic localization. For a 
long time DNA methylation and gene expression were considered as purely anti-correlated (Razin and 
Cedar, 1991), with hypomethylation promoting active transcription. Regarding promoter regions and in 
particular CpG islands, this dogma certainly holds true, but in other regulatory elements such as enhancers 
and insulators or along the gene body, the situation appears to be much more complex. For example, DNA 
methylation is often enriched in exons of transcribed genes and apparently has an effect on alternative 
splicing (Shayevitch et al., 2018) or inhibits unwanted spurious initiation of transcription (Neri et al., 2017). 
Taken together, also an increase of DNA methylation can exert a regulatory effect on the upregulation of 
transcription, and hypomethylation can still result in downregulated or deregulated gene expression. Thus, 
the analysis of genome-wide epigenomic data should not be solely restricted to regions with anti-correlated 
DNA methylation and gene expression changes, as also anti-dogmatic regions may still hold essential 
regulatory potential, even though not all mechanistic links are already known. 
Furthermore, DNA methylation can influence transcription factor binding dynamics. While most TFs bind to 
unmethylated DNA sequences (Grossman et al., 2018), there are also TFs that selectively bind methylated 
CpGs (Yin et al., 2017). Thus, the observed differential methylation of TF binding sites (Figure 20 A) may 
represent an additional layer of epigenetic zonation control in the human liver. This epigenetic zonation 
indicates a spatial activity of otherwise uniformly expressed TFs, which constitutes an interesting concept 
that could also play a role in other tissues. 
Both the transcriptomic and epigenomic zonation signatures are preserved in early non-alcoholic fatty liver 
disease (Figure 17). Donors with bland steatosis and early NASH showed consistent gene expression 
differences to normal and healthy obese controls corresponding to the severity of the disease across all 
zones (Sup. Figure 3). Yet, the relative zonated gene expression and DNA methylation patterns remain 
largely unchanged (Figure 16 B and Figure 18 B), which is compatible with the complete regeneration 
capacity of human liver in early NAFLD (Cohen et al., 2011). 
Our integrated epigenomic map of the human liver also allows to assess existing concepts on liver 
regeneration, which were largely developed by lineage-tracing experiments in mouse (Font-Burgada et al., 
2015; Pu et al., 2016; Wang et al., 2015). The strong transcriptional and epigenetic gradient of the Wnt 
signaling pathway and modulating factors (Figure 23), together with the pericentral expression of LGR5 and 
AXIN2 (Figure 24 A) and the corresponding gradient of the liver progenitor marker TBX3 (Lüdtke et al., 2009; 
Suzuki et al., 2008), indicate a pericentral source of hepatocyte regeneration in homeostatic liver tissue. 
Conversely, in periportal hepatocytes a JAG1, NOTCH and EPCAM signature (Figure 24) was observed. 




source of regeneration under injury conditions (Cardinale et al., 2011; Font-Burgada et al., 2015). 
Intriguingly, the interplay of Notch and Wnt signaling was previously suggested to regulate regeneration of 
hepatocytes in chronic liver disease (Boulter et al., 2012). This is further discussed in chapter 4.1.2, which 
is based on the zonal analysis of fibrotic and cirrhotic liver tissue, representing the chronic state of fatty liver 
disease. 
Taken together, the integrated spatial map of human liver provides a wealth of new positional insights into 
zonal networks controlled by epigenetic and transcriptional gradients. In addition, this dataset will serve as 
a valuable resource for further studies, such as the spatial integration of single cell data as discussed in 
chapter 4.2. 
 
4.1.2 Hepatic zonation in progressed fatty liver disease 
In the human, the onset of non-alcoholic fatty liver disease (NAFLD) as well as alcoholic liver disease (ALD) 
is characterized by the accumulation of lipid droplets in pericentral hepatocytes (Cohen et al., 2011), which 
strongly suggests the zone-specific analysis of fatty liver disease progression. Thus, the spatial dataset was 
extended to more progressed stages of fatty liver disease. The human cohort comprised different stages of 
NAFLD up to fibrosis state 3 (FIB3). Within the time frame of this thesis it was not possible to obtain fibrosis 
state 4 samples from donors with a non-alcoholic background. In order to still allow the analysis of the final 
irreversible stage of fatty liver disease, a set of cirrhosis samples from donors with an alcoholic background 
was included. In this context, it should be emphasized that even though many features are shared, NAFLD 
and alcoholic fatty liver disease (ALD) are distinct pathologies (Rowell and Anstee, 2015). Thus, findings 
obtained from ALD should not be transferred to NAFLD without careful consideration, and need to be 
confirmed in liver tissue derived from non-alcohol cirrhosis. 
It should be noted that the proportions of NPCs in liver tissue can differ between disease stages, as in 
particular fibrosis and cirrhosis samples are characterized by a pronounced infiltration of immune cells. 
These shifts in cell-type proportions are major confounders of transcriptional and especially epigenetic 
changes in whole tissue analysis (Lam et al., 2016). Thus, the LCM based approach, which allows the 
predominant analysis of hepatocytes, represents a major advance over whole tissue analysis and allows to 
decipher hepatocyte-specific deregulations in fatty liver disease. On the other hand, different NPC types, as 
well as their composition, play a major role in the onset and progression of fatty liver disease (Choi et al., 
2019; Sato et al., 2019). To understand a tissue during disease development as a whole, a next step would 
be to integrate information of all involved cell-types. Compared to hepatocytes, NPC types are 
underrepresented in the liver parenchyma. Thus, it is to date not feasible to analyze them by our LCM based 
sequencing approach. A possible future alternative might be the integrative analysis of single cell 
sequencing data coupled to sophisticated imaging technology to gain a better understanding of the interplay 
of diverse cell-types creating a complex spatial microenvironment. 
The present analysis aims to unravel transcriptional and epigenetic signatures of hepatocytes. Low 
contamination rates of NPCs were verified by the assessment of marker gene expression. Although 




2016), no major differences between controls, early and progressed disease stages were observed (Sup. 
Figure 1 A), confirming the applicability of our microdissection approach. Interestingly, cirrhotic samples 
showed slightly elevated levels of cholangiocyte markers. Indeed, this could be attributed to a higher amount 
of contamination. However, other NPC markers did not show increased expression levels in cirrhosis, and 
the amount of cholangiocytes should not differ drastically between phenotypes. Thus, it is rather unlikely to 
have a high cholangiocyte contamination in ACI samples. The upregulation of expression levels of 
cholangiocyte-specific genes might be explained by transdifferentiation of hepatocytes towards a 
cholangiocyte-like phenotype, which was reported to occur during sever liver injury (Michalopoulos et al., 
2005). 
In progressed disease stages, pronounced deregulations were observed both on the transcriptional and 
epigenetic level. The highest count of significant DEGs was detected in the pericentral zone. Yet, the number 
of detected DEGS may not be conclusive, as the number of replicates for phenotype-specific differential 
analysis (Figure 30) was rather low, limiting statistical power. Moreover, genes just above FDR cut-off (> 
0.01), which might still be biologically relevant, would not be included. To prevent a biased data interpretation 
based on DEG number, zone-specific DEGs were rather compared by correlation analysis of log fold 
changes, which does not rely on thresholds and gives a better overview on the whole picture. This analysis 
revealed that the majority of differential gene expression was detected uniformly across all hepatic zones 
(Figure 33 C). However, distinct zone-specific differences, which intriguingly comprised among others a set 
of morphogens involved in the regulation of hepatic zonation (Figure 34 A), might have decesive regulatory 
impact. Thus, within the scope of this thesis, data analysis focused on hepatic zonation signatures, which 
represent a unique feature of this dataset that is not feasible in published NGS based studies of fatty liver 
disease (Gerhard et al., 2018; Ryaboshapkina and Hammar, 2017). 
A major finding of the zonal analysis of steatohepatitis, fibrosis and cirrhosis is the progressive loss of 
transcriptional and epigenetic zonation in late stages of fatty liver disease (Figure 29 A and B). Of particular 
interest is the observed portalization of pericentral hepatocytes, as it might represent a key step of disease 
progression. This effect was most obvious on the level of gene expression, with expression profiles of 
zonated genes resembling those in periportal hepatocytes (Figure 28, Figure 32 A and B). Moreover, the 
zonated gradient of mitochondrial abundance, which is characterized by an increasing amount of 
mitochondria from pericentral to periportal hepatocytes in normal tissue (Figure 21 A), was disrupted in 
cirrhotic tissue, as in the pericentral zone the same ratio of mitochondrial reads was detected as in the 
intermediate and periportal zone (Figure 33 C). In normal liver tissue, the mitochondrial abundance reflects 
the known oxygen gradient along the porto-central axis and the resulting oxidative capacity (Kietzmann, 
2017), which again corresponds to the specialized metabolic functions of each hepatic zone (Gebhardt, 
2014). Thus, the disruption of the mitochondrial gradient in cirrhosis might contribute to the portalization of 
pericentral hepatocytes, which ultimately results in the loss of pericentral liver functions such as xenobiotic 
metabolism (Talal et al., 2017). 
In liver with normal histology, Wnt signaling, which is probably initiated by the endothelial cells of the central 
vein (Preziosi et al., 2018; Wang et al., 2015) forms a pronounced pericentral gradient (Figure 23), 
representing a major regulator of hepatic zonation (Figure 53, Birchmeier, 2016). Thus, Wnt signalling is 




al., 2018). Intriguingly, in progressed stages of fatty liver disease, a considerable downregulation of Wnt 
signaling was observed in pericentral hepatocytes (Figure 33 A and C, Sup. Figure 8). 
Extracellular matrix organization plays a major role in fibrotic and cirrhotic liver tissue (Arriazu et al., 2014), 
as excessive amounts of type I collagen are deposited around the central vein, thereby forming the so called 
fibrous septa (Figure 26), which build a kind of physical barrier between the endothelial cells of the central 
vein and pericentral hepatocytes. Thus, the proper formation of the endothel-initiated Wnt signalling gradient 
in the pericentral zone might be prevented (Figure 53), which in turn might lead to the observed 
downregulation of genes that feature pericentral expression profiles in normal liver tissue (Figure 28 A, 
Figure 32 A).  
 
Figure 53: Model of morphogen gradients in normal liver tissue and fibrotic or cirrhotic liver. Fibrotic tissue (grey) forms 
a barrier that prevents formation of the pericentral Wnt signaling (green), thereby allowing the extension of the periportal 
Notch (blue) signaling gradients with significant upregulation of SOX9 and EPCAM (orange) towards the pericentral 
zone. 
Moreover, Wnt signaling might be essential to control periportal Notch signaling. There are multiple reports 
describing a repressive effect of Wnt signaling on the Notch signaling pathway (Boulter et al., 2012; Huang 
et al., 2014; VanHook, 2012). The underlying molecular mechanisms remain poorly understood, although 
studies in zebrafish and human cell lines report several proteins such as NUMB or Disheveled to play a role 
in this regulatory crosstalk. However, neither of them was differentially expressed in our human liver dataset. 
While Notch signaling itself shows only a trend towards pericentral upregulation in cirrhosis, the periportal 
morphogen SOX9 is considerably upregulated in pericentral hepatocytes (Sup. Figure 9). Interestingly, 
SOX9 corresponds to the Notch signaling pathway in a positive feedback loop (Leung et al., 2016; Yin, 
2017). However, SOX9 also interacts with the Wnt signaling pathway. While it can apparently directly 
activate gene expression of several pathway members (Huang et al., 2017; Leung et al., 2016), SOX9 was 
also reported to inhibit Wnt signaling by promoting β-catenin phosphorylation in the nucleus (Topol et al., 
2009). The zone-specific analysis progressed fatty liver disease indicates that morphogens usually 
expressed in the periportal zone might be upregulated in pericentral hepatocytes (Figure 34 A, Sup. Figure 
9) as a consequence of missing Wnt signaling (Figure 53). However, the morphogens deregulated in liver 
fibrosis and cirrhosis form a complex interaction network (Figure 34 B), whereof underlying molecular 
mechanisms have to be resolved in future studies. 
Taken together, the portalization of pericentral hepatocytes suggests the periportal hepatocyte profile as a 




pericentral hepatocyte population. This hypothesis is in line with the presumed regenerative capacity of each 
zone. While pericentral hepatocytes might play a role in hepatic regeneration during normal liver 
homeostasis (Wang et al., 2015), periportal hepatocytes apparently represent the major source of hepatic 
regeneration in chronic liver disease (Font-Burgada et al., 2015), which is characterized by a massive 
proliferation capacity (Corlu and Loyer, 2012). Thus, in addition to the loss of endothelial Wnt signalling, the 
periportally driven regeneration of the liver parenchyma could further contribute to the observed portalization 
of hepatocytes in severe chronic fatty liver disease. As the pericentral zone is crucial for proper metabolic 
liver functions, in particular regarding xenobiotic metabolism, triglyceride synthesis and glycolysis (Gebhardt, 
2014), the portalization of pericentral hepatocytes might be a key factor of liver failure in cirrhosis. If this 
hypothesis holds true, it may give rise to new research avenues for the development of curative drugs 
targeting the signaling pathways deregulated in chronic fatty liver disease.  
In the human, liver metabolism exhibits a high inter-individual variability, as it depends heavily on individual 
lifestyle factors such as diet, alcoholic consumption, smoking or drug intake. In addition, the mammalian 
liver exhibits pronounced sex differences (Saito et al., 2013) and a circadian rhythm (Vollmers et al., 2009) 
that impact gene expression profiles. To avoid circadian bias in our analysis, all samples were obtained at 
the same time of day. Moreover, patients were fasted, which should decrease direct dietary effects on gene 
expression. Still, especially on the epigenetic level a considerable inter-individual heterogeneity was 
observed, which intriguingly increased in donors with liver fibrosis and cirrhosis (Sup. Figure 7 A). This 
observation might suggest an undirected deregulation of DNA methylation patterns in late fatty liver disease. 
Moreover, on the level of DNA methylation, phenotype-specific zonation patterns were detected (Figure 29 
B), which were however not reflected on the transcriptional level (Figure 29 A). As replicate numbers per 
phenotype were rather low (Figure 31), it should be considered that these phenotype-specific zonal DMRs 
might be of low confidence, detected merely due to statistical artefacts. However, their standard deviations 
were in the same range as of those DMRs which were shared between phenotypes, suggesting the validity 
of the phenotype-specific DMRs. It should be noted that with increasing CpG coverage more DMRs per 
comparisons might be detected, which might also increase the overlap of zonal DMRs between phenotypes. 
In addition, most DMRs detected in the zone-wise comparison between HO controls and the other 
phenotypes (Figure 31) were not associated with differential gene expression as well. Thus, only a minor 
fraction of DNA methylation changes was associated to differential gene expression (Sup. Figure 7 F). In 
this context it should be noted that the association of DMRs to genes was done in a very simplistic way by 
annotating the closest gene. Of course, DNA methylation differences in regulatory regions that effect genes 
over long distance interactions would not be appropriately reflected by this approach. While chromatin 
conformation assays such as HiC are very useful to unravel long distance interactions between regulatory 
elements, due to low resolution and extremely high sequencing costs, their applicability in a large set of 
primary human samples is still not feasible (Díaz et al., 2018). Thus, to date, there is no reasonably improved 
way to comprehensively connect DMRs with gene expression in a complex human dataset. Yet, this will 
probably only affect a small fraction of DMRs, as the majority of detected DMRs was localized directly within 
gene context (Sup. Figure 7 A). 
Thus, the vast majority of DMRs is apparently not directly associated with the regulation of gene expression, 




by the profound metabolic changes within the cell due to chronic inflammation and the constant production 
of ECM (Arriazu et al., 2014; Dietrich, 2016). For instance, sustained CYP2E1 mediated ethanol metabolism 
results in oxidative stress (Bardag-Gorce et al., 2006), and resulting reactive oxygen species might cause 
aberrant DNA methylation alterations (Weitzman et al., 1994). 
Moreover, both NAFLD and ALD patients with liver cirrhosis have a significantly higher risk of developing 
hepatocellular carcinoma (HCC, Kanwal et al., 2018; Seitz et al., 2018). In line with the higher variability of 
DNA methylation differences observed in fibrotic and cirrhotic samples (Sup. Figure 7 A), DNA methylation 
signatures might also be indicative of future disease progression. In cirrhosis, which is described as a 
gateway for the development of HCC (Ramakrishna et al., 2013), multiple oncogenes such as MYC, CCND1, 
PAX8, and RAF1 were associated with differential DNA methylation. Thus, it could be possible that a 
tumorigenic potential is already beginning to manifest on an epigenetic level, while not yet detectable on 
transcriptional or even morphological levels. To substantiate this hypothesis, fibrotic and cirrhotic DNA 
methylation profiles would ideally have to be compared with compatible HCC data. However, the increasing 
cell-type heterogeneity in tumor tissue (Kurebayashi et al., 2018) might interfere with the microdissection of 
hepatocytes. Thus, additional LCM independent experiments such as DNA methylation profiling of FACS 
sorted nuclei or even of single cells would be of avail. If the hypothesis holds true, it might open new research 
directions for DNA methylation signatures as predictive markers for HCC development, which might be more 
reliable than current serum markers (Zhao et al., 2013). Moreover, DNA methylation based markers that 
could already be observed in early stages of liver disease would lead to earlier detection and allow the 
preventive treatment of patients with a high risk for HCC development, which could significantly improve 
prognosis. 
In summary, these results demonstrate the relevance of spatial tissue orientation and the added value 
gained by integrating positional information into the analysis of tissues in health and disease. Beyond the 
intriguing observations regarding the regulation of human liver zonation in health and complex metabolic 
disease, the spatial map of human liver tissue can serve as a valuable reference for data integration, which 














4.2 Spatial reconstruction of single cell data 
The intriguing observations obtained by integrative analysis of liver zone-specific transcriptome and DNA 
methylome profiles of human hepatocytes demonstrate the relevance of spatial tissue orientation and the 
added value gained by integrating positional information into the analysis of tissues in health and disease. 
Multiple observations indicate a gradient-like regulation of hepatic zonation along the porto-central axis. In 
line with previous findings in mouse liver (Halpern et al., 2017) and a recent single cell study in human liver 
(Aizarani et al., 2019), differential gene expression analysis across hepatic zones suggests a monotonic 
expression gradient (Figure 16 B), instead of distinct hepatic zones with well-defined expression profiles. 
However, the inherent low resolution of our laser capture microdissection based approach limits the more 
detailed analysis of expression gradients. 
To this end, RNA sequencing of single hepatocytes dissociated from whole liver represents a 
complementary approach to resolve hepatic zonation at single cell level, even though it entails several 
issues that have to be taken into account. In particular high-throughput 3‘-tag scRNA-seq methods, which 
can cover more than 10,000 single cells per experiment, result in sparse data, which are prone to increased 
technical noise, and yield high drop-out rates as well as low numbers of reads (< 50,000) and covered genes 
per cell (< 2,000, Kolodziejczyk et al., 2015). Moreover, due to single cell resolution, there is also a 
considerable amount of biological noise, including heterogeneity arising from inter-individual variability, 
transcription kinetics, biological processes such as cell cycle and apoptosis, but also from cell-types and 
subpopulations. Therefore, it is of utmost importance to distinguish between technical and biological 
variability, and to separate biological heterogeneity of interest from biological noise arising from unwanted 
factors such as cell cycle phase or donor variability. Thus, stringent quality control and proper data 
normalization are required prior to downstream data analysis and interpretation. 
Even though scRNA-seq is a relatively new method, extremely rapid progress is made regarding data 
analysis methods. Already well established workflows comprise for example marker gene and clustering 
based characterization of cell-types and subpopulations, the identification of genes, which drive biological 
processes, as well as differential expression analysis between single cell samples or clustered populations. 
There are also attempts to perform differential splicing between subpopulations and even to analyze allelic 
expression patterns (Kolodziejczyk et al., 2015). Moreover, pseudotemporal lineage tracing (Trapnell, 2017), 
which can be used to track cellular processes over time, and transcription factor regulon activity inference 
(Aibar et al., 2017) to identify distinct regulatory networks in subpopulations can be applied to answer 
numerous intriguing questions of single cell biology.  
In contrast, spatial analysis of single cell transcriptomes remains, to date, a major challenge and is not yet 
feasible for most experimental settings. A major drawback of scRNA-seq approaches is that they require 
tissue dissociation and isolation of single cells, thereby loosing information regarding their spatial origin. 
There are few published approaches using special experimental settings, which rely on a set of reference 
genes with known local expression patterns, to achieve spatial reconstruction of single cell transcriptomes 
into tissue orientation. A study in zebrafish proposed a spatial reconstruction strategy that relies on mapping 
of imputed single cell expression data to a binary 3 dimensional landmark gene matrix obtained from RNA 
fluorescence in situ hybridization (FISH) of 47 known marker genes (Satija et al., 2015). Similar, spatial 




weighted mRNA profile mapping to a reference FISH atlas (Achim et al., 2015). Both approaches are based 
on binarized reference data, which entails the binarization of scRNA-seq data prior to spatial reconstruction, 
resulting in a loss of quantitative expression information. Thus, they yield convincing results in tissues with 
clear-cut regional expression profiles of distinct marker genes. In cases of monotonic expression gradients 
across a tissue, these approaches are however not ideal. For our single hepatocyte transcriptome dataset, 
the approach by Achim et al. correctly identified hepatocytes close to the central and portal veins, but was 
not able to assign hepatocytes from the intermediate zone, as these cells do not express zone-specific 
marker genes (data not shown). More recently, quantitative single-molecule FISH (smFISH), which allows 
detailed transcript quantification at single cell resolution, albeit only for a small number of selected genes, 
was used for the generation of a continuous reference map of the hepatic lobule in mouse (Halpern et al., 
2017). Single hepatocytes were then assigned into 9 layers along the porto-central axis by probabilistic 
spatial inference based on 6 reference genes. Halpern et al. correctly identified monotonic expression 
gradients, as suggested by smFISH data, but also non-monotonic expression profiles with highest 
expression in intermediate layers. Although this approach evidently represents a valid strategy for spatial 
tissue reconstruction, it relies only on a small subset of known landmark genes as reference. This can be a 
major drawback, for instance for spatial reconstruction in liver disease such as cirrhotic tissue with 
deregulated zonation profiles (Figure 27 A), but also in tissues with no known landmark genes to easily build 
a smFISH reference. Additionally, single cell data, especially those generated by high-throughput methods 
such as droplet-based 10X, are inherently noisy and have high drop-out rates. Hence, relying on few marker 
genes for spatial reconstruction could lead to biased spatial embeddings. 
In this context, laser capture microdissection coupled to RNA-seq (LCM RNA-seq) represents a reasonable 
alternative for the generation of spatial reference maps without prior knowledge of landmark genes (Moor et 
al., 2018). As we already generated high quality zonal expression reference maps for human liver by LCM, 
yielding genome-wide, continuous expression values, it was reasoned that these data might serve as a 
valuable resource to anchor spatial mapping of single cell data. Compared to smFISH, LCM RNA-seq 
derived data have the advantage of providing spatial information for all expressed genes in the analyzed 
cell-type. However, a limitation is that our LCM approach averages about 100 cells per zone and does not 
reach single cell resolution. Thus, probabilistic inference as performed by Halpern et al. would not result in 
a detailed expression gradient, but rather mirror the resolution of the three microdissected zones. Although 
this would already add a valuable covariate for single cell data interpretation, a more fine-grained modelling 
of single cells would be preferable. To overcome this limitation, a complementary approach, which allows 
the spatial reconstruction at single cell resolution, but is still anchored to low-resolution LCM based reference 
data, was developed.  
The hepatic porto-central axis effectively represents a 1-dimensional structure with radial symmetry that 
exhibits a functional spatial zonation (Gebhardt, 2014). As in healthy liver this hepatic zonation is a major 
driver of variance in gene expression data (Sup. Figure 2 A), it was reasoned that it should be possible to 
capture spatial profiles in multi-dimensional single cell transcriptome data using dimensionality reduction 
approaches. To this end, several algorithms widely used for scRNA-seq data analysis, including PCA, tSNE, 
UMAP and diffusion map, were assessed (Figure 35). Based on all highly variable genes (HVGs) in the 




approximation (Haghverdi et al., 2015), showed the most promising performance (Figure 35 D). Diffusion 
distances, which are the probabilities of a cell to transition into other cells, are calculated for the k nearest 
neighbors based on a Gaussian kernel with width sigma. In context of spatial reconstruction, a small diffusion 
distance between two cells can be considered as an indication for neighboring localization in the tissue of 
origin. After density normalization to incorporate only transition probabilities between different cells, an 
eigendecomposition of the transition probabilities is performed, which yields diffusion components with 
decreasing eigenvalues  (Haghverdi et al., 2015). Thus, diffusion component 1 (DC1) usually represents the 
major driver of variance. The reference-free diffusion map based on all HVGs showed separation by 
pericentral and periportal zones along DC1 (Figure 35 D). However, the separation remained rather noisy, 
and particularly the intermediate zones was not sufficiently resolved, which can probably be explained by 
the high amount of variability inherent to single cell data (Kolodziejczyk et al., 2015). 
Thus, reducing the gene set to HVGs that show a zonal expression profile in healthy liver should increase 
the ratio of variability actually caused by spatial origin of single cells. Indeed, anchoring the diffusion map 
on zonated HVGs, as defined by our LCM based reference dataset, resulted in a strikingly clear separation 
of hepatic zonation along DC1 (Figure 35 H), which neatly resembled the presumed orientation of 
hepatocytes along the porto-central axis. Thus, the diffusion map on zonated HVGs was selected as the 
most promising of the tested approaches for dimensionality reduction based reconstruction of hepatic 
pseudospace. 
In principle, DC1 coordinates could be used to assign each cell a discrete localization in hepatic 
pseudospace. However, to achieve a more robust modelling, DC1 was rather considered as the probability 
to belong to a certain hepatic zone (Figure 37 A). To ensure a valid zonal assignment, DC1 thresholds for 
zone definition were determined by expression patterns of all zonated HVGs (n = 107). For visualization of 
low abundance genes imputed expression values were used to allow a meaningful assessment of 
expression gradients. Previous approaches rely also on imputed expression data for the spatial 
reconstruction itself (Satija et al., 2015), although data imputation might introduce additional variation into 
the dataset (Andrews and Hemberg, 2019). As the diffusion map was mainly driven by highly expressed 
genes with pronounced zonation profiles (Figure 36 C – D), which yielded consistent and reasonable spatial 
embeddings (Figure 36 C – D, Figure 37 C), there was no need for data imputation for diffusion map 
calculation, thereby avoiding the potential introduction of additional bias. 
Although the diffusion map based spatial reconstruction approach was mainly developed for sparse high-
throughput scRNA-seq data, it is also feasible in small datasets with higher coverage, such as our 
Smartseq2 PHH single cell expression dataset (Sup. Figure 11). Interestingly, this dataset comprised 3 
individual human donors. Using a deconvolution based normalization method (Lun et al., 2016), it was 
possible to reduce inter-individual variability in order to allow proper diffusion map based pseudospace 
inference even across different donors. This further highlights the robustness and applicability of the 
diffusion map based spatial reconstruction. 
Tissue disintegration prior to scRNA-seq library preparation usually results in a loss of cells. Thus, the final 
dataset does not represent all cells of the tissue sample, and some cellular subpopulations might be 
preferentially lost during tissue homogenization, which might result in biased cell number proportions 




tissue symmetry of the hepatic lobule with few cells neighboring the central vein and more cells localized 
around the portal field (Figure 37 B), which is in physical space much larger and can thus harbor more cells 
(Gebhardt, 2014). In addition, spatial reconstruction of single cells yielded subdivision of the three defined 
hepatic zones, which show meaningful expression gradients and might therefore represent actual hepatic 
layers (Figure 37 B and C). Interestingly, further analysis of these layers indicated non-monotonic gene 
expression for a subset of zonated genes (Figure 37 C). This is in line with previous findings in mouse 
(Halpern et al., 2017). In our LCM RNA-seq dataset there was no indication for non-monotonic genes 
expression, which could however be attributed to the inherent low cellular resolution of this approach. On 
the other hand, the expression levels of these genes were rather low, which resulted in an overestimation 
of expression differences in the scaled heatmap illustration (Figure 37 C). As these expression differences 
might merely arise from noise in the single cell data, these results should be considered with care. Thus, 
independent validation of expression profiles in the human hepatic lobule, for example by smFISH, would 
be necessary to validate non-monotonic gene expression. 
A recent pre-print available on bioarxiv suggests to handle spatial reconstruction as a generalized optimal 
transport problem (Nitzan et al., 2018). This intriguing approach is based on the mathematical transport 
theory, which was originally proposed in the 18th century by Gaspard Monge and mathematically established 
in the 1920s to determine optimal routes for cargo transport (Grattan-Guinness, 1994). In a nutshell, a 
transport problem aims to find minimal physical distances, thus it can be readily applied as a spatial 
assignment problem of single cells. Nitzan et al. apply this approach amongst others to the previously 
described mouse hepatocyte dataset (Halpern et al., 2017), robustly identifying hepatic expression 
gradients. Although conceptually designed as a reference-free pseudospace inference, they also find that 
anchoring to a reference dataset outperforms the unsupervised reconstruction. Moreover, accuracy 
apparently increases with the number of reference genes (Nitzan et al., 2018), which again advocates the 
use of LCM for reference dataset generation. 
The transport problem related approach and the diffusion map based spatial reconstruction both effectively 
model hepatocyte localization along the porto-central axis. In this context, it should also be considered that 
the hepatic lobule is a 3-dimensional tissue, which also comprises non-parenchymal cell-types (NPCs). The 
spatial mapping of NPCs, such as endothelial cells of central respective portal veins, is especially 
challenging, as these cells have a rather low mRNA content and do not feature distinct expression of 
landmark genes. Recently, this challenge was met by an intriguing approach using paired-cell sequencing 
based on inefficient digestion of mouse liver, which resulted in a high fraction of duplets in the sequencing 
library. The spatial information gained by the hepatocyte part of the cell duplet allowed the spatial inference 
of the attached endothelial cell (Halpern et al., 2018). Even though this approach contributes a first 
approximation of liver endothelium reconstruction, the data remain sparse and other NPCs such as 
cholangiocytes or immune cells were not considered. Thus, future work will be needed to improve spatial 
mapping of NPCs, for instance by highly sophisticated machine learning based combination of single cell 
RNA-seq with advanced imaging solutions such as sequential FISH (Eng et al., 2019). 
Even though the predominant spatial signature of hepatocytes is the localization along the porto-central 
axis, the ultimate modelling of hepatic tissue would require to additionally infer the second and third 




sequence of hepatocytes of the same zonation layer, while the third dimension consists out of stacked, 
repeating functional units. It is important to note that diffusion component 2 (Figure 37 A) most likely does 
not represent a spatial dimension of the hepatic lobule, but captures other sources of transcriptional variation 
such as inter-individual heterogeneity (Sup. Figure 11 D). With the porto-central axis representing the 
functional spatial separation within the liver lobule, there is only a weak intra-layer cell to cell variability of 
hepatocytes localized in the same hepatic zone (Halpern et al., 2017). Thus, using existing approaches, 
modelling of the second and third spatial dimensions based on gene expression variability is probably not 
feasible. However, spatial reconstruction of hepatocytes into their functional units along the porto-central 
axis will already allow the elucidation of many intriguing questions of liver biology. 
 
Figure 54: Three-dimensional illustration of the hepatic lobule. The first dimension (1D, red arrow) represents the proto-
central axis. The second dimension (2D, orange arrow) is composed of the concentric layers of hepatocytes, while the 
third dimension (3D, purple arrow) consists out of stacked hexagonal subunits. 
Interestingly, an organ scale, zone-specific quantification of the onset of steatosis, which is in contrast to 
human localized in the periportal zone, using sequential slices for hematoxylin eosin and Glutamine 
Synthetase (GLUL) stainings in mouse liver, showed distinct zonal onset of lipid droplet accumulation, but 
also revealed a considerable heterogeneity regarding the extent of steatosis across the organ (Schwen et 
al., 2016). This finding raises the question whether underlying expression programs and in particular zonated 
expression signatures show this heterogeneity as well. This might not only be important for the proper spatial 
reconstruction of steatotic liver tissue, but could in principle also play a role in healthy liver. To date, 
systematic studies regarding the variability of liver zonation programs in the mammalian liver are lacking. 
An interesting approach that might contribute to the better understanding of hepatocyte variability in 3 
dimensional liver tissue could be based on microdissection of hepatocytes of the second and third hepatic 
dimensions. Capturing hepatocytes along the porto-central axis in one microdissection at multiple locations 
in the hepatic lobule would allow the assessment of hepatocyte variability along the second radial dimension 
(Figure 54). Microdissection of the third dimension would probably be more challenging, as it might be rather 
difficult to visually identify on the cryosection. In addition to a better understanding of intra-zonal hepatocyte 
variability allowing more accurate spatial reconstruction, resulting data might serve as a valuable reference 
to design methods for the spatial deconvolution of bulk RNA-seq data, which are typically generated from 




Although spatial reconstruction of single cells along the porto-central axis appears to be rather robust, the 
identification of zonated gene expression from single cells assigned to hepatic zones remains challenging 
(Figure 39). Based on Kruskal-Wallis statistics, the study by Halpern et al. (2017) on mouse liver detected 
about 50 % of expressed genes to be significantly zonated. This is several orders of magnitude higher than 
was previously reported for mouse (Saito et al., 2013). The analysis of zonated gene expression of the 
human single cell dataset was adapted from the strategy by Halpern et al., with the exception of using all 
cells in the respective zone instead of only the most extreme layers (cells directly neighboring to portal field 
or central vein), and yielded almost twice as many zonated genes as the laser capture microdissection based 
approach (Figure 39 A). On the one hand this might be attributed to the higher resolution of reconstructed 
single cell data. However, LCM can be considered as a kind of gold standard for spatial analysis, as it retains 
spatial information of samples and does not rely on bioinformatical pseudospace inference. In addition, the 
low overlap of detected zonated genes derived from the spatially reconstructed dataset and the LCM dataset 
strongly suggests an overestimation of zonated gene expression in the single cell dataset. The approach by 
Halpern et al., which relies on Kruskal-Wallis test between the expression levels of pericentral and periportal 
cells, might not be the most appropriate method for differential expression analysis between hepatic zones 
at single cell resolution. Thus, future work is needed to develop more advanced algorithms for differential 
expression analysis of spatially reconstructed single cell data, which should ideally consider reconstructed 
pseudospace as single cell localization probabilities, thereby taking uncertainties and inaccuracies of spatial 
mapping into account to obtain more robust results. 
Still, interspecies analysis of one-to-one matching orthologues identified 113 genes with conserved zonation 
signatures (Figure 39 A), comprising highly expressed landmark genes, such as GLUL, CYP2E1, SDS and 
APOF, but also morphogens like LGR5 and SOX9 with low transcript levels. The remaining 202 one-to-one 
matching orthologues zonated in human were not detected as zonated in the mouse. Most of these non-
corresponding genes showed rather low expression level in the mouse single cell dataset as compared to 
our deeply sequenced human data. Thus, differences in zonated gene expression between human and 
mouse might be attributed to technical factors, such as the low expression profiling efficiency of single cell 
datasets. Therefore, a more effective interspecies analysis should rely on the same method, ideally on the 
more robust LCM based approach, which would preclude technical artifacts and allow a more 
comprehensive data interpretation. As the genes with conserved zonation patterns comprise enzymes with 
known metabolic zonation and importantly morphogens associated to Wnt and Notch signaling, the 
interspecies analysis indicates similarities between the regulation of hepatic zonation in human and mouse. 
This is crucial for the translational interpretation of findings derived from mouse experiments, such as the 
lineage tracing based identification of a TBX3 expressing pericentral hepatocyte subpopulation as potential 
hepatic stem cell niche under steady state conditions (Wang et al., 2015), which could be relevant in the 
human as well (Figure 24). 
Spatial reconstruction of high-throughput single cell RNA sequencing data and LCM based RNA-seq can 
be considered as complementary approaches. In a more complex biological setting, containing additional 
sources of transcriptional variation, spatial reconstruction may be more challenging. The proper identification 
of genes driving individual sources of variation, such as spatial, temporal, inter-individual differences, as 




genes that are major contributors to spatial variance in a liver single cell dataset can be isolated and used 
for spatial reconstruction of the hepatic lobule. Nevertheless, this approach has certain limitations. For 
instance, it was shown that in liver cirrhosis hepatic zonation profiles are disturbed (Figure 27 A) and 
pericentral hepatocytes express periportal-like profiles (Figure 28 A). Thus, zonation markers defined by the 
analysis of healthy tissue (Figure 16 B) are not suited for proper reconstruction of cirrhotic tissue. A possible 
solution could be the complementary analysis of scRNA-seq data with matching LCM-RNA-seq data from 
the same sample, which might yield genes with intact zonation profiles that could be used to anchor diffusion 
map based tissue reconstruction as described for healthy liver tissue (Figure 37 A). Thus, in an ideal 
experimental set-up, single cell RNA-seq and LCM RNA-seq would be performed on the same sample, 
thereby decreasing unwanted variability and enhancing accuracy of spatial reconstruction. However, since 
in most cases this will not be feasible due to cost restraints, using our phenotype-specific LCM based 
reference dataset as anchor for spatial reconstruction of new single cell RNA-seq datasets represents a 
readily applicable alternative. Finally it should be noted that the application of LCM anchored diffusion map 
based pseudospace inference is not restricted to liver tissue, but could be used to capture spatial covariates 
in other tissues with spatial expression gradients, such as in intestinal epithelium (Moor et al., 2018). In 


























4.3 Epigenomic characterization of in vitro differentiated HLCs 
The in vitro differentiation of induced pluripotent stem cells (iPSCs) into hepatocyte-like cells (HLCs) shows 
promise as a future alternative to cryopreserved primary human hepatocytes (PHH, Gebhardt et al., 2003; 
Godoy et al., 2013; Wang et al., 2017), which represent the current gold standard for toxicological and 
pharmacological in vitro studies (Hengstler et al., 2000). Although there is room for improvement (Godoy et 
al., 2018), in vitro differentiated HLCs have already proven useful. For instance, a patient-specific HLC 
system was recently used in a drug screen for the treatment of homozygous familial hypercholesterolemia, 
a heritable metabolic liver disease (Cayo et al., 2017). However, many studies aiming to further optimize 
differentiation protocols are based on few marker genes (Asumda et al., 2018; Wang et al., 2017), which 
does not allow a comprehensive interpretation of the HLC differentiation state. Indeed, microarray and NGS 
based studies concluded that current differentiation protocols yield HLCs that start to emulate a PHH 
phenotype, but still show massive expression differences compared to PHH (Cahan et al., 2014; Camp et 
al., 2017; Godoy et al., 2015, 2018). Interestingly, HLCs apparently rather resemble fetal hepatocytes (Camp 
et al., 2017), and also show mixed characteristics of other cell-types, such as the expression of colon 
markers (Godoy et al., 2015). 
In principle, the presented analysis builds on a previous publication based on gene expression microarray 
analysis (Godoy et al., 2015), which discovered a set of transcription factors, including CAR, FXR and PXR, 
as putative key TFs to improve HLC differentiation (Figure 55 A). Moreover, markers of unfavorable 
expression signatures like CDX2 and KLF5 were identified (Godoy et al., 2015). Hepatic differentiation is a 
complex process, regulated by interacting signaling pathways and stage-specific cascades of transcription 
factors. Thus, it seems unlikely that the massive gene expression differences observed between HLCs and 
PHH (Figure 47 B) would be attributed only to the activity of few TFs. Up to 85.9 % of expressed genes in 
the dataset showed significant differences, which suggests fundamental disparity also on the level of 
epigenetic mechanisms, which play a crucial role in the regulation of the TFs involved in hepatic 
differentiation (Snykers et al., 2009). For instance, promoter regions of certain stem cell marker genes such 
as OCT4 and NANOG are methylated with the onset of differentiation (Yeo et al., 2007). Moreover, it has 
been shown that chromatin remodeling agents such as HDAC inhibitors can improve hepatic differentiation 
(Ye et al., 2016). Thus, we aimed to achieve a comprehensive transcriptional and epigenomic 
characterization of the in vitro differentiation process. To this end, we analyzed besides iPSCs and HLCs, 
as start and end point of differentiation, also definitive endoderm as an intermediate point of cell fate decision 
(Figure 40). In addition, a detailed comparison of HLCs and PHH was performed on single cell level to gain 
a better understanding of underlying regulatory networks (Figure 41). Instead of using a high throughput 
method to profile expression signatures of thousands of single cells, we manually isolated single cells into 
96 well plates and performed a Smartseq2 (Picelli et al., 2013) scRNA-seq approach, which allowed the 
highly sensitive analysis of full-length transcriptomes with saturated per cell sequencing coverage. 
Moreover, compatible external single fetal hepatocyte transcriptome data (Camp et al., 2017) provided the 





Figure 55: In vitro differentiation of HLCs. A – PCA of the 1,000 most variable transcript identified by gene expression 
microarray analysis of stem cells, HLCs and human hepatocytes (Godoy et al., 2015, modified). B – Diffusion map 
integrating gene expression, DNA methylation and chromatin accessibility throughout in vitro differentiation of iPSCs 
over DE to HLCs in comparison with PHH. Diffusion components were calculated separately for each assay based on 
the 1,000 most variable transcripts (RNA-seq), the 5,000 most variable CpGs with coverage above 5 in all samples 
(DNA methylation), and the 50,000 most variable 100 bp regions (ATAC-seq). Resulting coordinates were plotted into 
one panel. Diffusion components of DNA methylation were inverted prior to plotting. iPSCs are colored in brown, DE in 
red, HLCs in olive and PHH in blue. Border colors reflect the depicted assay with gene expression in black, DNA 





Two different protocols for in vitro HLC differentiation in 2-dimensional cell culture were assessed – the 
Cellartis (CEL) protocol, which is already commercially available at Takara Bio, and a protocol developed 
by the group of David Hay (University of Edinburgh, Wang et al., 2017). Prior to differentiation, iPSCs were 
cultivated for 4 days to obtain clean stem cell populations. Then, differentiation over DE to HLCs was 
completed within 25 days using the CEL protocol, while the HAY protocol achieved differentiation after only 
18 days (Figure 40). For both protocols, a mixture of Laminin 521 and Laminin 111, which was optimized in 
preceding experiments by Patrick Nell and David Feuerborn (IfADo), was used to mimic the extracellular 
matrix (ECM) of liver tissue. However, further comparison of the two protocols regarding differentiation 
inducing compounds is not possible, as the detailed components of the CEL protocol remain confidential. 
Moreover, both on transcriptional and epigenetic level HAY HLCs appeared to be less differentiated than 
CEL HLCs (Figure 55 B), and also featured higher expression levels of undesired genes such as CDX2 
(Figure 43). Thus, rather than comparing both protocols, more detailed analysis focused on the apparently 
more promising CEL in vitro differentiation system. 
Interestingly, pseudotime analysis of single cell transcriptomes indicates separate differentiation trajectories 
for in vivo and in vitro hepatogenesis (Figure 44), which is in line with distinct underlying regulatory networks 
(Figure 45). Moreover, TF network inference confirmed that HLCs resemble fetal hepatocytes more closely 
than adult PHH (Camp et al., 2017). It should also be noted that a considerable batch to batch variability of 
HLCs was observed. While replicates 2 and 3 showed a very similar differentiation state, replicate 1 
appeared to be less differentiated (Figure 43), although all replicates, which were generated from the same 
iPSC line, should reach a similar differentiation state. Thus, optimized differentiation protocols should also 
aim to eliminate batch to batch variability to ensure the applicability of HLCs as a reliable tool for in vitro 
studies. In addition, putative regulators of a hepatocyte-like cell fate were identified, comprising among 
others FXR, PXR and CAR (Figure 46), which were already described as potential key factors by Godoy et 
al. (2015). Interestingly, PXR and CAR were exclusively active in PHH, while FXR activity was also observed 
in the subpopulation of HLCs that expressed ALB. Thus, FXR, which encodes the nuclear farnesoid X 
receptor that can be activated by bile acids (Lefebvre et al., 2009), might be a direct regulator of ALB 
expression in HLCs, while PXR and CAR are probably rather involved in the regulation of other hepatocyte-
specific programs. On the other hand, previously reported potential regulators of undesired gene expression 
profiles such as CDX2 and KLF5 were confirmed, while an additional set of unfavorable regulons including 
FOSL2 and GATA5 were discovered as well (Sup. Table 13). It should be noted that activity of both 
hepatocyte and intestine specific regulons could be detected within the same single hepatocyte-like cell 
(Figure 46). Thus, instead of a clear transition from DE to a hepatocyte-like phenotype, HLCs apparently 
rather represent a heterogeneous phenotype showing some characteristics of hepatocytes, but also 
expression signatures of other DE derived cell-types. 
This mixed phenotype of HLCs might be explained by the lack of a properly regulated microenvironment in 
cell culture. Definitive endoderm represents a major point of cell fate decision that still harbors the capacity 
to differentiate into multiple cell-types. During in vivo development these cell fate specifications are regulated 
by a complex interplay of temporal and spatial TF cascades from surrounding tissues and cell-types. For 




the formation of the gastrointestinal tract (Stringer et al., 2012), while upon inhibition of Wnt signaling the 
ventral forgut endoderm gives rise to a population of bipotent hepato-pancreatic progenitors (Russell and 
Monga, 2018). As in vitro differentiation seems to recapitulate several aspects of in vivo hepatogenesis, the 
use of Wnt antagonists might lead to a more targeted differentiation of HLCs towards a hepatocyte-like 
phenotype. 
Intriguingly, gene expression, DNA methylation and chromatin accessibility followed similar trajectories 
modelling the HLC in vitro differentiation process (Figure 55 B). Bulk RNA-seq confirmed and extended the 
previously reported massive gene expression differences between HLCs and PHH (Godoy et al., 2015). 
During differentiation of iPSCs to DE a general increase of chromatin accessibility was observed, while the 
chromatin structure became again more closed in HLCs (Figure 49 A). Yet, PHH showed an even lower 
number of accessible chromatin regions, which is in line with the reduced number of expressed genes. 
Overall, differential chromatin accessibility was considerable more indicative of gene expression changes 
than differential DNA methylation (Figure 51 E – H, Figure 52 B). Moreover, a pronounced DNA 
hypermethylation was observed in cultured cells, which increased with cultivation time (Figure 48 A, Sup. 
Figure 15 B), while in vivo derived PHH showed considerably lower DNA methylation levels (Figure 48 C). 
Nevertheless, it should be noted that in comparison with PHH cultured cells also featured some 
hypomethylated regions. In HLCs, hypermethylated regions were more frequently localized in intergenic 
regions (Figure 48 D), and an increase of highly methylated domains was obvious on a genome-wide scale 
(Sup. Figure 15 B). Moreover, while differential chromatin accessibility frequently correlated with gene 
expression changes, DNA methylation patterns were rarely indicative of gene expression (Figure 52 B). 
Taken together, these observations suggest an undirected hypermethylation of HLCs, which might even 
persist when differentiated HLCs are cultured for longer periods. This is in line with a previous study reporting 
aberrant DNA hypermethylation during the differentiation of embryonic stem cells, which apparently 
resembled DNA methylation signatures frequently observed in primary tumors (Meissner et al., 2008). As 
differentiated HLCs can be maintained in cell culture for more than 30 days (Carpentier et al., 2016), this is 
of great interest regarding their applicability for long-time studies. Ideally, differentiated HLCs should show 
a stable phenotype during maintenance cell culture, as cultivation induced epigenetic and transcriptional 
changes might heavily bias experiments such as drug screenings. Yet, it should be noted that the cultivation 
of PHH also results in transcriptional differences (Godoy et al., 2015). Interestingly, cultured PHH resemble 
gene expression profiles of certain liver disease phenotypes such as NAFLD and cirrhosis (Godoy et al., 
2016), which highlights the overall need for improved in vitro systems.  Thus, further epigenetic profiling of 
differentiated HLCs maintained for an extended period in culture should unravel the stability of the HLC 
differentiation state over time, which might suggest additional cultivation measures to further optimized the 
HLC phenotype. 
Furthermore, the pronounced hypermethylation of cultured cells can likely be explained by the strong 
upregulation of DNMTs during in vitro differentiation (Sup. Figure 16). The highest expression level of 
DNMTs is observed in iPSCs and decreases over DE to HLCs. Interestingly, the de novo DNA 
methyltransferases DNMT3a and DNMT3b are upregulated in all stages of in vitro cultivation, while 
maintenance DNMT1 is only upregulated in iPSCs and DE, which are still in a proliferative phase. It should 




mediate active DNA de-methylation by iterative oxidation of 5-methyl-cytosine (5mC) into 5-
hydroxymethylcytosine (5hmC), 5-formyl-cytosine (5fC) and 5-carboxy-cytosine (5cC, Ito, 2011; Tahiliani et 
al., 2009; Wossidlo, 2011). The upregulation of TET1 expression might be reflected in the hypomethylated 
regions detected in cultured cells (Figure 48 A). However, the bisulfite conversion method used for 
preparation of RRBS libraries (chapter 2.2.1.2) does not allow to disentangle these oxidized derivates. 
Actually, 5hmC is not distinguished from 5mC (Huang et al., 2010), while 5fC and 5cC are mostly detected 
as unmethylated CpGs (Tierling et al., 2018). Thus, part of the observed DNA hypermethylation might be 
attributed to 5hmC, which would suggest high DNA methylation dynamics during in vitro differentiation. 
Hence, the HLC system would also represent an in interesting model to assess DNA methylation and de-
methylation dynamics by using specialized sequencing methods that allow the analysis of oxidative 5mC 
derivates at base resolution (Skvortsova et al., 2017).  
The integration of gene expression, chromatin accessibility and DNA methylation allowed the definition of 
gene sets with distinct epigenetic patterns. Remarkably, only for genes that showed a correlation of 
upregulated gene expression and increasing chromatin accessibility, but were also associated with DNA 
hypermethylation in HLCs, specific key regulators could be identified (Figure 52 D, cluster 5 and 8). For 
differentially expressed genes that were associated with other epigenetic patterns, such as upregulated 
gene expression, less accessible chromatin and DNA hypermethylation in HLCs (Figure 52 D, cluster 6), 
high numbers of individual TFs were detected as putative regulators. Interestingly, these TFs were highly 
enriched for proteins involved in chromatin remodeling, which suggests a high epigenetic dynamic 
associated with these genes. Moreover, SIX2 was detected as a novel putative master regulator of genes 
hypermethylated, more accessible and strongly upregulated in HLCs. This TF does not seem to play a role 
during in vivo hepatogenesis, but rather during the development of other organs such as stomach and kidney 
(Ohto et al., 1998; Self et al., 2006, 2009). During kidney development SIX2 seems to keep multipotent 
progenitor cells in an undifferentiated state (Kobayashi et al., 2008), which suggests that SIX2 might be 
involved in retaining in vitro differentiated HLCs in a hepatoblast-like state. Thus, the downregulation of SIX2 
during in vitro differentiation might benefit HLCs towards a more adult hepatocyte-like phenotype. In addition, 
for genes hypomethylated, more accessible and upregulated in PHH FXR was confirmed as the key 
regulator, which highlights FXR as the most promising target for cell culture interventions in order to 
upregulated PHH expression patterns in HLCs. 
Taken together, the observed epigenetic patterns during in vitro differentiation (Figure 55 B) suggest the 
following model: The starting population of induced pluripotent stem cells already features a quite accessible 
chromatin structure. During early events of differentiation from iPSCs to DE the overall chromatin structure 
becomes even more accessible in order to allow a wide-spread transcriptional activation of a multitude of 
genes. This would also explain the predominant DNA hypermethylation in cultured cells, as well as its lack 
of association with differential gene expression, as a kind of unspecific bystander effect due to the 
upregulation of DNMT expression. Then, during further differentiation from DE to HLCs the chromatin 
structure becomes more closed again. Actually, the progressive restriction of chromatin accessibility might 
be a key feature of cellular differentiation (Atlasi and Stunnenberg, 2017), defining the increasingly 
specialized and tightly regulated expression profiles of terminally differentiated cell-types. This is in line with 




chromatin structure than PHH. Hence, while on the level of chromatin accessibility HLCs would need to be 
more restricted, e.g. more tightly controlled, on the level of DNA methylation the persisting DNA 
hypermethylation of HLCs indicates some kind of overshooting effect. Thus, possible cell culture 
interventions also should entail the manipulation of epigenetic modifiers to reach a similar epigenetic state 
as PHH (Figure 55 B). 
Furthermore, it is important to note the complex interplay of hepatocytes with non-parenchymal cell-types 
and extracellular matrix components, as well as the intricate network of oxygen gradient and morphogen 
interactions (Kietzmann, 2017) that shape the specialized phenotype of spatially distinct hepatocytes in liver 
tissue (chapter 4.1). This tightly controlled 3-dimensional microenvironment is most probably key to obtain 
fully differentiated adult hepatocytes. However, modelling this complex microenvironment in cell culture 
remains a major challenge, which is not feasible in conventional 2-dimensional cell culture. Several attempts 
including co-culture with other cell-types as well as 3-dimensional organoid cultures have been made (Prior 
et al., 2019). For instance, Camp et al. (2017) report liver bud organoids differentiated from a co-culture of 
hepatic endoderm, endothelial and mesenchymal cell, which model human liver bud development in vitro. 
Although organoid-derived hepatocytes exhibited only an immature hepatoblast-like phenotype (Camp et 
al., 2017), organoids certainly represent a promising approach to achieve a more reliable liver-like in vitro 
system. In this context, it would be interesting to study the epigenome of organoids during differentiation 
and compare it to the epigenetic profiles of 2-dimensional HLC cultures. Then, the cell culture interventions 
developed from the characterization of 2-dimensional HLC differentiation presented in this thesis might be 
of use in the optimization of liver organoid cultures as well.  
In summary, the presented integrative analysis suggests an epigenetic model of in vitro differentiation 
(Figure 55 B), and furthermore represents the basis for the development of reasonable cell culture 
interventions. It should be noted that sole over-expression of TFs such as FXR might indeed result in a 
slightly improved HLC phenotype, but the massive gene expression differences between HLCs and PHH 
will most probably not be overcome. A more promising – though challenging – approach would be a 
combination of several interventions, such as overexpression of key TFs together with downregulation of 
unfavorable colon-specific TFs and additional interventions on the epigenetic level. For instance, HDAC 
inhibitors such as TSA and valproic acid have been shown to exhibit a positive effect on hepatic in vitro 
differentiation, although they do not exhibit targeted effects (Dong et al., 2013; Karantzali et al., 2008; Kondo 
et al., 2014). However, these compounds exhibit an undirected effect on chromatin accessibility (Li and Sun, 
2019). In the case of HLCs a targeted restriction of chromatin accessibility would be favorable. To this end, 
the increasingly popular CRISPR/Cas9 technology might offer possibilities to perform targeted epigenome 
editing (Xie et al., 2018). In addition, the observed DNA hypermethylation in cultured cells could be 
prevented by directly targeting the expression of DNMTs. Moreover, supplementing the differentiation 
medium with certain modulating compounds might have a beneficial effect as well. For instance, the activity 
of FXR could be increased by bile acids, while Wnt signaling induced CDX2 expression might be reduced 
by Wnt antagonists in the medium. In order to quickly assess the success of these interventions the use of 
differentiation marker genes such as HNF4α, ALB, AFP and CDX2 by quantitative PCR would be a 
reasonable first step. Nevertheless, in order to obtain a conclusive view on the state of HLC differentiation 




In conclusion, the comprehensive integrated analysis of transcriptomic and epigenomic data together with 
an in-depth analysis of single cell transcriptomes of selected cells represents a workflow that might be 
applicable to other experimental settings and could provide deeper insights into many biological questions 
beyond the in vitro differentiation of HLCs. In addition, the putative key regulators identified by this analysis 
provide now the means to develop and assess reasonable cell culture interventions that could readily 
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6.1 Supplementary Figures 
 
 
Supplementary Figure 1: Marker transcript expression levels for hepatocytes ad non-parenchymal cell-types in 
experiment V0.1 and V0.2. A – RNA abundance is displayed as log (CPM + 1). B – Kupffer cell and macrophage marker 
CD69 expression levels as CPM by phenotypic group. C – Heatmap of average marker gene expression normalized for 






Supplementary Figure 2: Pearson correlation with corresponding p-values of principle components obtained from PCA 
of zonal expression and DNA methylation data with zonation, phenotype, donor, sex, BMI, Age, and diabetes diagnosis. 
A – V0.1. B – V0.2, including correlations with batch and CpG Coverage to identify possible batch effects between V0.1 
and V0.2. Increasing correlation values are indicated in a white to red to dark red color ramp. Significant p values (< 







Supplementary Figure 3: Differential gene expression in steatosis (Brosch et al., 2018). A – Venn diagram depicting 
the overlap of DEGs between steatotic samples (STEA and EARLY, n = 10) and samples with normal liver histology 
(NC and HO, n = 9) for individual zones (CV, IZ and PV) determined using edgeR with |log2FC| > 1 and FDR < 0.01. B 
– Scatterplot of CV versus PV log2 fold changes of genes significantly deregulated in steatosis in any of the three zones 






Supplementary Figure 4: Pearson correlation with corresponding p-values of group-wise principal components derived 
from PCA of the 1000 most variable transcripts from LCM-RNA-seq data (V0.2) with hepatic zonation (Zone) and donor. 






Supplementary Figure 5: Zone-specific expression levels of all pericentrally (A) and periportally (B) zonated genes 
during fatty liver disease progression from normal controls (NC) to cirrhosis (ACI). Expression levels are displayed as 






Supplementary Figure 6: Differential gene expression during fatty liver disease progression. The annotation legend 
displays controls (NC) in light blue, healthy obese (HO) in dark blue, non-alcoholic steatosis (STEA) in red, early NASH 
(EARLY) in orange, progressed NASH (NASH) in dark red, fibrosis (FIB3) in black and alcoholic cirrhosis (ACI) in grey. 
Pericentral samples are annotated in green, intermediate in grey and periportal in blue. A – Canberra clustering of scaled 
log2 fold changes (logFC) of all DEGs detected in any comparison described in Figure 30 (n = 2941, grey). Red indicates 
downregulation in disease, white corresponds to no expression change compared to HO (|logFC| < 1), and blue to 
upregulation in disease. B – Boxplots of inter-individual variance of expressed genes within groups after filtering of 
unexpressed genes. C – Average zonal expression levels of exemplary DEGs for individual phenotypic groups, which 






Supplementary Figure 7: DNA methylation in progressed fatty liver disease stages. A – Boxplot of absolute standard 
deviation of zone-specific DMRs detected between phenotypes and healthy obese controls (HO) as described in Figure 
31. B – Exemplary genomic annotation of DMRs detected in the pericentral zone between alcoholic cirrhosis and HO 
for hypomethylated and hypermethylated regions. Proportions of genomic annotations of DMRs detected in other 
comparisons (Figure 31) were distributed similarly. C – Pearson correlations between zone-specific methylation 
differences between ACI and HO. D – Methylation level heatmap of the 1000 most variable DMRs between ACI and HO 
in the pericentral zone. E – Methylation level heatmap (left panel) and corresponding z-score illustration (right panel) of 
the 1239 pericentral DMRs between ACI and HO associated with genes that are zonally expressed in healthy liver 
tissue. F – Association between zonation in healthy liver, DEGs and DMRs of the comparisons described in Figures 30 
and 31. DEGs not associated with zonation or DMRs are colored in green, DMR associated DEGs in blue, DEGs zonated 






Supplementary Figure 8: Transcriptional and epigenetic deregulation of the Wnt signaling pathway in pericentral (A) 
and periportal (B) hepatocytes in alcoholic cirrhosis. Fill color illustrates differential DNA methylation between alcoholic 
cirrhosis and healthy obese controls, with red corresponding to hypermethylation and blue to hypomethylation, 
respectively. Accordingly, genes framed in red are transcriptionally downregulated in alcoholic cirrhosis, while blue 






Supplementary Figure 9: Zone-specific NOTCH3 and SOX9 expression levels as average log (CPM + 1) of individual 
phenotypes during progression of fatty liver disease. The annotation legend displays controls (NC) in light blue, healthy 
obese (HO) in dark blue, non-alcoholic steatosis (STEA) in red, early NASH (EARLY) in orange, progressed NASH 




Supplementary Figure 10: Quality metrics of a single cell dataset generated from human hepatocytes using the 10X 
Genomics Chromium platform. A – Number of detected genes, UMI count and percentage of mitochondrial reads for 
8411 cells already pre-filtered for low respective high gene and UMI counts. Purple lines indicate chosen thresholds for 
filtering of low quality cells. B – PCA on HVGs detected in 8181 single cells after initial filtering of low quality cells. The 
dataset was further filtered for PCA outliers, retaining only cells encircled purple. Additionally cells with log2 normalized 
UMI count < 4 for Albumin (yellow in upper panel) and > 4 for CD47 (purple in lower panel) were excluded to obtain only 






Supplementary Figure 11: Diffusion map of a small, deeply sequenced scRNA-seq dataset comprising 3 donors of 
PHH (286 cells, in average 1.8 million reads per cell) based on all HVGs (A and B) or 38 HVGs with zonated expression 
profiles in healthy human liver (C and D). Plots are colored by normalized CYP3A4 expression (pericentral marker, A 






Supplementary Figure 12: Batch effect assessment and correction of the StemNet scRNA-seq dataset including 
external data from Camp et al. (2017). A – kBET rejection rate of the logCPM normalized dataset, and after MNN and 
Combat correction. Corresponding PCA silhouette scores are highlighted in green. Details are described in chapter 
2.2.2.2. B – PCA of the 1000 most variable transcripts of the dataset normalized as log counts per million (logCPM, 
same panel as Figure 47 D more convenient comparison with batch corrected datasets). Cells are colored by sample 
annotation (black – external adult PHH (Camp et al., 2017), external fetal PHH – shades of red, CEL HLCs – shades of 
green, HAY HLCs – orange, PHH – shades of blue). C –Dimensionality reduction plot after MNN correction. D – 
Dimensionality reduction plot after Combat correction.  
 
Supplementary Figure 13: Fetal hepatocyte subgroup (week 10.5) detected by pseudotime analysis (Figure 49) 
expresses markers of fetal liver erythropoiesis. A – Figure 49 A. B – Reduced representation map colored by KLF1 and 





Supplementary Figure 14: Exemplary genome browser view of expression levels of the differentiation marker genes 
ALB, AFP, CDX2, HNF4A and NANOG. The figure displays the CEL differentiation process from iPSCs to DE to HLC 
in 4 replicates. Coverage tracks were normalized for sequencing depth. 
 
 
Supplementary Figure 15: Segmentation of DNA methylation patterns during HLC differentiation. A – PCA of DNA 
methylation levels of the 5,000 most variable CpGs. iPSCs are colored in brown, DE in red, HLCs in olive and PHH in 
blue. The annotation legend displays corresponding symbols for CEL (n = 4), HAY (n = 1) as well as female (n = 3) and 
male PHH (n = 3). B – Percentage of the genome segmented into highly methylated domains (HMDs, red), lowly 
methylated domains (LMDs, grey), partially methylated domains (PMDs, yellow) and unmethylated regions (UMRs, blue) 
in iPSCs, DE, HLCs and PHH. C – Average methylation levels in HMDs, LMRs, PMDs and UMRs. Standard deviations 






Supplementary Figure 16: Expression levels of DNA methyltransferases and Tet Methyl-cytosine Dioxygenases. 
Expression is displayed as average log (CPM + 1). Error bars illustrate standard deviations. iPSCs are colored in brown, 
DE in red, HLCs in olive and PHH in blue. 
 
 
Supplementary Figure 17: Quality assessment of chromatin accessibility analysis by ATAC-seq. A – Principal 
component analysis of ATAC-seq coverage in the 50,000 most variable 100 bp windows, based on log (CPM + 1) counts 
calculated after removal of blacklist regions. iPSCs are colored in brown, DE in red, HLCs in olive and PHH in blue. The 
annotation legend displays corresponding symbols for CEL (n = 4), HAY (n = 1) and PHH (n = 3). B – Boxplot of MACS2 
peak counts per sample group. C – Boxplot of peak length per sample group. D – Length of differentially accessible 






Supplementary Figure 18: Exemplary genome browser representation of accessible chromatin detected by ATAC-seq 
coverage at the marker genes ALB, AFP, CDX2, HNF4a and NANOG that exhibit strong expression differences during 
in vitro HLC differentiation and in comparison of HLCs with PHH. CEL iPSC coverage tracks are colored in brown, CEL 
DE in red, CEL HLCs in olive, PHH in blue and HAY samples in orange. Tracks were normalized by sequencing depth.  
 
 
Supplementary Figure 19: Exemplary genome browser representation of multiple putative regulatory regions with 
differential accessibility within a single gene. ATAC-seq coverage is illustrated in purple, RNA-seq in black. Tracks were 





6.2 Supplementary Tables 
Due to page limitations tables with differentially expressed genes (DEGs), differentially methylated regions 
(DMRs) and differentially accessible regions (DARs) are not included in this thesis. Already published zonal 
DEGs and DMRs (chapter 3.1.1) can be accessed in the supplement of the online version of the publication 
(DOI:10.1038/s41467-018-06611-5). 
 
Supplementary Table 1: LCM RRBS data quality parameters including total read count, mapping rate, average (avg) 
genome coverage, average CpG coverage and number of called CpGs. All libraries featured a bisulfite conversion rate 
of 0.99. 









6963_I 31,237,654 0.90 3.71 4.32 6,750,373 
6976_C 52,370,899 0.89 4.78 6.35 10,484,681 
6976_I 46,628,637 0.86 4.81 6.40 7,725,009 
6976_P 45,382,784 0.88 5.28 6.98 8,200,269 
7185_C 53,035,309 0.85 4.86 6.23 8,183,361 
7185_I 41,534,700 0.89 4.46 5.55 7,895,321 
7196_C 41,878,187 0.87 4.76 5.84 6,114,403 
7196_I 62,237,205 0.92 5.38 6.95 11,479,617 
7196_P 42,534,844 0.91 4.02 4.97 9,702,319 
7203_C 59,458,140 0.90 5.42 7.40 10,633,989 
7203_I 50,701,560 0.90 5.08 6.96 10,210,581 
7203_P 55,597,887 0.88 5.35 7.32 10,512,605 
7259_C 48,430,881 0.86 4.87 6.64 9,004,706 
7259_I 60,341,166 0.88 5.41 7.29 9,484,792 
7263_C 40,343,552 0.85 4.71 6.01 6,807,134 
7263_I 46,800,889 0.85 4.07 5.09 10,018,604 
7263_P 52,841,913 0.89 4.84 6.30 10,714,432 
7286_C 39,269,942 0.85 3.62 4.57 9,596,088 
7299_C 42,691,345 0.86 4.31 5.57 8,133,411 
7299_I 36,432,089 0.86 4.04 4.94 6,863,182 
7299_P 41,053,207 0.84 5.50 7.48 6,241,629 
7319_C 14,411,270 0.85 2.20 2.48 5,300,883 
7319_I 36,065,390 0.86 3.79 4.73 8,889,714 
7319_P 43,218,212 0.87 4.11 5.10 9,916,216 
7322_C 36,871,314 0.91 4.03 5.26 9,580,698 
7322_I 52,590,839 0.85 4.63 5.83 10,545,381 
7322_P 55,128,731 0.88 6.15 7.91 7,813,691 
7373_C 32,165,152 0.86 4.09 4.98 5,800,733 
7373_I 48,867,245 0.88 4.34 5.40 10,426,844 
7373_P 35,426,905 0.86 3.91 5.19 8,311,389 
7415_C 59,192,095 0.88 5.51 7.69 11,104,197 




7425_C 46,543,806 0.83 4.30 5.68 9,532,779 
7425_I 45,527,226 0.87 4.72 6.09 9,623,470 
7425_P 46,701,866 0.93 4.92 6.42 9,996,168 
7468_P 50,169,169 0.91 4.48 5.56 10,406,403 
7479_C 40,702,090 0.82 4.03 5.01 8,646,800 
7479_I 71,540,290 0.91 6.33 8.74 11,135,028 
7479_P 45,411,948 0.90 4.15 5.10 10,453,561 
7484_C 51,679,137 0.87 5.23 7.08 10,446,553 
7484_P 41,204,288 0.82 4.87 7.06 9,033,837 
7490_C 66,161,203 0.73 5.17 6.90 10,137,990 
7490_I 62,015,639 0.83 6.55 10.28 8,337,233 
7490_P 53,625,135 0.91 4.84 6.40 11,085,013 
7519_C 64,626,975 0.87 5.61 7.58 10,879,717 
7519_I 53,084,167 0.93 4.93 6.47 10,723,037 
7519_P 53,162,202 0.87 4.75 6.05 9,047,933 
7580_P 46,340,321 0.81 4.25 5.45 9,333,561 
7522_C 46,315,010 0.89 4.64 6.38 10,063,482 
7522_I 56,646,933 0.90 5.44 7.23 11,216,226 
7522_P 54,107,863 0.83 5.19 7.18 9,816,943 
6610_C 78,873,787 0.95 6.95 11.50 11,072,674 
6758_C 65,118,522 0.97 6.26 8.02 12,988,344 
6922_C 53,535,977 0.96 5.09 6.63 12,407,130 
6967_C 60,589,957 0.97 5.55 7.09 12,672,545 
7012_C 86,281,707 0.95 7.79 11.97 12,132,444 
7041_C 50,432,583 0.97 4.95 6.00 12,115,510 
7137_C 54,099,099 0.96 5.36 7.22 11,545,614 
7157_C 54,893,801 0.97 5.36 6.73 12,378,537 
7172_C 54,508,741 0.97 4.85 5.63 12,414,924 
7173_C 42,424,640 0.96 4.46 5.81 10,988,989 
7181_C 50,658,273 0.96 4.74 6.12 11,775,374 
7188_C 53,048,049 0.96 4.76 5.83 12,343,298 
7194_C 49,942,423 0.96 5.27 6.83 11,719,014 
7213_C 53,473,699 0.97 4.97 5.83 12,506,037 
7230_C 79,439,403 0.96 6.75 8.62 13,540,026 
7252_C 50,772,112 0.97 4.80 6.05 11,646,830 
7279_C 47,178,956 0.97 4.44 5.03 11,888,831 
7344_C 45,618,003 0.97 4.49 5.07 11,327,475 
6610_I 80,974,977 0.97 7.27 10.49 12,776,895 
6758_I 51,114,249 0.95 5.65 8.55 11,292,503 
6922_I 63,000,603 0.96 6.34 9.07 12,131,656 
6967_I 53,426,925 0.96 5.32 7.71 10,831,087 
7012_I 114,390,363 0.94 9.37 15.51 11,592,568 
7041_I 47,927,194 0.97 4.69 5.90 11,531,708 
7137_I 31,550,093 0.97 4.14 5.33 9,712,824 




7172_I 45,150,619 0.97 4.53 5.28 11,646,988 
7173_I 47,267,857 0.97 4.53 5.65 12,191,182 
7181_I 57,127,165 0.97 5.44 6.82 12,235,195 
7188_I 57,094,561 0.95 5.25 7.79 11,277,766 
7213_I 57,242,623 0.97 5.98 8.41 11,440,290 
7230_I 71,647,920 0.96 6.18 7.63 13,588,307 
7251_I 52,293,589 0.97 5.08 6.09 12,070,208 
7252_I 54,044,401 0.97 4.78 5.88 12,330,420 
7279_I 48,115,574 0.97 4.74 5.81 11,457,334 
7344_I 46,550,121 0.97 4.80 5.75 11,559,383 
6610_P 105,023,932 0.97 8.68 12.35 13,915,388 
6758_P 59,318,066 0.96 5.94 8.91 11,217,679 
6922_P 49,744,185 0.97 5.14 6.75 11,969,638 
6967_P 50,403,324 0.96 4.83 6.09 11,995,433 
7012_P 82,860,127 0.95 7.35 10.25 12,713,596 
7041_P 59,789,547 0.97 5.73 7.20 12,513,637 
7137_P 47,437,176 0.96 4.84 6.37 10,950,516 
7157_P 52,059,151 0.97 5.29 6.86 12,243,916 
7173_P 53,230,505 0.96 5.00 6.54 11,542,335 
7181_P 46,074,659 0.97 4.32 5.12 11,773,561 
7188_P 34,069,091 0.95 4.12 5.83 9,378,995 
7194_P 55,465,687 0.93 5.66 9.19 9,439,465 
7213_P 48,550,564 0.96 5.32 7.92 9,570,016 
7230_P 164,377,644 0.94 12.58 19.87 13,078,626 
7251_P 51,879,923 0.97 4.73 5.68 12,265,899 
7252_P 45,474,395 0.97 4.17 4.70 11,839,828 
7279_P 60,866,656 0.97 5.00 5.66 12,876,738 
7344_P 53,437,003 0.97 4.99 6.12 12,818,384 
6963_P 49,323,351 0.94 4.33 5.35 11,000,350 
 
 
Supplementary Table 2: LCM RNA-seq data quality control parameters including total read count, number of uniquely 
mapped reads, duplication rate, ribosomal (rRNA) rate, expression profiling efficiency (ratio of exonic reads of total 
reads), and the numbers of detected transcripts and genes.   
















6610_C 20,372,974 19,405,165 0.048 0.053 0.837 106,543 18,925 
6610_I 8,997,657 8,446,670 0.061 0.081 0.782 85,446 15,651 
6610_P 15,875,136 15,055,647 0.052 0.094 0.794 102,268 18,323 
6758_C 21,209,402 20,118,254 0.051 0.055 0.822 105,342 18,599 
6758_I 13,499,965 12,797,554 0.052 0.048 0.808 90,306 16,589 
6758_P 20,721,728 19,249,572 0.071 0.084 0.741 95,909 18,561 




6922_I 29,287,936 28,248,682 0.035 0.037 0.875 109,388 18,921 
6922_P 17,851,441 16,918,434 0.052 0.074 0.815 96,768 17,422 
6963_C 20,533,767 19,327,156 0.059 0.033 0.855 101,172 18,723 
6963_I 27,688,134 26,335,880 0.049 0.028 0.876 108,232 19,458 
6967_C 15,587,489 14,679,054 0.058 0.042 0.804 95,682 17,647 
6967_I 23,564,707 22,286,815 0.054 0.081 0.788 104,342 18,568 
6967_P 17,585,780 16,564,799 0.058 0.076 0.756 99,397 18,625 
6975_C 24,425,410 23,693,616 0.03 0.021 0.871 117,409 19,777 
6975_I 14,835,718 14,001,266 0.056 0.041 0.782 95,475 17,377 
6975_P 19,797,264 18,843,494 0.048 0.063 0.808 106,872 18,741 
6976_C 22,631,156 21,608,765 0.045 0.024 0.873 112,094 19,687 
6976_I 24,587,418 23,265,796 0.054 0.031 0.854 110,551 19,676 
6976_P 29,224,382 27,562,639 0.057 0.055 0.823 114,823 20,559 
7012_C 28,841,327 27,806,751 0.036 0.036 0.865 112,439 19,475 
7012_I 9,524,841 8,933,248 0.062 0.037 0.779 84,566 15,669 
7012_P 27,484,742 26,059,686 0.052 0.048 0.839 112,551 19,521 
7012_P 24,626,743 23,446,757 0.048 0.027 0.886 106,947 19,185 
7041_C 18,995,240 18,221,008 0.041 0.035 0.855 106,075 18,174 
7041_I 14,834,771 14,094,137 0.05 0.04 0.837 100,221 17,605 
7041_P 24,861,409 23,525,946 0.054 0.058 0.807 104,064 18,732 
7137_C 27,308,516 26,097,660 0.044 0.046 0.869 110,941 18,957 
7137_I 24,932,574 23,976,057 0.038 0.069 0.854 105,911 18,214 
7137_P 12,803,812 12,061,260 0.058 0.035 0.813 93,847 16,735 
7157_C 23,196,447 22,287,414 0.039 0.041 0.876 112,205 19,037 
7157_I 25,372,454 24,405,073 0.038 0.042 0.868 109,482 18,820 
7157_P 12,436,822 11,901,599 0.043 0.068 0.838 96,189 17,043 
7172_C 11,631,332 11,036,908 0.051 0.041 0.831 95,566 17,083 
7172_I 21,421,605 20,461,138 0.045 0.039 0.861 100,969 17,921 
7172_P 26,011,043 24,721,176 0.05 0.038 0.838 106,344 18,608 
7173_C 17,106,733 16,265,526 0.049 0.047 0.823 102,283 17,906 
7173_I 26,712,874 25,285,076 0.053 0.049 0.833 111,054 19,330 
7173_P 22,758,133 21,470,373 0.057 0.068 0.812 106,046 18,856 
7181_C 22,693,806 21,831,524 0.038 0.042 0.856 109,889 18,852 
7181_I 26,132,767 24,975,446 0.044 0.053 0.841 106,978 18,617 
7181_P 17,098,492 16,286,521 0.047 0.049 0.818 102,159 18,044 
7185_C 28,614,025 26,519,642 0.073 0.086 0.777 107,464 19,785 
7185_I 31,973,693 29,850,373 0.066 0.093 0.774 109,408 19,962 
7185_P 35,228,513 32,963,779 0.064 0.105 0.775 111,388 20,252 
7188_C 18,677,971 17,401,819 0.068 0.056 0.766 101,071 18,865 
7188_I 20,401,058 19,016,033 0.068 0.045 0.807 105,444 18,733 
7188_P 22,758,239 21,321,940 0.063 0.061 0.787 108,174 19,319 
7194_C 15,271,797 14,831,959 0.029 0.024 0.901 98,711 16,558 
7194_I 12,400,366 11,863,069 0.043 0.011 0.86 91,276 16,108 
7194_P 17,128,790 16,475,601 0.038 0.033 0.887 99,764 17,099 




7196_I 30,223,755 28,642,811 0.052 0.03 0.874 111,735 19,514 
7196_P 33,338,563 31,362,948 0.059 0.074 0.819 109,004 19,689 
7197_C 23,966,527 23,146,573 0.034 0.036 0.897 112,395 19,137 
7197_I 17,279,503 16,747,163 0.031 0.023 0.903 112,433 18,805 
7197_P 23,849,106 22,873,247 0.041 0.03 0.885 111,843 19,012 
7203_C 25,254,071 24,383,578 0.034 0.029 0.903 112,065 18,979 
7203_I 18,590,241 18,045,090 0.029 0.025 0.921 107,588 18,175 
7203_P 22,958,604 22,141,837 0.036 0.034 0.903 106,952 18,228 
7213_C 19,309,703 18,602,695 0.037 0.027 0.868 104,062 18,276 
7213_I 21,410,104 20,457,136 0.045 0.037 0.832 106,438 19,125 
7213_P 24,525,289 23,615,864 0.037 0.037 0.869 109,233 19,065 
7230_C 17,941,689 17,253,606 0.038 0.022 0.86 103,509 17,843 
7230_I 20,543,200 19,716,310 0.04 0.028 0.87 103,501 18,025 
7230_P 20,598,592 19,785,637 0.039 0.034 0.874 101,850 18,211 
7251_C 23,909,560 22,839,134 0.045 0.041 0.846 112,255 19,116 
7251_I 11,673,679 11,001,378 0.058 0.04 0.815 95,699 16,670 
7251_P 24,678,676 23,424,149 0.051 0.043 0.843 109,620 18,835 
7252_C 24,215,508 23,444,087 0.032 0.025 0.875 114,709 19,237 
7252_I 17,506,347 16,963,448 0.031 0.027 0.877 108,192 18,104 
7252_P 23,468,671 22,807,197 0.028 0.029 0.898 110,737 18,431 
7259_C 26,515,318 25,710,690 0.03 0.027 0.918 112,388 18,703 
7259_I 20,387,796 19,729,099 0.032 0.025 0.918 105,426 17,762 
7259_P 23,976,406 23,261,309 0.03 0.032 0.917 109,973 18,358 
7263_C 24,182,550 23,482,575 0.029 0.025 0.921 104,925 17,627 
7263_I 19,630,794 19,149,193 0.025 0.019 0.932 110,904 18,372 
7263_P 29,395,685 28,508,284 0.03 0.027 0.918 106,439 17,705 
7265_C 28,585,322 27,738,533 0.03 0.033 0.913 118,878 19,851 
7265_I 23,719,174 22,974,159 0.031 0.03 0.919 118,533 19,874 
7265_P 24,590,322 23,799,093 0.032 0.034 0.909 115,785 19,178 
7279_C 23,718,587 22,966,163 0.032 0.022 0.879 120,027 19,997 
7279_I 18,167,341 17,714,739 0.025 0.019 0.882 112,481 18,574 
7279_P 19,405,294 18,762,239 0.033 0.032 0.878 109,473 18,576 
7286_C 39,366,753 37,224,458 0.054 0.038 0.868 113,893 20,364 
7286_I 21,834,569 21,009,220 0.038 0.03 0.884 107,599 18,880 
7286_P 31,605,763 30,299,156 0.041 0.044 0.877 111,701 19,891 
7299_C 26,190,796 24,203,843 0.076 0.034 0.852 109,762 19,455 
7299_I 27,967,935 26,608,751 0.049 0.029 0.864 112,989 20,022 
7299_P 29,517,612 28,178,451 0.045 0.026 0.891 114,323 20,080 
7319_C 30,765,509 28,399,363 0.077 0.054 0.821 108,826 19,980 
7319_I 29,868,677 28,623,584 0.042 0.031 0.886 115,861 20,152 
7319_P 20,784,206 19,588,923 0.058 0.056 0.842 105,166 19,327 
7322_C 34,612,804 32,929,900 0.049 0.028 0.879 114,422 19,869 
7322_I 36,861,112 35,117,865 0.047 0.031 0.879 111,805 19,797 
7322_P 18,659,566 17,549,091 0.06 0.049 0.837 100,050 18,241 




7326_I 19,884,561 19,348,350 0.027 0.026 0.92 110,806 18,675 
7326_P 25,014,359 24,198,610 0.033 0.03 0.905 108,251 18,609 
7344_C 20,031,835 19,208,074 0.041 0.025 0.879 112,469 18,850 
7344_I 21,041,237 20,338,404 0.033 0.03 0.874 115,262 19,208 
7344_P 9,905,518 9,391,313 0.052 0.029 0.844 98,126 16,751 
7373_C 22,062,382 21,124,461 0.043 0.02 0.892 110,052 19,289 
7373_I 23,970,163 23,089,257 0.037 0.021 0.907 108,725 18,813 
7373_P 24,604,473 23,669,820 0.038 0.025 0.906 108,204 18,877 
7383_C 24,943,235 24,149,834 0.032 0.03 0.912 111,010 18,544 
7383_I 19,187,601 18,630,416 0.029 0.028 0.918 111,965 18,747 
7383_P 22,859,272 22,198,371 0.029 0.028 0.92 110,486 18,453 
7415_C 43,520,134 41,396,777 0.049 0.028 0.876 118,655 21,123 
7415_I 37,249,272 35,642,501 0.043 0.021 0.888 116,181 20,393 
7415_P 38,347,162 34,329,132 0.105 0.038 0.81 111,334 20,204 
7425_C 31,577,255 30,138,217 0.046 0.028 0.879 119,588 20,963 
7425_I 27,099,881 25,421,483 0.062 0.037 0.847 111,862 19,972 
7425_P 40,708,236 38,288,682 0.059 0.054 0.835 113,391 20,911 
7468_C 24,305,220 23,101,839 0.05 0.035 0.866 110,613 19,722 
7468_I 20,638,278 19,788,220 0.041 0.028 0.888 109,869 19,058 
7468_P 21,405,864 20,428,346 0.046 0.037 0.886 106,766 18,867 
7479_C 22,262,283 21,637,572 0.028 0.031 0.921 112,100 18,777 
7479_C 25,600,534 24,817,200 0.031 0.037 0.922 115,225 19,519 
7479_I 19,305,954 18,735,219 0.03 0.041 0.918 113,366 18,956 
7479_P 23,767,148 23,087,716 0.029 0.033 0.921 109,505 18,526 
7479_P 19,376,288 18,707,456 0.035 0.034 0.917 107,497 18,314 
7484_C 24,307,239 23,032,112 0.052 0.038 0.874 110,682 19,673 
7484_I 24,067,021 23,020,500 0.043 0.034 0.889 109,163 19,120 
7484_P 21,755,073 20,441,234 0.06 0.055 0.838 104,979 19,069 
7490_C 27,408,005 26,603,200 0.029 0.033 0.917 113,965 19,106 
7490_I 19,181,172 18,674,884 0.026 0.023 0.933 113,733 18,798 
7490_P 26,361,599 25,502,535 0.033 0.032 0.912 113,554 19,107 
7505_C 26,659,140 25,823,080 0.031 0.03 0.909 107,070 18,008 
7505_C 22,003,484 21,230,286 0.035 0.032 0.912 105,152 17,922 
7505_I 17,080,722 16,635,370 0.026 0.023 0.927 104,550 17,474 
7505_P 27,252,275 26,511,917 0.027 0.026 0.921 108,117 18,134 
7505_P 21,645,094 20,951,310 0.032 0.03 0.916 104,387 17,875 
7519_C 30,296,908 28,431,965 0.062 0.03 0.833 110,779 20,191 
7519_I 27,325,559 25,933,976 0.051 0.028 0.863 109,488 19,587 
7519_P 24,931,257 22,781,072 0.086 0.063 0.785 101,215 19,293 
7522_C 11,092,691 10,749,825 0.031 0.037 0.9 96,836 16,855 
7522_I 20,163,430 19,564,184 0.03 0.022 0.917 108,983 18,484 






Supplementary Table 3: In silico analysis of TF binding motives in pericentrally (CV) hypomethylated DMRs using 
HOMER (Brosch et al., 2018). The table includes TFs with enriched binding motives, p-values and the percentage of 




enriched TF P-value target [%] enriched TF P-value target [%] enriched TF P-value target [%]
NF1 1.00E-65 48.82% TCFL2 1.00E-16 1.83% Gata4 1.00E-06 16.77%
HNF4a 1.00E-62 15.04% Olig2 1.00E-15 43.78% HNF6 1.00E-05 8.30%
c-Myc 1.00E-56 14.10% HIF2a 1.00E-15 9.76% Pbx3 1.00E-05 5.29%
SCL 1.00E-54 82.37% RUNX-AML 1.00E-14 17.13% TR4 1.00E-05 3.70%
RXR 1.00E-52 34.09% BMYB 1.00E-14 27.91% ARE 1.00E-05 5.92%
ZFX 1.00E-48 44.20% Tcf4 (TCF7L2) 1.00E-13 9.22% SPDEF 1.00E-05 22.15%
Erra 1.00E-46 61.69% Smad4 1.00E-12 39.66% AP-1 1.00E-05 14.00%
Tcf12 1.00E-46 31.50% RUNX 1.00E-12 16.45% STAT4 1.00E-05 18.21%
MyoG 1.00E-40 32.02% CEBP:AP1 1.00E-11 14.61% Stat3 1.00E-05 11.32%
n-Myc 1.00E-39 20.97% Nur77 1.00E-11 3.62% ETV1 1.00E-05 30.87%
USF1 1.00E-39 13.99% FOXP1 1.00E-11 7.86% CHR 1.00E-05 10.78%
Ap4 1.00E-39 35.20% AP2gamma 1.00E-11 30.72% HRE 1.00E-04 3.61%
Myf5 1.00E-39 20.99% Stat3+il23 1.00E-10 15.56% Smad3 1.00E-04 59.64%
FOXA1 1.00E-36 23.07% MafA 1.00E-10 18.54% Sox3 1.00E-04 29.59%
Foxa2 1.00E-35 14.89% Usf2 1.00E-10 10.48% Elk4 1.00E-04 11.68%
Max 1.00E-34 18.60% NF1:FOXA1 1.00E-10 1.19% Fli1 1.00E-03 24.22%
Esrrb 1.00E-31 18.22% Gata1 1.00E-10 10.15% VDR 1.00E-03 5.95%
MyoD 1.00E-30 23.57% Smad2 1.00E-10 38.66% Atf4 1.00E-03 4.44%
NF1 1.00E-30 15.79% RBPJ:Ebox 1.00E-09 10.26% GRE 1.00E-03 2.82%
Tcf3 1.00E-30 5.48% Bach1 1.00E-09 1.31% E-box 1.00E-03 2.00%
ZNF711 1.00E-29 58.77% Tbx20 1.00E-08 4.81% p53 1.00E-03 0.21%
AR 1.00E-29 72.75% Nanog 1.00E-08 68.70% PAX5 1.00E-03 3.14%
FOXA1 1.00E-28 19.46% GATA-IR4 1.00E-08 1.21% GRE 1.00E-03 4.50%
PPARE 1.00E-27 27.85% E2A 1.00E-08 52.05% ERE 1.00E-02 7.73%
bHLHE40 1.00E-26 4.93% Bach2 1.00E-08 4.41% PU.1 1.00E-02 10.60%
Nr5a2 1.00E-26 20.12% RUNX2 1.00E-07 17.99% Chop 1.00E-02 3.23%
Fox:Ebox 1.00E-25 21.06% CTCF 1.00E-07 3.51% RARg 1.00E-02 1.15%
Nr5a2 1.00E-25 14.94% Bcl6 1.00E-07 27.88% Hoxc9 1.00E-02 7.73%
HIF-1a 1.00E-25 7.69% AP-2alpha 1.00E-07 29.24% GABPA 1.00E-02 19.96%
EBF1 1.00E-23 35.23% PR 1.00E-07 42.42% EBF 1.00E-02 6.99%
NeuroD1 1.00E-23 24.62% Tcfcp2l1 1.00E-07 3.73% Ets1 1.00E-02 6.15%
Tlx 1.00E-22 15.35% Gata2 1.00E-07 11.11% ETS1 1.00E-02 22.55%
ATF3 1.00E-22 5.58% RUNX1 1.00E-07 22.11% NFAT 1.00E-02 15.29%
FXR 1.00E-21 12.92% HEB 1.00E-07 20.42% Tbx5 1.00E-02 73.18%
Atoh1 1.00E-21 31.31% ERG 1.00E-06 35.37% NF-E2 1.00E-02 1.30%
c-Myc 1.00E-20 15.84% Hnf1 1.00E-06 2.14% MafK 1.00E-02 5.86%
Ptf1a 1.00E-18 70.78% Foxo1 1.00E-06 37.94% TEAD4 1.00E-02 18.92%
CEBP 1.00E-17 17.16% Arnt:Ahr 1.00E-06 15.47% p63 1.00E-02 9.41%





Supplementary Table 4: In silico analysis of TF binding motives in periportally (PV) hypomethylated DMRs using 
HOMER (Brosch et al., 2018). The table includes TFs with enriched binding motives, p-values and the percentage of 




enriched TF P-value target [%] enriched TF P-value target [%] enriched TF P-value target [%]
Fli1 1.00E-35 31.82% Sox6 1.00E-08 30.46% Hoxc9 1.00E-04 8.86%
NF1 1.00E-35 17.54% HIF2a 1.00E-08 10.01% RXR 1.00E-04 31.54%
Ap4 1.00E-34 38.87% Nanog 1.00E-08 71.75% USF1 1.00E-04 12.28%
ERG 1.00E-28 42.40% FOXP1 1.00E-08 8.74% c-Myc 1.00E-03 15.03%
MyoD 1.00E-27 26.97% Pdx1 1.00E-08 17.68% EBF 1.00E-03 7.57%
GABPA 1.00E-25 25.67% Sox2 1.00E-08 17.90% NF-E2 1.00E-03 1.51%
Tcf12 1.00E-25 33.48% Nr5a2 1.00E-07 14.96% Cdx2 1.00E-03 12.03%
ETV1 1.00E-25 37.32% HOXA9 1.00E-07 12.43% Tcfcp2l1 1.00E-03 3.83%
SCL 1.00E-24 83.85% ELF1 1.00E-07 14.09% Maz 1.00E-03 37.07%
EWS:FLI1 1.00E-23 17.11% Sox3 1.00E-07 33.33% TEAD4 1.00E-03 20.49%
Myf5 1.00E-23 23.83% AP-1 1.00E-07 15.88% NFAT 1.00E-03 18.00%
EWS:ERG 1.00E-22 19.30% Smad3 1.00E-07 61.28% ATF3 1.00E-03 4.80%
ZFX 1.00E-21 44.46% GATA3 1.00E-07 28.29% Rfx1 1.00E-03 4.87%
MyoG 1.00E-20 34.11% BMYB 1.00E-07 29.73% PR 1.00E-03 44.48%
NF1 1.00E-20 47.35% Gata4 1.00E-07 19.06% HOXD13 1.00E-03 19.13%
ETS1 1.00E-20 28.31% Bach2 1.00E-06 5.00% FXR 1.00E-02 12.26%
Atoh1 1.00E-19 33.96% STAT1 1.00E-06 6.67% GRE 1.00E-02 3.36%
Ets1 1.00E-16 8.88% Max 1.00E-06 17.92% AP-2alpha 1.00E-02 28.23%
SPDEF 1.00E-16 27.06% c-Myc 1.00E-06 12.58% GRE 1.00E-02 5.21%
Elk4 1.00E-16 15.81% Stat3 1.00E-06 12.82% STAT6 1.00E-02 10.95%
Tlx 1.00E-16 15.98% Rbpj1 1.00E-06 37.05% NFkB-p65 1.00E-02 14.56%
Elk1 1.00E-14 15.79% ELF5 1.00E-06 17.87% ETS:E-box 1.00E-02 2.78%
Foxa2 1.00E-14 16.15% Arnt:Ahr 1.00E-06 15.96% CArG 1.00E-02 6.06%
Olig2 1.00E-14 46.29% n-Myc 1.00E-06 19.49% CHR 1.00E-02 11.65%
Fox:Ebox 1.00E-13 21.49% Jun-AP1 1.00E-06 5.80% Erra 1.00E-02 56.69%
FOXA1 1.00E-12 23.85% EBF1 1.00E-06 35.07% STAT6 1.00E-02 10.65%
AR 1.00E-12 74.22% Gata2 1.00E-05 12.58% PU.1 1.00E-02 11.92%
Foxo1 1.00E-12 42.40% Egr2 1.00E-05 5.36% Unknown 1.00E-02 11.63%
FOXA1 1.00E-11 20.15% Hoxb4 1.00E-05 3.89% TATA-Box 1.00E-02 23.59%
ZNF711 1.00E-11 56.60% STAT5 1.00E-05 7.40% RFX 1.00E-02 1.83%
NeuroD1 1.00E-11 25.50% Esrrb 1.00E-05 17.09% X-box 1.00E-02 2.32%
EGR 1.00E-10 6.40% NFkB-p65-Rel 1.00E-04 1.87% Hnf1 1.00E-02 2.15%
STAT4 1.00E-10 21.23% TEAD 1.00E-04 15.52% IRF4 1.00E-02 8.69%
Smad4 1.00E-10 41.49% ETS 1.00E-04 8.50% MafK 1.00E-02 6.18%
Bcl6 1.00E-10 31.78% RBPJ:Ebox 1.00E-04 11.07% PU.1-IRF 1.00E-02 30.10%
MafA 1.00E-09 20.00% ARE 1.00E-04 6.74% HOXA2 1.00E-02 2.02%
Lhx3-like 1.00E-09 18.79% HEB? 1.00E-04 20.09% bHLHE40 1.00E-02 4.46%
Nr5a2 1.00E-09 20.23% Gata1 1.00E-04 11.22% AP2gamma 1.00E-02 28.82%
Smad2 1.00E-09 40.34% NF1:FOXA1 1.00E-04 1.30% HIF-1a 1.00E-02 6.80%





Supplementary Table 5: The table summarized published experimental and in silico data for TF binding preferences 
to methylated or unmethylated DNA with respective references provided as Pubmed IDs and the full citations below the 
table. In addition, an analysis of methylation in HepG2 cells at respective TFBS was performed using DEEP WGBS data 
(01_HepG2_LiHG_Ct1_WGBS_S_1.fullDEEP) tiled into 500 bp windows (coverage > 10) overlapping TF ChIP-seq 
peaks (ENCODE V3). TFs preferentially binding methylated CpGs are printed in red. 
 
 
TF Methylation status preference Assay
Methylation binding 
sites in HepG2 [%]
Reference
ARID3A NA NA 23,01 NA
ATF3 unmethylated DNA  in vitro 10,91 28473536
BHLHE40 unmethylated DNA  in vitro 14,84 28473536
BRCA1 unmethylated DNA  predicted 5,55 29145608
CEBPB methylated CpGs  in vitro 33,38 28473536
CEBPD moderate influence of CpG methylation / only at specific CpG positions  in vitro 11,81 28473536
CHD2 unmethylated DNA  predicted 6,92 29145608
CTCF moderate influence of CpG methylation / only at specific CpG positions  in vivo 31,74 26257180
ELF1 unmethylated DNA  in vitro 13,18 28473536
EP300 NA NA 23,22 NA
ESRRA NA NA 18,04 NA
EZH2 NA NA 21,23 NA
FOSL2 unmethylated DNA  in vitro 25,74 23434322
FOXA1 moderate influence of CpG methylation / only at specific CpG positions  in vitro 29,43 21029866
FOXA2 NA NA 27,69 NA
GABPA unmethylated DNA in vitro 9,00 28473536
GRp20 NA NA 3,71 NA
HDAC2 NA NA 16,77 NA
HNF4A NA NA 22,62 NA
HNF4G unmethylated DNA predicted 22,12 29145608
HSF1 inconclusive in vitro 13,73 28473536
IRF3 inconclusive in vitro 7,01 28473536
JUN unmethylated DNA in vitro 27,53 28473536
JUND unmethylated DNA in vitro 27,26 28473536
MAFF unmethylated DNA in vitro 34,58 28473536
MAFK moderate influence of CpG methylation / only at specific CpG positions predicted 35,16 29145608
MAX unmethylated DNA in vitro 11,17 28473536
MAZ NA NA 9,68 NA
MBD4 moderate influence of CpG methylation / only at specific CpG positions in vitro 19,91 21029866
MXI1 unmethylated DNA predicted 12,86 29145608
MYBL2 unmethylated DNA in vitro 19,26 28473536
MYC unmethylated DNA in vitro 8,99 28473536
NFIC methylated CpGs in vitro 19,80 24015356
NR2C2 NA NA 9,66 NA
NRF1 unmethylated DNA in vitro 5,49 23434322
POLR2A NA NA 29,74 NA
PPARGC1A NA NA 16,97 NA
RAD21 moderate influence of CpG methylation / only at specific CpG positions predicted 28,38 29145608
RCOR1 NA NA 12,07 NA
REST unmethylated DNA predicted 14,05 29145608
RFX5 methylated CpGs in vitro 15,43 23434322
RXRA methylated CpGs in vitro 19,49 24015356
SIN3AK20 NA NA 8,75 NA
SMC3 NA NA 26,08 NA
methylated CpGs in vitro 28473536
unmethylated DNA in vivo 8090226
SP2 methylated CpGs in vitro 17,65 28473536
SREBP1 NA NA 7,35 NA
SRF unmethylated DNA predicted 18,69 29145608
TAF1 unmethylated DNA predicted 6,64 29145608
TBP unmethylated DNA predicted 7,74 29145608
TCF12 unmethylated DNA in vitro 13,73 28473536
TCF7L2 unmethylated DNA predicted 20,04 29145608
TEAD4 NA NA 23,16 NA
USF1 unmethylated DNA in vitro 24,00 28473536
USF2 unmethylated DNA in vitro 18,55 28473536
YY1 unmethylated DNA in vitro 11,77 28473536
methylated CpGs in vitro 28473536
unmethylated DNA in vivo 23693142
ZBTB7A unmethylated DNA in vitro 11,38 28473536
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Supplementary Table 6: Gene ontology enrichment analysis of genes with upregulated expression in pericentral 
hepatocytes. GO terms detected as significantly enriched (p ≤ 0.05) in the gene set associated to pericentrally 









Term Description Gene count PValue Fold Enrichment
GO:0006805 xenobiotic metabolic process 9 5.6E-06 9.23
GO:0055114 oxidation-reduction process 22 1.6E-05 2.97
GO:0046483 heterocycle metabolic process 4 3.7E-05 53.31
GO:0016098 monoterpenoid metabolic process 4 3.7E-05 53.31
GO:0017144 drug metabolic process 5 3.3E-04 14.81
GO:0016055 Wnt signaling pathway 10 5.7E-04 4.28
GO:0019373 epoxygenase P450 pathway 4 1.4E-03 17.77
GO:0006706 steroid catabolic process 3 1.5E-03 47.98
GO:0097267 omega-hydroxylase P450 pathway 3 5.2E-03 26.65
GO:0006954 inflammatory response 12 8.0E-03 2.53
GO:0030282 bone mineralization 4 8.6E-03 9.41
GO:0042738 exogenous drug catabolic process 3 9.4E-03 19.99
GO:0089711 L-glutamate transmembrane transport 3 1.1E-02 18.45
GO:0071300 cellular response to retinoic acid 5 1.1E-02 5.71
GO:0042573 retinoic acid metabolic process 3 1.3E-02 17.13
GO:0008202 steroid metabolic process 4 1.6E-02 7.44
GO:0090263 positive regulation of canonical Wnt signaling pathway 6 1.7E-02 4.00
GO:0032332 positive regulation of chondrocyte differentiation 3 2.3E-02 12.63
GO:0051968 positive regulation of synaptic transmission. glutamatergic 3 2.3E-02 12.63
GO:0050776 regulation of immune response 7 2.4E-02 3.14
GO:0021761 limbic system development 2 2.5E-02 79.96
GO:0038018 Wnt receptor catabolic process 2 2.5E-02 79.96
GO:0019226 transmission of nerve impulse 3 2.5E-02 11.99
GO:0030178 negative regulation of Wnt signaling pathway 4 2.7E-02 6.15
GO:0007155 cell adhesion 12 2.9E-02 2.09
GO:0045163 clustering of voltage-gated potassium channels 2 3.7E-02 53.31
GO:0060349 bone morphogenesis 3 4.4E-02 8.88
GO:0014047 glutamate secretion 3 4.7E-02 8.57
GO:0043276 anoikis 2 4.9E-02 39.98
GO:0034653 retinoic acid catabolic process 2 4.9E-02 39.98
GO:0006778 porphyrin-containing compound metabolic process 2 4.9E-02 39.98
GO:0038026 reelin-mediated signaling pathway 2 4.9E-02 39.98
GO:0021800 cerebral cortex tangential migration 2 4.9E-02 39.98




Supplementary Table 7: Gene ontology enrichment analysis of genes with upregulated expression in periportal 
hepatocytes. GO terms detected as significantly enriched (p ≤ 0.05) in the gene set associated to periportally 
hypomethylated DMRs are printed in red. 
 
Term Description Gene count PValue Fold Enrichment
GO:0001525 angiogenesis 19 1.4E-06 4.01
GO:0007155 cell adhesion 27 5.7E-06 2.77
GO:0030198 extracellular matrix organization 16 2.0E-05 3.84
GO:0019370 leukotriene biosynthetic process 6 5.0E-05 14.11
GO:0007219 Notch signaling pathway 11 1.7E-04 4.50
GO:0070374 positive regulation of ERK1 and ERK2 cascade 13 3.6E-04 3.49
GO:0006939 smooth muscle contraction 5 4.8E-04 13.07
GO:0006749 glutathione metabolic process 7 1.2E-03 5.88
GO:0051216 cartilage development 7 1.5E-03 5.58
GO:0009612 response to mechanical stimulus 7 1.5E-03 5.58
GO:0042127 regulation of cell proliferation 12 2.0E-03 3.05
GO:0030818 negative regulation of cAMP biosynthetic process 4 2.3E-03 14.47
GO:0030217 T cell differentiation 5 3.5E-03 7.84
GO:0070098 chemokine-mediated signaling pathway 7 3.9E-03 4.64
GO:0010628 positive regulation of gene expression 14 4.1E-03 2.51
GO:0003203 endocardial cushion morphogenesis 4 4.3E-03 11.76
GO:0006750 glutathione biosynthetic process 4 4.3E-03 11.76
GO:0007220 Notch receptor processing 4 4.3E-03 11.76
GO:0010634 positive regulation of epithelial cell migration 5 5.0E-03 7.13
GO:0048146 positive regulation of fibroblast proliferation 6 5.6E-03 5.23
GO:0001503 ossification 7 7.0E-03 4.12
GO:0023019 signal transduction involved in regulation of gene expression 4 7.1E-03 9.90
GO:0019229 regulation of vasoconstriction 4 8.2E-03 9.41
GO:0001942 hair follicle development 5 8.3E-03 6.19
GO:0001657 ureteric bud development 5 8.3E-03 6.19
GO:0007399 nervous system development 14 8.5E-03 2.29
GO:0007626 locomotory behavior 7 8.8E-03 3.92
GO:0030199 collagen fibril organization 5 9.1E-03 6.03
GO:0006520 cellular amino acid metabolic process 5 1.0E-02 5.88
GO:0090023 positive regulation of neutrophil chemotaxis 4 1.1E-02 8.55
GO:0030574 collagen catabolic process 6 1.1E-02 4.41
GO:0001504 neurotransmitter uptake 3 1.2E-02 17.64
GO:0010976 positive regulation of neuron projection development 7 1.2E-02 3.70
GO:0030155 regulation of cell adhesion 5 1.3E-02 5.47
GO:0007165 signal transduction 37 1.4E-02 1.50
GO:0061314 Notch signaling involved in heart development 3 1.5E-02 15.68
GO:0031638 zymogen activation 3 1.5E-02 15.68
GO:0006954 inflammatory response 16 1.5E-02 1.99
GO:0030900 forebrain development 5 1.6E-02 5.11
GO:0007507 heart development 10 1.6E-02 2.57
GO:0071300 cellular response to retinoic acid 6 1.6E-02 4.03
GO:0030335 positive regulation of cell migration 10 1.7E-02 2.56
GO:0006260 DNA replication 9 1.8E-02 2.73
GO:0060174 limb bud formation 3 1.8E-02 14.11
GO:0003184 pulmonary valve morphogenesis 3 1.8E-02 14.11
GO:0001771 immunological synapse formation 3 1.8E-02 14.11
GO:0060411 cardiac septum morphogenesis 3 1.8E-02 14.11
GO:0006268 DNA unwinding involved in DNA replication 3 1.8E-02 14.11
GO:0008347 glial cell migration 3 1.8E-02 14.11
GO:0048863 stem cell differentiation 4 1.9E-02 6.97
GO:0001569 patterning of blood vessels 4 2.1E-02 6.72
GO:0048247 lymphocyte chemotaxis 4 2.1E-02 6. 2
GO:0007204 positive regulation of cytosolic calcium ion concentration 8 2.4E-02 2.81
GO:0006936 muscle contraction 7 2.6E-02 3.08
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity 4 2.7E-02 6.07
GO:0001558 regulation of cell growth 6 2.7E-02 3.53
GO:0006814 sodium ion transport 6 2.9E-02 3.48
GO:0071356 cellular response to tumor necrosis factor 7 3.0E-02 2.99
GO:0001974 blood vessel remodeling 4 3.0E-02 5.88
GO:0003215 cardiac right ventricle morphogenesis 3 3.0E-02 10.85
GO:0033630 positive regulation of cell adhesion mediated by integrin 3 3.0E-02 10.85
GO:1900025 negative regulation of cell spreading 3 3.0E-02 10.85
GO:0031274 positive regulation of pseudopodium assembly 3 3.0E-02 10.85
GO:0051926 negative regulation of calcium ion transport 3 3.0E-02 10.85
GO:0001666 response to hypoxia 9 3.0E-02 2.46
GO:0045747 positive regulation of Notch signaling pathway 4 3.2E-02 5.70
GO:2000147 positive regulation of cell motility 3 3.4E-02 10.08
GO:0001837 epithelial to mesenchymal transition 4 3.5E-02 5.53
GO:0030097 hemopoiesis 5 3.6E-02 3.99
GO:0017158 regulation of calcium ion-dependent exocytosis 4 3.8E-02 5.38
GO:0048661 positive regulation of smooth muscle cell proliferation 5 3.8E-02 3.92
GO:0050679 positive regulation of epithelial cell proliferation 5 3.8E-02 3.92
GO:0035050 embryonic heart tube development 3 3.9E-02 9.41
GO:0048469 cell maturation 4 4.0E-02 5.23
GO:0008284 positive regulation of cell proliferation 17 4.1E-02 1.72
GO:0070378 positive regulation of ERK5 cascade 2 4.2E-02 47.04
GO:0048866 stem cell fate specification 2 4.2E-02 47.04
GO:0035759 mesangial cell-matrix adhesion 2 4.2E-02 47.04
GO:0051965 positive regulation of synapse assembly 5 4.2E-02 3.79
GO:0006940 regulation of smooth muscle contraction 3 4.4E-02 8.82
GO:0001568 blood vessel development 4 4.6E-02 4.95
GO:1902476 chloride transmembrane transport 6 4.8E-02 3.03
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling 5 4.9E-02 3.62
GO:0006953 acute-phase response 4 4.9E-02 4.82
GO:0048791 calcium ion-regulated exocytosis of neurotransmitter 4 4.9E-02 4.82
GO:0048265 response to pain 3 4.9E-02 8.30







Supplementary Table 8: Zone-specific gene ontology enrichment of DEGs in alcoholic cirrhosis (ACI) compared to 
healthy obese donors (HO). Positive z-scores (grey) for significantly enriched (p ≤ 0.05) GO terms represent upregulation 
in cirrhosis, while negative z-scores (blue) relate to downregulation. The table displays z-scores with corresponding 
log10 p-values for the top 100 GO terms enriched in the pericentral (C), intermediate (I) or periportal (P) zone. Z-scores 
for GO terms also enriched in the corresponding zonal comparisons of NASH or FIB3 with HO are printed in bold. 
 
Term Description Gene count PValue Fold Enrichment
GO:0001525 angiogenesis 19 1.4E-06 4.01
GO:0007155 cell adhesion 27 5.7E-06 2.77
GO:0030198 extracellular matrix organization 16 2.0E-05 3.84
GO:0019370 leukotriene biosynthetic process 6 5.0E-05 14.11
GO:0007219 Notch signaling pathway 11 1.7E-04 4.50
GO:0070374 positive regulation of ERK1 and ERK2 cascade 13 3.6E-04 3.49
GO:0006939 smooth muscle contraction 5 4.8E-04 13.07
GO:0006749 glutathione metabolic process 7 1.2E-03 5.88
GO:0051216 cartilage development 7 1.5E-03 5.58
GO:0009612 response to mechanical stimulus 7 1.5E-03 5.58
GO:0042127 regulation of cell proliferation 12 2.0E-03 3.05
GO:0030818 negative regulation of cAMP biosynthetic process 4 2.3E-03 14.47
GO:0030217 T cell differentiation 5 3.5E-03 7.84
GO:0070098 chemokine-mediated signaling pathway 7 3.9E-03 4.64
GO:0010628 positive regulation of gene expression 14 4.1E-03 2.51
GO:0003203 endocardial cushion morphogenesis 4 4.3E-03 11.76
GO:0006750 glutathione biosynthetic process 4 4.3E-03 11.76
GO:0007220 Notch receptor processing 4 4.3E-03 11.76
GO:0010634 positive regulation of epithelial cell migration 5 5.0E-03 7.13
GO:0048146 positive regulation of fibroblast proliferation 6 5.6E-03 5.23
GO:0001503 ossification 7 7.0E-03 4.12
GO:0023019 signal transduction involved in regulation of gene expression 4 7.1E-03 9.90
GO:0019229 regulation of vasoconstriction 4 8.2E-03 9.41
GO:0001942 hair follicle development 5 8.3E-03 6.19
GO:0001657 ureteric bud development 5 8.3E-03 6.19
GO:0007399 nervous system development 14 8.5E-03 2.29
GO:0007626 locomotory behavior 7 8.8E-03 3.92
GO:0030199 collagen fibril organization 5 9.1E-03 6.03
GO:0006520 cellular amino acid metabolic process 5 1.0E-02 5.88
GO:0090023 positive regulation of neutrophil chemotaxis 4 1.1E-02 8.55
GO:0030574 collagen catabolic process 6 1.1E-02 4.41
GO:0001504 neurotransmitter uptake 3 1.2E-02 17.64
GO:0010976 positive regulation of neuron projection development 7 1.2E-02 3.70
GO:0030155 regulation of cell adhesion 5 1.3E-02 5.47
GO:0007165 signal transduction 37 1.4E-02 1.50
GO:0061314 Notch signaling involved in heart development 3 1.5E-02 15.68
GO:0031638 zymogen activation 3 1.5E-02 15.68
GO:0006954 inflammatory response 16 1.5E-02 1.99
GO:0030900 forebrain development 5 1.6E-02 5.11
GO:0007507 heart development 10 1.6E-02 2.57
GO:0071300 cellular response to retinoic acid 6 1.6E-02 4.03
GO:0030335 positive regulation of cell migration 10 1.7E-02 2.56
GO:0006260 DNA replication 9 1.8E-02 2.73
GO:0060174 limb bud formation 3 1.8E-02 14.11
GO:0003184 pulmonary valve morphogenesis 3 1.8E-02 14.11
GO:0001771 immunological synapse formation 3 1.8E-02 14.11
GO:0060411 cardiac septum morphogenesis 3 1.8E-02 14.11
GO:0006268 DNA unwinding involved in DNA replication 3 1.8E-02 14.11
GO:0008347 glial cell migration 3 1.8E-02 14.11
GO:0048863 stem cell differentiation 4 1.9E-02 6.97
GO:0001569 patterning of blood vessels 4 2.1E-02 6.72
GO:0048247 lymphocyte chemotaxis 4 2.1E-02 6.72
GO:0007204 positive regulation of cytosolic calcium ion concentration 8 2.4E-02 2.81
GO:0006936 muscle contraction 7 2.6E-02 3.08
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity 4 2.7E-02 6.07
GO:0001558 regulation of cell growth 6 2.7E-02 3.53
GO:0006814 sodium ion transport 6 2.9E-02 3.48
GO:0071356 cellular response to tumor necrosis factor 7 3.0E-02 2.99
GO:0001974 blood vessel remodeling 4 3.0E-02 5.88
GO:0003215 cardiac right ventricle morphogenesis 3 3.0E-02 10.85
GO:0033630 positive regulation of cell adhesion mediated by integrin 3 3.0E-02 10.85
GO:1900025 negative regulation of cell spreading 3 3.0E-02 10.85
GO:0031274 positive regulation of pseudopodium assembly 3 3.0E-02 10.85
GO:0051926 negative regulation of calcium ion transport 3 3.0E-02 10.85
GO:0001666 response to hypoxia 9 3.0E-02 2.46
GO:0045747 positive regulation of Notch signaling pathway 4 3.2E-02 5.70
GO:2000147 positive regulation of cell motility 3 3.4E-02 10.08
GO:0001837 epithelial to mesenchymal transition 4 3.5E-02 5.53
GO:0030097 hemopoiesis 5 3.6E-02 3.99
GO:0017158 regulation of calcium ion-dependent exocytosis 4 3.8E-02 5.38
GO:0048661 positive regulation of smooth muscle cell proliferation 5 3.8E-02 3.92
GO:0050679 positive regulation of epithelial cell proliferation 5 3.8E-02 3.92
GO:0035050 embryonic heart tube development 3 3.9E-02 9.41
GO:0048469 cell maturation 4 4.0E-02 5.23
GO:0008284 positive regulation of cell proliferation 17 4.1E-02 1.72
GO:0070378 positive regulation of ERK5 cascade 2 4.2E-02 47.04
GO:0048866 stem cell fate specification 2 4.2E-02 47.04
GO:0035759 mesangial cell-matrix adhesion 2 4.2E-02 47.04
GO:0051965 positive regulation of synapse assembly 5 4.2E-02 3.79
GO:0006940 regulation of smooth muscle contraction 3 4.4E-02 8.82
GO:0001568 blood vessel development 4 4.6E-02 4.95
GO:1902476 chloride transmembrane transport 6 4.8E-02 3.03
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling 5 4.9E-02 3.62
GO:0006953 acute-phase response 4 4.9E-02 4.82
GO:0048791 calcium ion-regulated exocytosis of neurotransmitter 4 4.9E-02 4.82
GO:0048265 response to pain 3 4.9E-02 8.30













GO:0043401 steroid hormone mediated signaling pathway 4.24 -3.36 3.45 -2.50 3.41 -2.89
GO:0030522 intracellular receptor signaling pathway 3.45 -3.32 1.39 -1.89 1.67 -2.65
GO:0045893 positive regulation of transcription, DNA-templated 4.16 -3.00 1.49 -2.48 3.57 -3.22
GO:0060070 canonical Wnt signaling pathway 1.36 -2.89 1.62 -2.31 0.00 0.00
GO:0008152 metabolic process 5.64 -2.83 4.64 -2.27 3.94 -1.22





GO:0006631 fatty acid metabolic process 2.34 -2.71 5.22 -2.84 2.55 -2.53
GO:0006805 xenobiotic metabolic process 5.49 -2.68 5.47 -1.61 4.43 -0.50
GO:0046487 glyoxylate metabolic process 1.39 -2.45 0.00 0.00 0.00 0.00
GO:0006699 bile acid biosynthetic process 1.77 -2.45 1.31 -2.24 0.00 0.00
GO:0006069 ethanol oxidation 2.93 -2.45 4.21 -2.65 2.41 -1.34
GO:0042632 cholesterol homeostasis 2.14 -2.31 2.97 -3.05 0.00 0.00
GO:0009083 branched-chain amino acid catabolic process 1.31 -2.24 0.00 0.00 0.00 0.00
GO:0043691 reverse cholesterol transport 1.39 -2.24 0.00 0.00 0.00 0.00
GO:0030193 regulation of blood coagulation 1.47 -2.24 1.61 -1.34 2.64 -2.45
GO:0006810 transport 2.15 -2.21 1.51 -2.74 1.48 -2.92
GO:0006629 lipid metabolic process 2.18 -2.13 1.43 -0.94 1.68 0.24
GO:0017144 drug metabolic process 2.52 -2.12 0.00 0.00 0.00 0.00
GO:0006633 fatty acid biosynthetic process 2.34 -2.11 2.65 -1.51 1.52 -1.41
GO:0055114 oxidation-reduction process 11.40 -2.06 10.99 -2.47 9.07 0.00
GO:0006706 steroid catabolic process 2.43 -2.00 0.00 0.00 0.00 0.00
GO:0042135 neurotransmitter catabolic process 1.76 -2.00 1.87 -2.00 0.00 0.00
GO:0070327 thyroid hormone transport 1.61 -2.00 1.72 -2.00 1.90 -1.00
GO:0055085 transmembrane transport 2.32 -1.98 0.00 0.00 0.00 0.00
GO:0005978 glycogen biosynthetic process 4.16 -1.90 4.50 -2.53 1.80 -2.45
GO:0008209 androgen metabolic process 3.15 -1.89 2.49 -1.63 1.93 -1.34
GO:0006210 thymine catabolic process 1.80 -1.73 1.88 -1.73 0.00 0.00
GO:0032922 circadian regulation of gene expression 2.53 -1.73 0.00 0.00 2.27 -1.90
GO:0010906 regulation of glucose metabolic process 1.68 -1.63 0.00 0.00 1.44 -1.34
GO:0015695 organic cation transport 2.44 -1.63 0.00 0.00 2.91 -1.63
GO:0009636 response to toxic substance 2.00 -1.60 0.00 0.00 1.59 -0.90
GO:0008285 negative regulation of cell proliferation 1.34 -1.26 0.00 0.00 1.82 -2.54
GO:0006071 glycerol metabolic process 1.36 -1.00 2.33 -1.34 0.00 0.00
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules1.51 -1.00 1.74 -1.67 0.00 0.00
GO:0051443 positive regulation of ubiquitin-protein transferase activity 1.68 -0.82 2.56 -0.38 1.44 -1.34
GO:0070328 triglyceride homeostasis 1.39 -0.82 1.55 -1.63 1.80 -0.82
GO:1901215 negative regulation of neuron death 1.57 -0.71 1.78 -1.41 0.00 0.00
GO:0001678 cellular glucose homeostasis 1.77 -0.45 0.00 0.00 1.35 -2.00
GO:0036498 IRE1-mediated unfolded protein response 0.00 0.00 1.35 3.00 1.69 3.00
GO:0098609 cell-cell adhesion 0.00 0.00 1.55 3.78 1.35 2.04
GO:0000302 response to reactive oxygen species 0.00 0.00 1.34 2.65 1.62 2.65
GO:0051603 proteolysis involved in cellular protein catabolic process 0.00 0.00 1.38 1.41 2.80 3.16
GO:0090263 positive regulation of canonical Wnt signaling pathway 0.00 0.00 1.81 1.50 2.80 2.67
GO:0002223 stimulatory C-type lectin receptor signaling pathway 0.00 0.00 0.00 0.00 2.51 3.87
GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent0.00 0.00 0.00 0.00 4.25 3.74
GO:0031145 anaphase-promoting complex-dependent catabolic process 0.00 0.00 0.00 0.00 2.71 3.61
GO:0038061 NIK/NF-kappaB signaling 0.00 0.00 0.00 0.00 3.42 3.61
GO:0006521 regulation of cellular amino acid metabolic process 0.00 0.00 0.00 0.00 3.86 3.46
GO:0051437 positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition0.00 0.00 0.00 0.00 2.36 3.46
GO:0051436 negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle0.00 0.00 0.00 0.00 2.59 3.46
GO:0000209 protein polyubiquitination 0.00 0.00 0.00 0.00 2.27 3.27
GO:0050852 T cell receptor signaling pathway 0.00 0.00 0.00 0.00 2.62 2.98
GO:0038095 Fc-epsilon receptor signaling pathway 0.00 0.00 0.00 0.00 2.44 2.84
GO:0043488 regulation of mRNA stability 0.00 0.00 0.00 0.00 2.17 2.67
GO:0060071 Wnt signaling pathway, planar cell polarity pathway 0.00 0.00 0.00 0.00 4.13 2.67







GO:0051092 positive regulation of NF-kappaB transcription factor activity 0.00 0.00 1.45 2.50 0.00 0.00
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process 0.00 0.00 0.00 0.00 1.82 2.40
GO:0000165 MAPK cascade 0.00 0.00 0.00 0.00 1.98 2.35
GO:0032930 positive regulation of superoxide anion generation 0.00 0.00 1.72 2.00 0.00 0.00
GO:0030970 retrograde protein transport, ER to cytosol 0.00 0.00 0.00 0.00 1.35 2.00
GO:0060337 type I interferon signaling pathway 0.00 0.00 0.00 0.00 1.94 1.90
GO:0007017 microtubule-based process 0.00 0.00 1.49 1.89 0.00 0.00
GO:0006099 tricarboxylic acid cycle 0.00 0.00 0.00 0.00 2.24 1.89
GO:0006487 protein N-linked glycosylation 0.00 0.00 0.00 0.00 1.62 1.89
GO:0060736 prostate gland growth 0.00 0.00 1.87 -2.00 0.00 0.00
GO:0090009 primitive streak formation 0.00 0.00 1.59 -2.00 0.00 0.00
GO:0046889 positive regulation of lipid biosynthetic process 0.00 0.00 1.37 -2.00 0.00 0.00
GO:0046628 positive regulation of insulin receptor signaling pathway 0.00 0.00 0.00 0.00 1.44 -2.00
GO:0006367 transcription initiation from RNA polymerase II promoter 0.00 0.00 0.00 0.00 1.50 -2.00
GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase 0.00 0.00 1.53 -2.24 0.00 0.00
GO:0005978 glycogen biosynthetic process 0.00 0.00 0.00 0.00 1.80 -2.45
GO:0001889 liver development 0.00 0.00 1.97 -1.73 2.96 -0.83
GO:0005977 glycogen metabolic process 0.00 0.00 1.93 -2.65 0.00 0.00
GO:0031016 pancreas development 0.00 0.00 1.31 -1.34 1.51 -1.34
GO:0007623 circadian rhythm 0.00 0.00 1.54 -1.51 1.53 -1.26
GO:0040018 positive regulation of multicellular organism growth 0.00 0.00 1.55 -1.13 1.84 -1.89
GO:0050821 protein stabilization 1.90 0.23 4.40 1.22 3.04 0.69
GO:0034614 cellular response to reactive oxygen species 2.57 0.38 1.37 1.34 1.58 0.45
GO:0008286 insulin receptor signaling pathway 1.53 0.58 1.81 1.15 1.43 0.63
GO:0050918 positive chemotaxis 1.87 0.71 1.55 0.38 1.84 1.89
GO:0006103 2-oxoglutarate metabolic process 2.06 0.82 1.53 0.45 1.74 1.34
GO:0098869 cellular oxidant detoxification 2.27 0.83 0.00 0.00 2.64 1.73
GO:2000379 positive regulation of reactive oxygen species metabolic process 1.67 1.13 1.31 1.63 0.00 0.00
GO:0071222 cellular response to lipopolysaccharide 1.38 1.29 1.38 1.60 0.00 0.00
GO:0043066 negative regulation of apoptotic process 3.57 1.34 1.60 1.68 0.00 0.00
GO:2001238 positive regulation of extrinsic apoptotic signaling pathway 2.63 1.41 2.17 1.13 0.00 0.00
GO:0002576 platelet degranulation 1.68 1.50 1.67 0.53 1.43 1.94
GO:0071260 cellular response to mechanical stimulus 1.43 1.51 1.31 1.26 0.00 0.00
GO:0006102 isocitrate metabolic process 1.32 1.73 1.40 1.73 1.52 1.73
GO:0019673 GDP-mannose metabolic process 1.52 1.73 1.60 1.73 0.00 0.00
GO:0033591 response to L-ascorbic acid 1.32 1.73 1.40 1.73 0.00 0.00
GO:0006935 chemotaxis 1.42 2.00 0.00 0.00 0.00 0.00
GO:0006163 purine nucleotide metabolic process 1.47 2.00 0.00 0.00 0.00 0.00
GO:0006954 inflammatory response 1.78 2.16 0.00 0.00 0.00 0.00
GO:0030198 extracellular matrix organization 1.44 2.29 0.00 0.00 0.00 0.00
GO:0006953 acute-phase response 3.35 2.31 3.02 1.26 1.62 2.12
GO:0070527 platelet aggregation 2.01 2.33 0.00 0.00 0.00 0.00
GO:0010951 negative regulation of endopeptidase activity 1.44 2.67 2.13 1.21 0.00 0.00




Supplementary Table 9: Spectrophotometric quality control of DNA and RNA extracted from iPSC, DE and HLC 









CEL R1 DE 153 1.89 199 1.94 
CEL R1 HLC 138 1.90 219 1.98 
CEL R1 iPSC 62 1.94 233 1.92 
CEL R2 DE 127 1.98 311 1.99 
CEL R2 HLC 108 1.89 198 1.99 
CEL R2 iPSC 120 1.90 348 1.99 
CEL R3 DE 69 1.93 260 1.93 
CEL R3 HLC 122 1.89 237 1.96 
CEL R3 iPSC 88 1.94 388 2.01 
CEL R4 DE 111 1.91 344 1.97 
CEL R4 HLC 72 1.96 259 1.98 
CEL R4 iPSC 131 1.90 398 1.99 
HAY R1 DE 75 1.96 173 1.95 
HAY R1 HLC 100 1.94 237 1.96 
HAY R1 iPSC 116 1.90 349 1.99 
 
Supplementary Table 10: StemNet RNA-seq data quality control parameters including total read count, number of 
uniquely mapped reads, duplication rate, ribosomal (rRNA) rate, expression profiling efficiency (ratio of exonic reads of 
total reads), and the numbers of detected transcripts and genes. 
















CEL_DE_R1 66,635,306 65,104,822 0.023 0.111 0.605 141,251 29,845 
CEL_HLC_R1 68,603,284 67,363,592 0.018 0.094 0.742 138,926 27,655 
CEL_iPSC_R1 28,015,364 26,942,622 0.038 0.080 0.502 134,295 28,102 
CEL_DE_R2 37,601,502 36,568,469 0.027 0.087 0.563 133,645 26,886 
CEL_HLC_R2 53,916,362 52,925,958 0.018 0.072 0.740 135,544 26,568 
CEL_iPSC_R2 23,930,588 23,239,334 0.029 0.114 0.620 126,785 23,147 
CEL_DE_R3 40,466,027 39,524,554 0.023 0.092 0.640 129,342 25,064 
CEL_HLC_R3 47,798,580 46,803,429 0.021 0.090 0.697 135,755 26,876 
CEL_iPSC_R3 70,461,192 68,777,602 0.024 0.105 0.658 144,244 29,552 
CEL_DE_R4 29,206,262 28,315,835 0.030 0.062 0.522 129,230 26,360 
CEL_HLC_R4 64,299,419 63,180,075 0.017 0.114 0.764 132,874 24,519 
CEL_iPSC_R4 44,840,143 43,691,370 0.026 0.122 0.626 137,336 26,541 
HAY_DE_R1 21,946,193 21,162,853 0.036 0.054 0.459 128,546 26,276 
HAY_HLC_R1 34,390,444 32,921,281 0.043 0.029 0.351 146,440 32,942 





Supplementary Table 11: StemNet RRBS data quality parameters including total read count, mapping rate, bisulfite 
conversion rate, average (avg) genome coverage, average CpG coverage and number of called CpGs. 












CEL_DE_R1 43,557,490 0.94 0.99 7.58 10.22 6,566,662 
CEL_HLC_R1 53,836,678 0.97 0.99 9.52 14.68 7,699,159 
CEL_iPSC_R1 48,966,686 0.97 0.98 8.99 13.68 7,315,052 
CEL_DE_R2 59,,447,079 0.96 0.99 9.63 14.3 7,457,099 
CEL_HLC_R2 47,986,185 0.94 0.98 7.44 9.7 7,501,635 
CEL_iPSC_R2 72,185,776 0.94 0.97 9.25 12.93 7,948,112 
CEL_DE_R3 59,588,906 0.94 0.99 9.45 14.39 7,331,907 
CEL_HLC_R3 52,633,477 0.97 0.98 9.44 13.77 7,600,784 
CEL_iPSC_R3 50,878,758 0.97 0.97 8.92 13.2 7,476,408 
CEL_DE_R4 44,957,261 0.92 0.98 7.21 10.06 6,642,690 
CEL_HLC_R4 36,710,571 0.97 0.99 6.05 8.13 7,288,060 
CEL_iPSC_R4 38,108,376 0.9 0.97 6.25 7.89 5,936,358 
HAY_DE_R1 28,173,493 0.9 0.99 4.8 5.7 5,460,617 
HAY_HLC_R1 41,799,606 0.95 0.99 8.01 11.58 6,607,657 
HAY_iPSC_R1 52,655,392 0.94 0.98 8.71 12.81 7,150,398 
 
Supplementary Table 12: StemNet ATAC-seq data quality parameters including total read count, uniquely mapped 
reads, duplication rate, the ratio of mitochondrial (mt) reads, MACS2 peak count and fraction of reads located in peaks 
(FriP). Critical values are printed in bold. 













CEL_DE_R1 62,211,956 28,314,190 0.545 0.376 116,564 0.251 
CEL_DE_R2 49,604,414 21,706,009 0.562 0.403 95,624 0.224 
CEL_DE_R3 71,404,549 31,432,607 0.560 0.382 123,399 0.248 
CEL_DE_R4 47,113,792 19,818,272 0.579 0.420 86,897 0.197 
CEL_HLC_R1 43,803,980 15,157,323 0.654 0.349 7,334 0.016 
CEL_HLC_R2 42,952,657 28,202,218 0.343 0.181 78,007 0.108 
CEL_HLC_R3 23,724,295 13,888,911 0.415 0.159 32,561 0.064 
CEL_HLC_R4 41,383,867 27,992,852 0.324 0.180 103,601 0.165 
CEL_iPSC_R1 39,558,795 12,284,214 0.689 0.513 55,762 0.135 
CEL_iPSC_R2 52,749,164 17,305,708 0.672 0.511 64,965 0.132 
CEL_iPSC_R3 32,870,552 11,787,419 0.641 0.491 44,215 0.099 
CEL_iPSC_R4 41,895,393 11,782,586 0.719 0.552 53,292 0.128 
HAY_DE_R1 48,286,327 20,974,314 0.566 0.386 117,677 0.202 
HAY_HLC_R1 39,342,022 16,864,979 0.571 0.359 125,903 0.386 
HAY_iPSC_R1 57,626,560 24,863,112 0.569 0.397 137,610 0.253 
PHH_AFJ 51,382,001 4,060,977 0.921 0.737 45,610 0.277 
PHH_DJJ 82,714,835 4,224,927 0.949 0.728 32,675 0.177 





Supplementary Table 13: Spearman correlations of CDX2, ALB and AFP expression levels and TF regulon activities 
in single cells. Positive correlations above 0.5 are highlighted in blue, negative correlations below 0.5 in grey.  
 
Regulon CDX2 ALB AFP Regulon CDX2 ALB AFP
HLF -0.45 0.82 -0.43 CREB5 0.36 -0.32 0.60
NR1I2 -0.41 0.81 -0.40 EBF4 0.56 -0.33 0.57
NFIC -0.45 0.81 -0.44 ATF3 0.68 -0.36 0.74
NR1I3 -0.40 0.81 -0.40 KLF6 0.64 -0.36 0.77
AR -0.42 0.80 -0.43 RELB 0.41 -0.37 0.52
NFIL3 -0.38 0.78 -0.31 CREB3L2 0.54 -0.38 0.71
CEBPD -0.47 0.76 -0.31 ETV5 0.52 -0.39 0.48
CEBPB -0.33 0.75 -0.37 CDX2 0.73 -0.40 0.65
HSF4 -0.50 0.75 -0.48 CREB3L1 0.54 -0.40 0.56
RXRB -0.44 0.74 -0.48 GATA5 0.66 -0.41 0.62
PPARG -0.48 0.74 -0.27 CEBPG 0.50 -0.43 0.68
PPARGC1A -0.42 0.68 -0.50 SP1 0.54 -0.43 0.57
CUX2 -0.49 0.68 -0.59 ARID5B 0.42 -0.44 0.55
NR1H4 -0.17 0.67 -0.21 ARID3A 0.51 -0.45 0.63
KLF15 -0.59 0.65 -0.67 BHLHE40 0.68 -0.47 0.73
ETV2 -0.55 0.65 -0.62 KLF7 0.39 -0.48 0.51
CREBL2 -0.56 0.64 -0.64 FOSL2 0.71 -0.50 0.68
PPARA -0.11 0.61 -0.11 GTF3C2 0.20 -0.50 0.09
SRY -0.39 0.57 -0.30 POLR2A 0.27 -0.51 0.40
ESR1 -0.33 0.57 -0.52 ELK3 0.17 -0.52 0.30
RXRA -0.21 0.57 -0.39 E2F8 0.10 -0.52 0.08
FOXP3 -0.42 0.56 -0.59 HDAC2 0.05 -0.52 0.12
RORA -0.47 0.55 -0.58 TAF7 0.13 -0.53 0.20
NR2F2 -0.45 0.55 -0.66 E2F4 0.10 -0.53 0.22
FOXA3 -0.41 0.54 -0.43 CLOCK 0.50 -0.53 0.55
CFL2 -0.44 0.51 -0.37 FOSL1 0.28 -0.54 0.47
ZNF841 -0.41 0.50 -0.44 ZNF516 0.34 -0.54 0.18
RARA -0.14 0.50 -0.18 IRF1 0.58 -0.54 0.49
POU2F3 -0.34 0.49 -0.52 MAZ 0.11 -0.54 0.14
KLF11 -0.62 0.49 -0.69 ETS1 0.26 -0.54 0.40
HSF1 -0.42 0.43 -0.62 BCLAF1 0.23 -0.55 0.41
POLE4 0.32 0.14 0.50 SRF 0.41 -0.56 0.58
SOX9 0.38 -0.08 0.64 JDP2 0.34 -0.56 0.39
ZNF189 0.32 -0.11 0.52 RUNX1 0.29 -0.56 0.43
HNF4G 0.64 -0.15 0.62 CREB3 0.52 -0.56 0.65
MAF 0.52 -0.17 0.48 BCL11A 0.39 -0.57 0.31
TFF3 0.62 -0.22 0.66 CREB1 0.16 -0.57 0.23
TCF7L2 0.63 -0.24 0.75 KLF13 0.30 -0.57 0.37
ETS2 0.36 -0.28 0.52 E2F7 0.12 -0.59 0.14
KLF5 0.69 -0.28 0.63 SOX4 0.65 -0.60 0.67
ELF3 0.64 -0.28 0.66 CTCF 0.25 -0.60 0.39
IRF6 0.54 -0.30 0.53 ELF1 0.39 -0.63 0.51
EGR1 0.65 -0.32 0.62 MAX 0.67 -0.63 0.65




Supplementary Table 14: Top 50 most significant (adjusted p-value < 0.05) key regulators of HLC differentiation 








TF adj. p TF adj. p TF adj. p TF adj. p TF adj. p TF adj. p TF adj. p TF adj. p
JARID2 1.24E-16 KDM2B 2.87E-22 KDM2B 3.79E-25 JARID2 7.65E-25 SIX2 0.026 CXXC1 1.81E-07 JARID2 2.18E-13 FXR 0.003
LMNB1 8.30E-16 MBD4 1.22E-21 CNOT3 8.00E-25 KMT2A 3.22E-16 ASXL1 1.81E-07 SUMO2 3.55E-09 SMC1A 0.022
MBD4 8.99E-15 KMT2A 5.71E-19 KMT2A 3.80E-24 CNOT3 3.38E-16 RAG2 9.67E-07 LMNB1 5.82E-09
KMT2A 1.71E-14 CNOT3 7.21E-19 TFAP2A 6.24E-23 HID1 2.62E-14 CDK9 1.17E-06 MBD4 1.26E-08
EOMES 1.43E-13 SUMO2 8.24E-19 SUMO2 9.45E-22 KDM2B 3.63E-14 ARNTL 1.17E-06 TFAP2A 3.71E-08
SMC1A 2.56E-13 SMC1A 9.54E-19 SMC1A 1.33E-20 TFAP2A 1.44E-13 GRHL2 1.70E-06 SMC1A 7.48E-08
CTNNB1 1.18E-12 TET2 4.01E-18 DPEP3 6.52E-19 MBD4 2.87E-13 KDM4C 1.70E-06 CTNNB1 1.52E-07
KDM2B 1.40E-12 TFAP2A 5.71E-17 CHD8 6.52E-19 PMEPA1 1.66E-12 KMT2A 1.75E-06 KDM2B 1.76E-07
PMEPA1 2.00E-12 JARID2 7.26E-17 RUNX1T1 6.80E-19 SUMO2 3.09E-12 CNOT3 1.75E-06 KMT2A 7.26E-07
CNOT3 3.07E-12 MYH11 3.60E-16 NIPBL 9.03E-19 DMC1 4.76E-12 BRPF3 1.75E-06 HID1 7.26E-07
TFAP2A 3.07E-12 ARNTL 3.60E-16 ASXL1 1.64E-18 SMC1A 2.83E-11 ZNF750 1.84E-06 CNOT3 8.12E-07
CHD8 3.61E-12 SMAD4 2.57E-15 MBD4 1.64E-18 ERG 7.27E-11 ING3 1.87E-06 ERG 1.16E-06
GRHL2 9.60E-12 DPEP3 2.84E-15 RAG2 2.73E-18 ARNTL 8.66E-11 KMT2D 2.57E-06 LMNA 1.34E-06
SMAD4 1.30E-11 ERG 1.03E-14 PMEPA1 6.64E-18 HIF1A 5.90E-10 ING5 4.27E-06 RUNX2 1.34E-06
SNAI2 2.25E-11 SNAI2 1.38E-14 ARNTL 2.09E-17 ZFP42 1.37E-09 BRD1 4.27E-06 PMEPA1 2.03E-06
MEF2B 2.76E-11 ZMYND8 1.38E-14 E2F3 2.77E-17 NIPBL 2.15E-09 ZMYND8 4.71E-06 CHD8 2.12E-06
TCF4 3.27E-11 GARS 1.78E-14 TET2 4.74E-17 KDM4A 2.57E-09 PHF2 4.78E-06 TOP2B 7.44E-06
ZNF217 4.47E-11 SMAD3 2.05E-14 ING3 4.74E-17 CHD8 2.75E-09 KDM2B 6.32E-06 YAP1 8.67E-06
RUNX2 4.47E-11 HID1 2.32E-14 PBX1 4.74E-17 TET2 2.94E-09 SUMO2 7.68E-06 EOMES 9.80E-06
LMNA 5.17E-11 CHD8 2.54E-14 HID1 7.81E-17 CDK9 7.09E-09 KLF5 9.65E-06 TET2 2.71E-05
HIF1A 1.06E-10 YAP1 2.64E-14 CDK9 7.81E-17 SNAI2 3.83E-08 TFAP2A 1.29E-05 TCF4 3.36E-05
TP63 1.43E-10 KDM4A 3.82E-14 FLI1 8.24E-17 TFAP2C 3.83E-08 MYH11 1.43E-05 SMAD4 1.12E-04
ESR2 1.54E-10 KDM4C 4.41E-14 KDM4C 8.24E-17 SMAD4 5.69E-08 FLI1 1.47E-05 DMC1 1.37E-04
DPEP3 2.50E-10 TFAP2C 1.11E-13 CXXC1 8.44E-17 GARS 7.23E-08 MBD4 1.47E-05 ZMYND8 4.42E-04
ING3 5.19E-10 NR1H3 1.64E-13 DMC1 9.66E-17 GRHL2 9.34E-08 SMC1A 1.47E-05 GTF2I 4.42E-04
PPARD 5.88E-10 FLI1 2.34E-13 TFAP2C 1.80E-16 ESR2 2.33E-07 ZNF217 1.47E-05 MYH11 5.57E-04
PDX1 5.96E-10 MEF2B 2.79E-13 HOXA4 2.37E-16 PPARD 4.79E-07 RUNX1T1 1.47E-05 FLI1 0.002
YAP1 9.97E-10 CTNNB1 3.06E-13 MYH11 3.06E-16 CTBP2 7.30E-07 BCL6 1.47E-05 PPARG 0.002
ARNTL 1.39E-09 DMC1 4.00E-13 KMT2D 6.26E-16 RUNX1T1 9.49E-07 MYOD1 1.47E-05 ESR2 0.002
CDK9 2.12E-09 ING3 1.68E-12 HIF1A 7.13E-16 SPDEF 1.06E-06 BRD3 1.47E-05 TP63 0.002
NIPBL 2.86E-09 CXXC1 2.00E-12 KDM4A 7.16E-16 DPEP3 1.15E-06 NELFE 1.79E-05 CDK9 0.002
SIX2 3.26E-09 TCF4 2.61E-12 GTF2I 9.10E-16 CTNNB1 1.40E-06 GTF2B 1.79E-05 SNAI2 0.002
GARS 7.95E-09 BRPF3 2.92E-12 GRHL2 1.45E-15 FLI1 1.52E-06 HMGN3 1.79E-05 NIPBL 0.002
FOXO1 8.72E-09 CDK9 5.51E-12 BRD3 2.34E-15 YAP1 2.19E-06 CHD8 1.99E-05 PSIP1 0.002
SMAD3 9.35E-09 GRHL2 5.66E-12 SNAI2 2.77E-15 JMJD1C 2.25E-06 TCF3 2.29E-05 CREBBP 0.003
HID1 1.03E-08 NIPBL 7.32E-12 PPARG 3.28E-15 TCF3 2.39E-06 NIPBL 3.04E-05 HIF1A 0.003
KDM4A 1.30E-08 RAG2 7.37E-12 JARID2 6.42E-15 RAG2 2.66E-06 TET2 3.09E-05 CTBP2 0.003
SUMO2 1.83E-08 HIF1A 9.48E-12 NR1H3 1.52E-14 CREBBP 2.77E-06 LEO1 3.16E-05 DAXX 0.004
MYOD1 2.28E-08 SIX2 1.66E-11 BRPF3 2.35E-14 NR1H4 2.91E-06 AFF4 3.20E-05 PIAS1 0.004
KLF5 3.29E-08 PPARG 2.28E-11 MEF2B 3.63E-14 TCF4 2.91E-06 GTF2I 4.26E-05 KDM4A 0.004
FLI1 5.22E-08 PMEPA1 2.33E-11 YAP1 4.45E-14 PDX1 6.40E-06 NFKB1 4.64E-05 RREB1 0.005
TET2 5.84E-08 PBX1 6.12E-11 CTNNB1 4.45E-14 ASXL1 6.69E-06 VDR 4.84E-05 ARNTL 0.006
ERG 6.32E-08 ASXL1 8.10E-11 ERG 4.81E-14 PPARG 7.96E-06 SNAI2 5.39E-05 SIX2 0.006
AHR 7.05E-08 NKX2-1 8.93E-11 HMGN3 5.21E-14 PBX1 1.07E-05 LYL1 5.77E-05 GATA6 0.009
TFAP2C 7.12E-08 PGR 8.93E-11 BCL6 1.10E-13 MYH11 1.29E-05 PMEPA1 6.91E-05 PPARD 0.011
PSIP1 1.01E-07 CDK8 1.15E-10 KDM6B 1.68E-13 OTX2 1.68E-05 ESR2 7.16E-05 KDM3A 0.012
GTF2I 1.43E-07 E2F3 1.71E-10 LMO2 1.94E-13 LMNA 1.80E-05 NR1H3 8.82E-05 GRHL2 0.012
DAXX 1.43E-07 KLF5 2.07E-10 JMJD1C 2.07E-13 ZNF92 2.20E-05 MECOM 1.45E-04 PDX1 0.014
PPARG 1.48E-07 BCL6 2.08E-10 KLF5 2.94E-13 GTF2I 2.33E-05 DPEP3 1.48E-04 ZFP42 0.014
BRPF3 1.48E-07 TP63 2.14E-10 SMAD4 4.88E-13 MYOD1 2.33E-05 HOXA4 1.57E-04 RAG2 0.015
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5hmC     hydroxy-methylcytosine 
5fC         formy-cytosine 
5cC        carboxy-cytosine 
A adenine 
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